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Hypertension affects 1 in 4 adults in the United States and is a major contributor 
to cardiovascular morbidity and mortality.  Blood pressure control is observed in slightly 
less than two-thirds of those on antihypertensive pharmacologic treatment, and 
racial/ethnic disparities persist with significantly lower blood pressure control rates 
observed among minority populations.  Hypertension is a multifactorial disease, 
involving both genetic and environmental pathogenic mechanisms.  This dissertation 
used the Genetic Epidemiology Network of Arteriopathy (GENOA) study to examine (1) 
cross-sectional associations of individual characteristics (demographic, medical history, 
physiological, and lifestyle) with blood pressure outcomes, (2) cross-sectional 
associations of neighborhood socioeconomic environment with blood pressure outcomes, 
(3) familial aggregation of blood pressure outcomes, and (4) cross-sectional associations 
of gene-drug interactions with systolic blood pressure (SBP).  The first study found that 
blood pressure control rates were suboptimal among treated hypertensives, and blood 
pressure control rates were lower among African Americans, compared to non-Hispanic 
whites.  Increasing age and the presence of co-morbidities were associated with 
decreased odds of blood pressure control.  Individual education was significantly 
associated with blood pressure control in African Americans, but not non-Hispanic 
whites, even after control for other individual level factors.  The second study found that 
neighborhood socioeconomic environment was associated with increased odds of 
 xii 
 
combination antihypertensive pharmacological therapy, but not blood pressure control, 
among African Americans.  The third study found evidence of moderate familial 
aggregation of quantitative blood pressure measures and blood pressure control in both 
African Americans and non-Hispanic whites.  Among African subjects, sib-sib 
correlations of quantitative blood pressure values and familial aggregation of blood 
pressure control were detected among sibpairs in which both siblings resided in poor 
neighborhoods.  The fourth study found that single nucleotide polymorphisms in the 
SELE and VCAM1 genes had significant main effects, as well as gene-drug interaction 
effects, on SBP in both African Americans and non-Hispanic whites.  Findings from 
these studies illustrate the multifactorial nature of hypertension and the importance of 
understanding how multiple factors across multiple levels influence variation in blood 
pressure levels.  This dissertation research took important, novel steps in building 
connections between the physiological, lifestyle, socio-demographic, familial, genetic 
and antihypertensive therapy factors that influence blood pressure control in 












Hypertension, defined by a systolic blood pressure (SBP) ≥ 140 mmHg or 
diastolic blood pressure (DBP) ≥ 90 mmHg (1), affects more than 65 million adults in the 
United States (US) and is the most common disease for which adults seek medical 
attention (2, 3).  Uncontrolled hypertension is an established risk factor for 
cardiovascular, cerebrovascular, and renal disease morbidity and mortality (4).  Despite 
the recognized health and economic burdens of hypertension, the prevalence of 
hypertension is increasing (5) and success in achieving and maintaining target blood 
pressure levels necessary to reduce cardiovascular risk has been limited.  Data from the 
National Health and Nutrition Examination Survey (NHANES) from 1999-2002 indicate 
that the age- and sex- adjusted prevalence of hypertension across racial groups (non-
Hispanic white, non-Hispanic black, and Mexican American) is approximately 28.6%.  
Of those with hypertension, 63.4% were aware of their condition, 45.3% were receiving 
antihypertensive medication, and 29.3% had their blood pressure under control (<140/90 
mm Hg) (6).  Although national awareness, treatment, and control of hypertension have 
all increased in recent years (7), rates remain suboptimal and improvements in these 
measures are necessary to meet national health objectives (8) and to minimize the public 
health impact of hypertension and related morbidity and mortality.   
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Race and Ethnicity Differences 
 Hypertension prevalence, awareness, treatment, and control are distributed 
unevenly across racial/ethnic groups in the US (5, 6, 9).   According to recent NHANES 
data, hypertension prevalence is statistically significantly higher in non-Hispanic blacks 
(40.5%), compared to comparable rates in non-Hispanic whites (27.4%) and Mexican 
Americans (25.1%) (6).  Other studies (10, 11) have detected similar trends and have 
noted even higher hypertension prevalence rates for blacks in the range of 48-60%.  The 
racial/ethnic disparity in hypertension prevalence is a highly publicized public health 
issue that may contribute to higher levels of hypertension awareness and treatment among 
blacks compared to whites.  Findings from a recent NHANES analysis indicate that 
blacks have higher percentages of hypertension awareness and treatment (70.3% and 
55.4%, respectively), compared to lower awareness and treatment rates among whites 
(62.9% and 48.6%, respectively), although these differences were not statistically 
significant (6). The percentages of treated individuals that had their condition under 
control were comparable between blacks and whites based on this national sample (6).  In 
contrast, other studies (10-12) have found that among those on antihypertensive 
treatment, blacks were less likely than whites to have their condition under control. 
 Based on recent national data, the prevalence of hypertension among Mexican 
Americans was lower, yet comparable, to rates among non-Hispanic whites and 
substantially lower than rates among non-Hispanic blacks. Despite having the lowest 
prevalence rates, Mexican Americans were the least likely to be aware of their condition 
(49.8%), to be undergoing treatment (34.9%), and to have their condition under control 
(17.3%), when compared nationally to whites and blacks, and these differences were 
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statistically significant (6).  In a separate analysis, Hispanics (including Hispanic 
subgroups other than Mexican Americans) were less likely to be taking antihypertensive 
medications, compared to whites and blacks (13), which may stem from low awareness 
among the Hispanic population (14) and may subsequently contribute to lower control 
rates among this group. 
Age and Sex Effects 
In addition to the racial/ethnic trends described above, other demographic factors 
influence the distribution of hypertension prevalence, awareness, treatment, and control.  
Results from NHANES (6) indicate that across racial/ethnic groups, hypertension 
prevalence statistically significantly increased with increasing age and was higher in 
women compared to men, although the sex difference was not statistically significant. 
The respective proportions of hypertensive individuals that were aware of their 
hypertension, were currently being treated, and had their blood pressure controlled all 
generally increased with age.  One notable exception to this general trend is a decrease in 
the percentage of individuals who had their blood pressure controlled among the oldest 
age category relative to previous younger age group.  Hypertension awareness, treatment, 
and control rates were all higher in women compared to men.  Recent research has also 
suggested that the age trajectories of adult hypertension prevalence follow steeper 
gradients for blacks (compared to whites) and women (compared to men), with black 
women having the highest rates of hypertension and the steepest age-gradient by the age 
of 40 (15).  
Hypertension as a Co-Morbidity 
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 Elevated blood pressure levels are associated with an increased risk for 
cardiovascular disease (CVD), independent of other risk factors.  Despite this consistent 
relationship, previous research (16) has demonstrated that the presence of additional CVD 
risk factors compounds the risk from hypertension alone.  In addition to contributing to 
an increased overall risk of developing CVD, the presence of other risk factors may also 
concurrently contribute to elevations in blood pressure levels, thereby hindering the 
ability to achieve target blood pressure control.  The presence of other CVD risk factors 
and/or resulting co-morbidities may also influence the probabilities of hypertension 
awareness, and control.  For instance, individuals that have been diagnosed with high 
cholesterol levels or diabetes may be more likely than their comparatively healthy 
counterparts to seek more frequent medical care and may be more likely to be aware of 
their hypertension status, by virtue of increased exposure to blood pressure measurements 
that are part of routine care.  The presence of co-morbidities may also impact the 
probabilities of hypertension treatment and subsequent control.  As discussed briefly 
below, African-American individuals typically respond favorably to diuretic therapy 
compared to other forms of treatment.  If, for example, a hypertensive African-American 
individual also has an established dyslipidemia profile of some type, treatment with 
certain diuretic regimens may be contraindicated (17), which could reduce both the 
probabilities of treatment (assuming prescription practices were influenced by knowledge 
of indications and contraindications) and control (if a drug that might normally prove 
efficacious were not administered as a result of directed prescribing).   Although these 
examples are hypothetical, they help to illustrate the importance of considering the 
influences of other CVD risk factors on blood pressure levels and hypertension 
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awareness, treatment, and control.  It is also intuitive, yet important to note that 
concurrent management of blood pressure and other CVD risk factors is essential in 
reducing overall CVD risk (1). 
Anthropometric Factors 
Obesity has become an epidemic problem in the US.  The strong positive 
association between body weight and hypertension is well documented, with both 
overweight and obesity related to increases in blood pressure levels.  Findings from 
recent NHANES data suggest that body mass index (BMI) is associated with 
hypertension prevalence after controlling for age, sex, and race/ethnicity and has 
contributed to more than half of the hypertension prevalence increase from 1998 – 2000 
(5).  Recent research has suggested that a higher intensity of treatment may be required to 
control blood pressure in obese individuals (18) and a lack of blood pressure control with 
both increasing BMI (4) and waist circumference (19) has been documented.  Decreases 
in BMI have been shown to reduce hypertension risk (20) and blood pressure levels (21), 
suggesting that lifestyle modifications leading to weight reductions are important in 
preventing hypertension and controlling blood pressure levels in hypertensive adults. 
Lifestyle Factors 
The adoption of healthy behaviors is essential in reducing and maintaining 
appropriate blood pressure levels, preventing hypertension incidence, improving 
antihypertensive drug efficacy, and reducing cardiovascular disease (CVD) risk (1).  
Lifestyle modifications should be used as initial therapy to control blood pressure and 
should be standard in all hypertensive patients (17).  The current recommended lifestyles 
with proven efficacy for preventing hypertension include: maintaining normal body 
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weight; adopting a diet that is low in sodium and saturated fats, and rich in fruits, 
vegetables, and potassium; engaging in regular aerobic physical activity; and limiting 
alcohol consumption (22).  Although cigarette smoking has not been established as an 
independent risk factor for hypertension, it does increase risk for both coronary heart 
disease and stroke.  As such, smoking cessation is suggested for overall CVD risk 
reduction (1). 
Results from a recent clinical trial on lifestyle interventions has suggested that 
combining two or more of the recommended behaviors may be even more effective at 
reducing and maintaining blood pressure levels (23).  Accordingly, combining a diet rich 
in fruits and vegetables (and hence potassium) with low dietary sodium intake has been 
shown to decrease SBP by at least 5 mmHg (24), a reduction that is comparable to the 
reductions obtained with an effective antihypertensive agent (17).  
Antihypertensive medications are among the most frequently used medications in 
the United States.  One of the challenges in achieving broad blood pressure control is the 
difficulty in predicting how effective a particular antihypertensive regimen will be for a 
particular patient.  Without a priori knowledge of how individuals will respond to a 
medication, a “trial-and-error” approach is typically employed to find the ideal drug for a 
given patient (25).  Furthermore, it is recognized that hypertension is a multifactorial 
disease and that combinations of antihypertensive agents, acting through different 
mechanisms at different sites, are often prescribed (17), with most patients requiring two 
or more drugs to achieve target blood pressure (26).  This illustrates the importance of 
incorporating lifestyle modifications into treatment plans and public health efforts, versus 
 7 
 
a predominant reliance on the prescription of antihypertensive medications, as a means of 
controlling blood pressure levels among hypertensive individuals. 
Genetic Factors 
A positive family history of hypertension is another known risk factor for 
developing hypertension.  In addition to the demographic and environmental factors 
discussed above, genetic factors play a role in inter-individual blood pressure variation 
(CITE GWAS STUDIES HERE), and the notion that hypertension results from complex 
interactions between genetic and environmental factors has become widely accepted.  
Single-gene disorders, including glucocorticoid-remediable aldosteronism, apparent 
mineralocorticoid excess and Liddle’s syndrome, are known to cause hypertension.  
However, these disorders are rare and are only likely to explain a small proportion of the 
total genetic variation in blood pressure (27).  Several linkage studies of hypertension 
have concluded that there is no single gene for hypertension (28-33).  It is more likely 
that hypertension is a polygenic disorder in which the additive and interactive effects of 
polymorphisms at numerous gene loci contribute to inter-individual blood pressure 
variation and differential risk of developing hypertension.  Variations in candidate genes, 
such as those encoding components of the renin-angiotensin-aldosterone-system (RAAS) 
(e.g. – angiotensinogen and angiotensin converting enzyme), may predispose individuals 
to hypertension by altering various blood pressure regulation pathways (34).  
Furthermore, genetic variation in the RAAS genes may contribute to differences in 
hypertension control between blacks and whites.  It has been suggested that hypertension 
among blacks is characterized by sodium dependence and low plasma renin and responds 
better to treatment with diuretics and calcium channel blockers.  Conversely, 
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hypertension among whites is characterized by high plasma renin and exaggerated 
sodium elimination, and responds better to ACE inhibitors, angiotensin blockers, and 
beta-blockade (35).  Investigating genetic variations in the RAAS and other pathways 
may offer insights into the etiology of hypertension and the reasons for disparities in 
blood pressure levels and hypertension control across various groups.   
Genome wide association studies (GWAS) analyze whole-genome information to 
identify genetic associations with observable traits and/or the presence of disease 
conditions.  Many GWAS on blood pressure are ongoing (36-39) and have identified a 
number of genomic regions that influence blood pressure levels.  Replication of findings 
across these and other GWAS may identify genomic regions involved in the pathogenesis 
of hypertension and/or blood pressure regulation.  
Although difficult to dissect and interpret, the potential for numerous 
gene*environment interactions should not be ignored.  In a discussion regarding genes, 
environment and cardiovascular risk, Sing et al. (40) have described the incidence of 
common chronic diseases such as CVD and hypertension as a consequence of a 
population’s distribution of susceptibility genetic factors interacting with the numerous, 
population–specific, environmental factors over time.  Under this paradigm, these 
researchers pose the following fundamental question:  
“…which variations, in which genes, and in which populations are useful for 
understanding disease and predicting which individuals will develop disease in which 
strata of environmental histories? (40)”  
 
Investigation of variations within genes and appropriately measured interactions with 
other genes and various environmental factors may offer insights into the etiology 
hypertension and possible explanations for blood pressure control for certain individuals 
within particular environmental contexts.   
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Socioeconomic Status and Education 
A comprehensive review of the literature indicates that there is a general inverse 
relationship between various SES measures (income, education, and occupation) and 
hypertension (41).  A recent trend analysis of NHANES data has found that, despite the 
overall decrease in the prevalence of hypertension, reductions in income- and education-
related disparities in hypertension have not followed suit.  Across all race/ethnicity 
groups, the age- and sex-adjusted prevalence of high blood pressure was consistently 
higher for individuals in lower income and education categories for each of the four-year 
periods investigated (1971-1974; 1976-1980; 1988-1994; and 1999-2002) (42).  A 
separate analysis of the NHANES data has confirmed that CVD risk factors, including 
hypertension, cluster according to SES status (43).  
Individual measures of SES, such as income and education level attained, are also 
likely to influence hypertension awareness, treatment, and control.  For example, 
individuals in higher SES categories may be more likely to have access to quality health 
care and more likely to seek routine medical care.  If this were the case, such individuals 
may also be more likely to be aware of their conditions, as  
“…awareness of hypertension presumes sufficient contact with a health care 
professional to permit an accurate diagnosis and communication of the finding to the 
effected party (44)”.   
 
SES status may also impact the probability that a hypertensive individual is currently 
being treated and has his or her condition under control.  For example, the cost of 
expensive antihypertensive medications, such as calcium channel blockers, may reduce 
the probability that a hypertensive individual in a low SES category is currently being 
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treated.  Furthermore, financial strain has been linked with non-adherence with 
medication (45), which may in turn reduce the probability of blood pressure control.   
Both low SES and lack of education are also associated with unhealthy behaviors, 
such as cigarette smoking (42).  Poor health behaviors are likely associated with less 
overall concern over health, and reduced likelihoods of adopting healthy lifestyles, 
seeking routine medical care, and adhering to recommended treatment regimens.  Further 
investigation of how individual measures of SES may contribute to the distributions of 
hypertension awareness, treatment, and control is important in determining why the 
recent reductions in hypertension prevalence are not uniformly seen in all segments of 
society. 
Familial Factors 
In addition to sharing similar genetic profiles, individuals within the same family 
share a number of environmental factors throughout the life course, such as physical 
environment, dietary habits, health beliefs and practices, and socioeconomic status.  
These familial genetic and environmental factors may condition a common blood 
pressure level.  If evident, such between-family variation in blood pressure levels would 
suggest that genetic and environmental (or interactions between the two) contextual 
effects could operate in ways that might influence individual blood pressure levels and/or 
the probability of hypertension control.  Furthermore, evidence for familial clustering of 
blood pressure levels and hypertension outcomes suggests that strategies for preventing 





Much of the CVD epidemiology research has focused on the contribution of 
individual-level risk factors (46).  Recently, there has been a resurgence of interest in 
examining the health consequences of living in particular areas or neighborhoods (47).  
The broad hypothesis surrounding neighborhood effects on health is that the contextual 
features of neighborhoods may be related to health outcomes, independently of 
individual-level characteristics (47, 48).  Many studies examining the potential role of 
neighborhood effects have used readily available, census-defined areas as proxies for 
neighborhoods and aggregate socioeconomic measures as proxies for specific features of 
neighborhoods (49).  A recent summary of the empirical research focusing on 
neighborhood effects has indicated that living in low SES neighborhoods is associated 
with increased coronary heart disease, cardiovascular mortality, and related CVD risk 
factors (including blood pressure), even after accounting for individual-level 
socioeconomic characteristics (46).  A recent study (50), investigating the extent to which 
neighborhood effects influence disparities in blood pressure levels and hypertension 
outcomes, has suggested that contextual features of neighborhoods may play a role in 
explaining social disparities in elevated blood pressure, and in hypertension prevalence 
and awareness, but not in hypertension treatment, or control.  To the authors’ knowledge, 
this was the only study to examine the potential neighborhood effects on continuous 
measures of blood pressure and dichotomous measures of hypertension prevalence, 
awareness, treatment, and control.  As such, additional investigation of the potential role 
of neighborhood contextual effects on these blood pressure/hypertension outcomes in 
other study samples is warranted.  Further investigations will contribute to this evolving 
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area of research and may offer additional insights into the etiology of hypertension and 
the contexts that shape the distribution of hypertension/CVD risk factors.   
Multilevel Analysis 
There is an inherent organizational structure that extends from biological systems 
within individuals to higher order groupings of individuals, such as families and 
neighborhoods, to even higher order classifications of such groupings, such as counties 
and states.  Within this natural organizational structure, a multitude of nesting structures 
are possible.  For example, one possible 2-level nesting structure is individuals nested 
within families, and this nesting structure could be extended to a 3-level structure of 
individuals nested within families that are in turn nested within neighborhoods.  In order 
to capture the relevant impact of these different data structures on a given outcome, 
multilevel analysis is a useful approach.  Multilevel analysis permits simultaneous 
examination of the effects of individual- and group-level characteristics on individual-
level outcomes, controls for correlations within groups, and allows for examination of 
both inter-individual (within-group) and inter-group (between-group) variation (51).     
 The degree to which group-level contexts exert “independent” effects on 
individual-level health outcomes may have important implications for public health 
efforts.  If group-level characteristics influence hypertension risk, apart from individual-
level characteristics, interventions that are directed towards the relevant group (e.g. 
families or neighborhoods) may prove beneficial in reducing blood pressure levels and 
increasing the levels of hypertension awareness, treatment, and control.   Accounting for 
group-level features may also be important in providing the context that determines the 
distribution of hypertension risk factors.  
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DISSERTATION RESEARCH OBJECTIVES 
  The goal of this dissertation was to investigate social and biological factors that 
influence interindividual variation in quantitative blood pressure measures and the 
relative odds of hypertension treatment and control.  The first paper (Chapter 2) 
examined the associations of individual characteristics (demographic, medical history, 
physiological, and lifestyle) with quantitative SBP and DBP measures, blood pressure 
treatment with a combination antihypertensive medication regimen, and blood pressure 
control among aware and treated hypertensives.  Analyses for this paper were conducted 
in an exclusively African American cohort and separately in an exclusively non-
Hispanic white cohort.  This stratification permitted racial/ethnic comparisons of the 
associations detected within each cohort.  The second paper (Chapter 3) examined how 
neighborhood-level socioeconomic variables, after controlling for individual-level risk 
factors, influenced quantitative blood pressure measures, blood pressure combination 
therapy, and blood pressure control among African Americans.  The third paper 
(Chapter 4), investigated sibling correlation structures of quantitative blood pressure 
measures and the degree to which blood pressure control aggregated within families.  
Additionally, the African American sib-sib correlation structures indexed by sib-sib 
concordance of neighborhood-level socioeconomic indicators were also investigated to 
determine if sibs living in similar (or dissimilar) types of neighborhoods demonstrated 
similar blood pressure outcomes.  Finally, the fourth paper (Chapter 5) examined effects 
of polymorphisms in inflammation genes (SELE and VCAM1) stratified by 
antihypertensive medication classes, in order to assess the potential influence of gene-
drug interactions on SBP.  As in the first paper, stratification by racial/ethnic group 
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permitted the investigation of the influence of gene-drug interactions on SBP in 
racially/ethnically homogeneous samples.   
STUDY POPULATION 
The Genetic Epidemiology Network of Arteriopathy (GENOA) 
In 1995, the National Heart, Lung and Blood Institute (NHLBI) established The 
Family Blood Pressure Program (FBPP) to assess the genetic influence on inter-
individual blood pressure variation and the occurrence of hypertension. One of the four 
networks established by the NHLBI to meet this objective is the Genetic Epidemiology 
Network of Arteriopathy (GENOA). Subject recruitment for GENOA was population 
based and took place in three geographic locations: Jackson, Mississippi; Starr County, 
Texas; and Rochester, Minnesota.  The Rochester field center recruited non-Hispanic 
whites (N=1578), the Jackson field center recruited African-Americans (N=1854), and 
the Starr County field center recruited Mexican-Americans (N=1804) (52).   
In Rochester and Jackson, recruitment was restricted to sibships containing a 
minimum of two individuals diagnosed with essential hypertension before the age of 60.  
Hypertensive probands in Rochester, MN and Jackson, MS were identified through the 
Rochester Epidemiology Project/Mayo Clinic diagnostic index (53) and the 
Atherosclerosis Risk in Communities (ARIC) study (54), respectively.  Due to the high 
prevalence of diabetes among Mexican-Americans, the Starr County recruitment was 
restricted to Mexican-American sibships containing at least two individuals diagnosed 
with type-2 diabetes mellitus.  Mexican American participants less than 60 years of age 
were identified from participants in the Starr County Health Studies (55).  In each cohort, 
all available siblings, including normotensive individuals, of the index sibling pairs were 
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invited to participate in interviews, physical examinations, and phlebotomy. Exclusion 
criteria for participation included secondary hypertension, alcoholism or drug abuse, 
pregnancy, insulin-dependent diabetes mellitus, or active malignancy.  Approximately 
67% of the GENOA sample was hypertensive. The initial phase of the GENOA study 
took place from September 1996 through June 2000 (52).  The analyses in this 
dissertation will focus on the African American and non-Hispanic white GENOA 
subjects, and will primarily focus on two general classes of reduced analytic samples: (1) 
all hypertensive subjects, regardless of hypertension awareness, treatment, or control 
status (African American, N=1329; non-Hispanic white, N=1129); and (2) hypertensive 
subjects that are aware of their hypertension diagnosis and are currently taking prescribed 
antihypertensive medication(s) to control their blood pressure (African American, 
N=1123; non-Hispanic white, N=970).   
PUBLIC HEALTH SIGNIFICANCE 
Uncontrolled blood pressure affects 1 in 4 adults in the US (2), accounts for 
nearly $1 billion annually in direct medical expenditures (56) and is a major contributor 
to cardiovascular morbidity and mortality (5).  Blood pressure control is observed in only 
64% of hypertensives on antihypertensive pharmacologic treatment.  Racial/ethnic 
disparities persist with minority populations (particularly non-Hispanic blacks) 
demonstrating poorer treated blood pressure control compared to non-Hispanic whites 
(7).  Identifying potential predictors of inadequate blood pressure control is crucial for 
determining key areas that public health and clinical efforts should concentrate on in 
order to reduce disparities, as well as the health and economic burdens related to 
hypertension.  Few studies focused on blood pressure have investigated the influence of 
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characteristics defined across a broad framework of health determinants.  This 
dissertation research took an important, novel step of attempting to build connections 
between the social, behavioral, physiological, genetic and antihypertensive therapy 
factors that influence variations in blood pressure levels and hypertension outcomes 
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Hypertension affects more than 65 million adults in the United States (US) and is 
the most common disease for which adults seek medical attention (1, 2).  Uncontrolled 
hypertension is an established risk factor for cardiovascular, cerebrovascular, and renal 
disease morbidity and mortality (3).  Despite the recognized health and economic burdens 
of hypertension, the prevalence of hypertension has increased in recent years (4) and 
success in achieving and maintaining target blood pressure levels necessary to reduce 
cardiovascular risk has been limited.  Recent age-adjusted data from the National Health 
and Nutrition Examination Survey (NHANES) indicate that among all individuals with 
hypertension, 54% were receiving antihypertensive medication and only 33% have their 
blood pressure under control.  The importance of adequate antihypertensive therapy is 
clear, as blood pressure control rates among treated individuals are markedly better at 
nearly 64% (4).  Although national rates of treatment and control of hypertension have 
increased in recent years (4), rates remain suboptimal and improvements in these 
measures are necessary to meet national health objectives (5) and to minimize the public 
health impact of hypertension and related morbidity and mortality.   
 One of the key goals of the Healthy People 2010 objective is to eliminate health 
disparities (5).  African Americans in the US have consistently higher prevalence of 
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hypertension in nationally representative samples (4)   and about 30% of mortality among 
African Americans is attributable to hypertension (6).  The racial/ethnic disparity in 
hypertension prevalence is a highly publicized public health issue that may contribute to 
higher levels of hypertension awareness and treatment among blacks compared to whites.  
Despite this, national data (4) and results from other studies (7-9) indicate that among 
those on antihypertensive treatment, blacks are less likely than whites to have their 
condition under control.     
 Many studies have illustrated the trends of hypertension prevalence, awareness, 
treatment, and control among the general US population (1, 4, 10, 11).  Fewer studies 
have examined the influence of specific determinants on blood pressure control among 
clinical populations of treated hypertensive individuals. The objective of this study was to 
examine the associations between various demographic, lifestyle, biological, and personal 
medical history factors and blood pressure control in a bi-ethnically diverse sample of 
hypertensive subjects, with the intentions of offering insights into the potential 
determinants of blood pressure control within racial/ethnic groups and identifying factors 
that may contribute to the observed disparities in blood pressure control. 
METHODS 
Study Population 
In 1995, the National Heart, Lung and Blood Institute (NHLBI) established The 
Family Blood Pressure Program (FBPP) to assess the genetic influence on inter-
individual blood pressure variation, hypertension, and hypertensive target organ damage. 
One of the four networks established by the NHLBI to meet this objective is the Genetic 
Epidemiology Network of Arteriopathy (GENOA).  GENOA field centers in Jackson, 
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MS, Starr County, TX, and Rochester, MN recruited hypertensive African American, 
Hispanic, and non-Hispanic white sibships, respectively, for linkage and family-based 
association studies. Subject were diagnosed with hypertension if they had a previous 
clinical diagnosis of hypertension by a physician with current antihypertensive treatment 
or an average systolic blood pressure (SBP) >=140 mmHg and/or an average diastolic 
blood pressure (DBP) >=90 mmHg.  
In Rochester, MN and Jackson, MS, recruitment was restricted to sibships that 
contained a minimum of two individuals diagnosed with essential hypertension before the 
age of 60.  Once this criterion was met, the entire sibship was invited to participate in the 
study. As the prevalence of diabetes among Mexican-Americans is high, the Starr County 
recruitment was restricted to Mexican-American sibships containing at least two 
individuals diagnosed with type-2 diabetes (12).  Data was collected through personal 
interviews, and physical and laboratory examinations.  The initial phase of the GENOA 
study took place from September 1995 through June 2001 (13).   
The study presented here focuses on 2458 hypertensive subjects from the 
Rochester, MN and Jackson, MS cohorts.  Although a majority of the subjects in both 
cohorts have been diagnosed as hypertensive, approximately 25% of the sibship members 
invited to participate were identified as normotensive during the baseline examination 
and have been excluded from this analysis. Other exclusion criteria included secondary 
hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes, or active 
malignancy.  Of the 1579 non-Hispanic white subjects enrolled in the study, 1129 (72%) 
subjects from 548 sibships were identified as having essential hypertension. Of the 1854 
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African American subjects enrolled in the study, 1329 (72%) subjects from 637 sibships 
were identified as having essential hypertension. 
Covariates 
Height was measured by stadiometer, weight by electronic balance, and body 
mass index (BMI) was calculated as weight in kilograms divided by the square of height 
in meters. Diabetes was defined as having a fasting glucose level ≥ 126 mg/dL or 
currently being treated with insulin or oral agents.  Blood was drawn by venipuncture 
after an overnight fast.  Serum cholesterol, triglycerides, and high-density lipoprotein 
(HDL) cholesterol were measured by standard enzymatic methods.  Subjects were 
categorized as having a positive high-risk lipid profile if one or more of the following 
criteria were met: high-density lipoprotein (HDL) cholesterol <35 mg/dL; triglycerides 
>200 mg/dL; total cholesterol >240 mg/dL; or total cholesterol to HDL ratio >6.  
Although calculation of low-density lipoprotein (LDL) cholesterol by the Friedewald 
formula (14) has been commonly used in epidemiologic studies and validated (15), 
calculated LDL values are invalid for subjects with very high (>400 mg/dL) triglyceride 
levels, as the ratio of LDL to triglycerides is not constant as triglyceride levels increase.  
A number of subjects from each racial/ethnic group (30 (2%) African Americans, 53 
(5%) non-Hispanic whites) with triglyceride values that exceeded the validated cutpoint 
of 400 mg/dL were excluded from the respective samples when calculating LDL values.  
Given these modest reductions in sample size for both racial/ethnic groups, LDL was 
investigated as an independent risk factor for the outcomes of interest, but was not 
included as criteria for the dichotomization of high-risk lipid profiles.  Trained 
interviewers asked subjects standard questions on numerous factors, including 
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sociodemographic, lifestyle, behavioral and cardiovascular health history.  Age in years 
was assessed on the baseline examination date.  Education was defined as the total 
number of years of education completed and was also categorized as < 12 years; ≥ 12 
years, < 16 years; and ≥ 16 years (reference group).  Marital status was based on self-
reports and was defined as “married” for subjects currently married and “single” 
otherwise.  Physical activity was based on the number of miles each subject jogged 
and/or walked per week. Current smoking status and alcohol consumption (sometimes 
versus never) were based on self-reports. Presence of coronary heart disease (CHD) was 
based on self reported positive history of heart attack, myocardial infarction, coronary 
bypass surgery, coronary angioplasty, coronary balloon dilation, and/or coronary stent.  
History of cerebrovascular disease was based on self-reported positive history of stroke 
and/or carotid artery surgery.  Where applicable, the duration of hypertension for each 
subject was based on the difference between the baseline examination date and the date 
of hypertension diagnosis. 
Measurement of Blood Pressure Outcomes 
Blood Pressure Readings 
Blood pressure measurements were made with random zero sphygmomanometers 
and cuffs appropriate for arm size. Three readings were taken in the right arm after the 
subject rested in the sitting position for at least five minutes according to the Seventh 
report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC-7, 2003) guidelines (16). The SBP and DBP 
values were determined by the first and fifth phase Korotkoff sounds, respectively, and 
the last two blood pressure readings were averaged for the analyses.  The diagnosis of 
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hypertension was established based on blood pressure levels measured at the study visit 
(≥140/90 mmHg), or a prior diagnosis of hypertension and current treatment with 
antihypertensive medications.  
Antihypertensive Medications 
Based on lists of all antihypertensive medications available in the US each 
prescription antihypertensive drug recorded at the study visit was assigned a code number 
corresponding to the first 6 digits of the Medi-Span Generic Product Identifier. This 
number, which identifies pharmacologically equivalent drug products, was used to 
categorize agents with similar mechanisms of antihypertensive action. The number of 
subjects classified for each antihypertensive medication group is summarized in Table 
2.4. 
Blood Pressure Awareness, Treatment and Control 
Subjects were considered to be “aware” of their hypertension status if they were 
(a) defined as hypertensive, and (b) answered yes to the question, “Have you ever been 
told by a physician that you have high blood pressure or hypertension?”  Conditional 
upon being hypertensive and aware of their hypertension status, subjects were considered 
to be “treated” if they answered yes to the questions, “Has medication ever been 
prescribed by a physician to lower your blood pressure?” and “During the last month, 
have you used any medication that was prescribed or recommended by a physician?”  
Official guidelines propose that patients with a SBP ≥ 140 mmHg or DBP ≥ 90 mmHg be 
considered as hypertensive (16, 17).  Accordingly, in this study controlled blood pressure 
was defined as SBP < 140 mmHg and DBP < 90 mmHg for a treated subject with 
hypertension. If either one, or both, of the two requirements were not met, a hypertensive 
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subject’s blood pressure was defined as uncontrolled.  In 1997, the sixth report of the 
Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of 
High Blood pressure (JNC-VI) put forth the recommendation that the threshold for 
control should be lowered to 130/85 mmHg for diabetic patients (18).  This more 
stringent definition of blood pressure control among diabetics was used to derive general 
blood pressure control rates for diabetics within each racial/ethnic group, in order to 
reflect the clinical recommendations that were in place during the study time period.  
Statistical Analysis 
 Means and standard deviations (SD) for continuous variables, and frequencies and 
percentages for categorical variables, were used to summarize the study sample 
characteristics.  Continuously distributed variables were examined graphically by 
histogram plots and analytically by subjective observations of associated skewness values 
to ensure approximation to the normal distribution.  Variable comparisons between male 
and female genders were assessed within racial/ethnic groups, and pooled sex variable 
comparisons were assessed between racial/ethnic groups.  Continuous variables were 
compared using standard t-tests, and categorical variables were compared using the χ2 
statistic.  To account for familial correlations in the data, linear mixed effects models, 
using maximum likelihood estimation methods, were used to assess linear associations 
between quantitative SBP and DBP values and baseline participant variables. 
Generalized linear mixed models, using penalized quasi-likelihood estimation 
methods, were used to assess associations where the probabilities of blood pressure 
treatment and blood pressure control were the designated outcomes of interest, and odds 
ratios (OR) and 95 % confidence intervals (CIs) were calculated for each variable.  
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Adjusted regression models including age and sex plus the baseline variable of interest 
were assessed to account for potential confounding by age and/or sex. An alpha-level of 
0.05 was used to determine statistical significance for all models.  Regression analyses 
were stratified by race/ethnicity, as they were carried out separately in the Rochester, MN 
(distinctly non-Hispanic White) and Jackson, MS (distinctly African American) cohorts. 
Since hypertension awareness and treatment were high in both racial/ethnic groups, the 
focus of all regression analyses was on reduced hypertensive samples containing subjects 
that were both aware of their hypertension diagnoses and taking antihypertensive 
medications to reduce blood pressure (African American n = 1123, non-Hispanic white n 
= 970).  The objective of investigating these reduced analytic samples was to provide 
insights into the potential reasons for (a) the observed lack of blood pressure control, 
even among treated hypertensives, and (b) blood pressure control disparities along 
racial/ethnic lines.  Analyses were performed using the R statistical language (19). 
Cross-Validation 
 The predictive ability of the variables of interest on quantitative blood pressure 
outcomes was assessed using cross-validation methods (20) and results are displayed in 
Appendices 2.1 and 2.2.  Cross-validation significantly reduces false positive results by 
eliminating associations that lack predictive ability in independent test samples. Four-fold 
cross-validation was performed by dividing the full sample into four equally sized 
groups. Three of the four groups were combined into a training dataset, and the modeling 
strategy outlined above was carried out to estimate model coefficients. These coefficients 
were then applied to the fourth group, the testing dataset, to predict the value of the 
outcome variable of each subject in the independent test sample. This process was 
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repeated for each of the 4 testing sets. Predicted values for all subjects in the test set were 








2ˆ . The total variability in the outcome (SST) – the difference between each 








2 . In order to estimate the proportion of variation in the outcome predicted in 
the independent test samples, the cross-validated R2 (CV R2) was calculated as follows: 
SST
SSESSTRCV −=2 . This cross-validation method provides a more accurate measure of 
the predictive ability of the regression models and will be negative when the model’s 
predictive ability is poor. Because random variations in the sampling of the four mutually 
exclusive test groups can potentially impact the estimates of CV R2, this procedure was 
repeated 10 times and the CV R2 values were averaged (21).   Covariate associations 
were considered cross-validated if the average percent variation predicted in independent 
test samples was greater than 0.5%. 
RESULTS 
 A total of 2458 subjects from the Rochester, MN and Jackson, MS phase I cohorts 
of the GENOA study were identified as being hypertensive.  The sample characteristics 
by racial/ethnic group are shown in Table 2.1.  Among all hypertensive subjects, SBP 
values were significantly higher among African Americans compared to non-Hispanic 
whites.  While DBP values did not differ by racial/ethnic group, overall blood pressure 
control (<140/90) was significantly lower among African Americans (44%) compared to 
non-Hispanic whites (52%).  The majority of both racial/ethnic groups were female.  
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African Americans were significantly older, had higher BMI, were diagnosed earlier with 
hypertension, were more likely to have diabetes, smoked more frequently, reported less 
physical activity, and completed fewer years of education compared to non-Hispanic 
whites.  Non-Hispanic whites had significantly poorer lipid profiles (higher total 
cholesterol and triglycerides, and lower high-density lipoprotein (HDL) cholesterol), 
reported higher positive history of CHD, and consumed alcoholic beverages more 
frequently compared to African Americans.   
 The distributions of hypertension awareness, treatment and control by sample 
characteristics are presented in Table 2.2 for African Americans and Table 2.3 for non-
Hispanic whites.  As awareness of previously diagnosed hypertension in two or more 
siblings was a criterion for participation in the GENOA study, the overall proportion of 
hypertension awareness was high and largely consistent by baseline characteristics in 
both racial/ethnic groups.  Similarly, a high proportion of subjects that were aware of 
their hypertension diagnosis were currently taking antihypertensive medications in both 
racial/ethnic groups.  While hypertension awareness was greater among African 
Americans, treatment (conditional on awareness) and blood pressure control (conditional 
on awareness and treatment) were lower compared to non-Hispanic Whites.  Blood 
pressure control is poorer among all (including untreated) hypertensive subjects in both 
racial/ethnic groups, which clearly illustrates the benefits of antihypertensive medication 
therapy.  Despite this parallel, a disparity still exists, with all African American 
hypertensive subjects having poorer blood pressure control, compared to their non-
Hispanic white counterparts (Figure 2.1).   
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Among the 1329 African American, hypertensive subjects, 1294 (97.4%) were 
aware of their hypertension diagnoses, 1123 (86.8%) of those that were aware were 
currently taking antihypertensive medications, and 590 (52.5%) of those that were both 
aware and taking antihypertensive medications had their blood pressure controlled.   
blood pressure control was achieved in less than half (44%) of African Americans, 
regardless of awareness or treatment status.  While awareness was high and did not differ 
greatly by baseline characteristics, subjects that were older, overweight or obese, 
diabetic, and had high-risk lipid profiles were significantly more likely to be aware of 
their hypertension diagnoses.  Treatment varied quite a bit by baseline characteristics.  
Subjects that were female, had greater BMI values, and had co-morbidities present, 
including diabetes, history of CHD, and history of CBVD, were significantly more likely 
to be taking antihypertensive medications compared to counterparts without co-
morbidities.  Subjects that did not smoke cigarettes or consume alcohol were also 
significantly more likely to be receiving treatment.  Blood pressure control among 
subjects that were both aware and treated was largely consistent by baseline 
characteristics, but older subjects were significantly less likely to have their blood 
pressure controlled to 140/90 mmHg.  Subjects with diabetes were much less likely to 
have their blood pressure controlled compared to their non-diabetic counterparts and had 
the lowest blood pressure control across all age, sex, co-morbidity, lifestyle, and 
education groups.   
Among all 1129 non-Hispanic white, hypertensive subjects, 1025 (90.8%) were 
aware of their hypertension diagnoses, 970 (94.6%) of those that were aware were 
currently taking antihypertensive medications, and 587 (60.5%) of those that were both 
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aware and taking antihypertensive medications had their blood pressure controlled.   
Blood pressure control was achieved in just over half (52%) of non-Hispanic whites, 
regardless of awareness or treatment status.  Awareness and treatment were generally 
high across age, sex, co-morbidity, lifestyle, and education groups, but older subjects 
were significantly more likely to be aware of their hypertension diagnoses, and women 
were significantly more likely to be aware and taking antihypertensive medications 
compared to men.  A marginally significant trend for awareness was detected among the 
education groups, with more educated subjects more likely to be aware of their 
hypertension diagnoses.   A marginally significant trend for treatment was detected 
among the BMI groups, with overweight and obese subjects less likely to be taking 
antihypertensive medications. Among subjects that were both aware and treated, subjects 
that were older (particularly those ≥ 60 years of age), reported positive histories of CHD, 
and were less educated were significantly less likely to achieve blood pressure control 
rates.  Women and subjects without diabetes had marginally better blood pressure control 
compared to men and those with diabetes, respectively. 
Systolic and Diastolic Blood Pressure 
 The least squares linear regression results for the covariates of interest regressed 
on SBP are shown in Appendix 2.1.  As expected, age, independent of sex, was a highly 
statistically significant and cross-validated predictor of SBP in both racial/ethnic groups, 
with estimated averages of 4.5% and 8.1% variation in SBP predicted in African 
Americans and non-Hispanic whites respectively.  Among African Americans, diabetes 
and years of education completed were also statistically significant and cross-validated 
predictors of SBP, after adjusting for age and sex.  Diabetics had SBP values that were on 
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average 5.5 mmHg higher than their non-diabetic counterparts and diabetes predicted an 
average of 1.1% variation in SBP.  For every year increase in education, SBP decreased 
by 0.5 mmHg and education  predicted an average of 0.6% variation in SBP.  Increases 
in total cholesterol and having hypertension for longer than 5 years both led to increases 
in SBP, however these associations only reached marginal significance.  Among non-
Hispanic whites, BMI was the only other covariate that demonstrated a statistically 
significant and cross-validated association with SBP, after controlling for age and sex.  
Per unit increase in BMI, SBP increased 0.19 mmHg and just over 0.5% variation in SBP 
was predicted by BMI.  Increased triglyceride levels were statistically significantly 
associated with increased SBP, however the association did not cross-validate.  Diabetic 
non-Hispanic white subjects also had higher SBP values compared to their non-diabetic 
counterparts, however this association only reached marginal significance. 
 The least squares linear regression results for the covariates of interest regressed 
on DBP are shown in Appendix 2.2.  Age, female sex, total cholesterol and LDL 
cholesterol all demonstrated statistically significant and cross-validated associations with 
DBP, in both racial/ethnic groups.  As with SBP, age, independent of sex, was the 
strongest predictor of DBP, with estimated averages of 6.9% and 8.4% variation in SBP 
predicted in African Americans and non-Hispanic whites respectively.  Contrary to 
increases in SBP with increasing age however, increases in age led to modest reductions 
in DBP levels in both racial/ethnic groups.  Since each of the analytic samples was 
comprised largely of older individuals, this relationship accurately reflects the slight 
decrease of DBP values commonly observed after 50 years of age (Figure 2.2., from Burt 
et al. (10)).  While no age-adjusted sex differences in SBP were noted in either 
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racial/ethnic group, females had statistically significantly lower DBP values compared to 
males in both groups.  The predictive ability of female sex on DBP was greater among 
non-Hispanic whites, compared to African Americans, as the estimated averages of 
variation predicted were 4.5% and 1.2% respectively.  Increases in total cholesterol and 
LDL cholesterol led to statistically significant increases in DBP and approximately 1% of 
the variation in DBP was predicted by each of these cholesterol types in both racial/ethnic 
groups.  Although a strong statistically significant association between diabetes and SBP 
was detected among African Americans, no such relationship was found for DBP.  
Conversely, diabetic non-Hispanic whites had statistically significantly lower DBP values 
on average, compared to their non-diabetic counterparts, although this association failed 
to cross-validate.  A marginal association between the number of years of education 
completed and DBP was detected among African Americans, with a one-year increase in 
education associated with a 0.20 reduction in DBP. 
Blood Pressure Treatment 
 Table 2.4 lists the use of antihypertensive drug classes verified at baseline among 
the aware and treated hypertensive GENOA subjects by race/ethnicity.  Diuretics were 
the most commonly used antihypertensive drug, regardless of race/ethnicity.  This is an 
expected result as diuretics are the most commonly prescribed drug as a first line defense 
against hypertension.  Among the main antihypertensive drug classes, the use of diuretics 
and calcium channel blockers was statistically significantly higher among African 
Americans, whereas the use of β-blockers and renin-angiotensin-aldosterone-system 
(RAAS) inhibitors was statistically significantly higher among non-Hispanic whites.  
This trend may reflect prescription patterns motivated by conventional wisdom that 
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African Americans tend to have lower renin activity compared to non-Hispanic whites 
and likely respond better to calcium channel blockers and diuretics, and less effectively to 
RAAS inhibitors and β-blockers (22).  The use of ‘other’ drugs, including α-blockers, 
vasodilators, and sympatholytics, was statistically significantly higher among African 
Americans.  While the majority of treated hypertensive GENOA subjects in both 
racial/ethnic groups were taking some type of antihypertensive drug as monotherapy 
regimens, the percentage was significantly higher in non-Hispanic whites compared to 
African Americans.  The use of antihypertensive drugs in combination was higher in 
African Americans compared to non-Hispanic whites, particularly among those taking 
three or more antihypertensive drugs.  This potentially reflects a general clinical attempt 
to treat African Americans more aggressively, given the consistently lower blood 
pressure control rates among African Americans on a national level (4).   
Overall, the percentage of antihypertensive treatment, conditional on being aware 
of hypertension status, was high in both racial/ethnic groups (87%, African Americans 
and 95%, non-Hispanic whites), and this low variability limited the ability to identify 
significant predictors of the antihypertensive treatment outcome..  There was, however, 
substantial variability among aware and treated subjects with respect to those that were 
taking antihypertensive drugs in monotherapy or combination form.  Table 2.5 lists the 
results of age- and sex-adjusted generalized linear mixed models examining potential 
significant predictors of taking antihypertensive drugs in combination versus 
monotherapy form.   
Many of the predictors investigated were statistically significantly associated with 
the odds of taking antihypertensive drugs in combination form, relative to monotherapy 
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form, and the results were largely consistent across the racial/ethnic groups.  Increasing 
age and BMI were associated with slight increased odds of combination therapy in both 
African Americans and non-Hispanic whites.  Each of the co-morbidities investigated, 
including Type 2 diabetes, history of CHD and history of CBVD, was associated with 
greatly increased odds of combination therapy (African American, OR=1.71, p<0.001, 
OR=3.62, p<0.001, OR=2.05, p=0.008; non-Hispanic white, OR=2.16, p<0.001, 
OR=1.58, p=0.041, OR=2.37, p=0.020), respectively).  These associations reflect not 
only the difficulty in managing blood pressure and the common need for multiple drugs 
in the presence of co-morbidities, but also that hypertensive patients with other 
conditions may have greater likelihoods of being both treated by health professionals and 
subsequently prescribed combination regimens.  In line with this, the duration of 
hypertension was also statistically significantly associated with increased odds of 
combination therapy, as expected, in both African Americans (OR=2.19, p<0.001) and 
non-Hispanic whites (OR=2.31, p<0.001).  Among non-Hispanic whites only, the odds of 
taking antihypertensive medications in combination form were higher among subjects 
with high-risk lipid profiles (OR=1.33, p=0.033) compared to those with moderate to low 
risk lipid profiles, and the odds of taking antihypertensive medications in combination 
form were lower among subjects that consumed alcohol (OR=0.72, p=0.025) compared 
to those that did not consume alcohol.  
Blood Pressure Control 
 Table 2.6 lists the results of age- and sex-adjusted generalized linear mixed 
models examining the influence of various predictors on blood pressure control (< 140/90 
mmHg) among treated hypertensive subjects, conditional upon being aware of their 
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hypertension diagnosis.  As expected, control was lower with increasing age, independent 
of sex, among African Americans (OR=0.97, p<0.001) and non-Hispanic whites 
(OR=0.95, p<0.001).  The duration of hypertension was also statistically significantly 
associated with decreased odds of blood pressure control, even after adjustment for age 
and sex, in both racial/ethnic groups.  African Americans that were diagnosed with 
hypertension for more than 5 years (prior to baseline) were less likely (OR=0.62, p 
=0.012) to have their blood pressure controlled compared to those with shorter durations 
of hypertension.  Similarly, non-Hispanic whites that had hypertension for more than 5 
years were less likely (OR=0.70, p=0.031) compared to non-Hispanic whites that were 
diagnosed with hypertension ≤ 5 years prior to baseline.   
Among non-Hispanic white subjects, the odds of blood pressure control were 
higher among current smokers (OR=1.58, p=0.039) compared to never and former 
smokers.  Although this relationship seems counterintuitive given the common risks 
associated with smoking, evidence does not support the role of smoking as a risk factor 
for hypertension as numerous studies (23-27) have demonstrated that, despite acute 
increases in blood pressure stemming from smoking, current smokers had lower blood 
pressure compared to former and never smokers.  The increased likelihood for controlled 
blood pressure detected among non-Hispanic white, current smokers may reflect the 
possibility that smokers are more likely to seek healthcare due to other complications 
related to smoking and an increase in healthcare visits may lead to appropriately guided 
blood pressure management.  This notion is supported by a recent study (28) that found 
current smoking was associated with higher healthcare utilization compared to former or 
never smokers.  
 39 
 
Among treated African American subjects, the odds of blood pressure control 
were lower among those with type 2 diabetes (OR=0.62, p<0.001) compared to non-
diabetics.  Among diabetic GENOA subjects, blood pressure control at the conventional 
<140/90 mmHg level was observed in 44% and 53% among African American and non-
Hispanic whites subjects, respectively.  blood pressure control rates to the more stringent 
<130/85 mmHg, as recommended for subjects with type 2 diabetes in JNC-VI (18), were 
poorer still, with control observed in 31% of the African American subjects and 28% of 
the non-Hispanic white subjects, reflecting the need for improvements in managing blood 
pressure in patients with type 2 diabetes.      
The odds of blood pressure control increased with increasing years of education 
completed among African Americans (OR=1.04, p=0.048), after controlling for age and 
sex differences.  This relationship was maintained (OR=1.04, p=0.044) after additional 
control for BMI, diabetes, history of CHD, history of CBVD, current smoking, and 
alcohol consumption.  Consistent with trends from recent national data (4), investigation 
of the pooled GENOA sample of African American and non-Hispanic white aware and 
treated hypertensive subjects (n=2093) indicated that African American race/ethnicity 
was statistically significantly associated with poorer blood pressure control compared to 
non-Hispanic white race/ethnicity, after adjustment for multiple covariates.  Table 2.7 
lists the odds of blood pressure control associated with African American race/ethnicity.  
An unadjusted model indicated that the odds of blood pressure control were lower among 
African Americans (OR=0.69, p<0.001) compared to non-Hispanic whites.  This 
association between African American race/ethnicity and blood pressure control was 
attenuated, but remained statistically significant, after adjustment for age, sex, BMI, and 
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co-morbidities including type 2 diabetes, history of CHD, and history of CBVD 
(OR=0.81, p=0.046).  The association of African American race/ethnicity was attenuated 
further and lost statistical significance with the additional adjustment for years of 
education completed (OR=0.84, p=0.100), providing additional supporting evidence that 
factors indexed by SES may influence blood pressure control and contribute to observed 
disparities in blood pressure control rates between racial/ethnic groups. 
DISCUSSION 
In recent years, national data suggest modest improvements in hypertension 
awareness, treatment, and control among the general hypertensive population, although 
hypertension prevalence has not declined and control remains suboptimal, particularly for 
minority populations (4).   Awareness and treatment rates among the hypertensive 
GENOA subjects were high, regardless of race/ethnicity, and substantially exceeded rates 
reported from national studies during the similar time period (4), although this reflects a 
selection bias since essential hypertension was a study inclusion criteria.  The GENOA 
control rates observed among treated hypertensives compared favorably with national 
rates for both African Americans and non-Hispanic whites (4).  Higher than nationally 
observed rates for both treatment and treated control among the GENOA African 
American subjects residing in the Jackson, MS area also compared favorably with rates 
recently observed among African Americans in the Jackson Heart Study (JHS) (29). As 
Wyatt et al. (29) point out, African Americans residing in the Jackson, MS area have 
benefited from participation in the Atherosclerosis Risk in Communities (ARIC) study 
(30) and increased exposure to health education through community outreach efforts of 
the JHS, and it is likely that such benefits have contributed to higher control rates.  As the 
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ARIC study population was utilized to identify African American hypertensive probands 
for the GENOA study, similar community resources have also benefited the African 
American subjects in the GENOA study and may have influenced comparably higher 
blood pressure control rates.  Despite the relative improvement in blood pressure control 
among African Americans within this particular community, rates remain suboptimal and 
are significantly lower compared to rates observed in this study among GENOA non-
Hispanic white subjects, as well as those reported for non-Hispanic whites in other 
population and community based samples (4, 7-9, 11, 29, 31, 32). 
 Epidemiologic studies have provided evidence that age is a key determinant of 
blood pressure (33).  Among the GENOA subjects, strong positive associations between 
increasing age and both SBP and DBP were observed.  The cross-validation of these 
associations in this study provides further evidence of the predictive ability of age on 
quantitative blood pressure values.  While awareness and treatment among the elderly 
GENOA subjects in both racial/ethnic groups were comparable to middle aged and 
younger subjects, the percentages of elderly subjects with controlled treated hypertension 
were lower in both groups.   A number of hemodynamic, metabolic, and nutritional 
factors certainly contribute to progressive increases in blood pressure values (34) and, 
subsequently, the difficulty in blood pressure control and simultaneous increased 
cardiovascular risk among the elderly.  Among these factors, hemodynamic alterations 
over the life-course, manifesting as increased vascular resistance earlier in life and 
shifting towards a predominance of large artery stiffness later in life (35), contribute to 
the commonly observed increasing SBP and decreasing DBP later in life.  This shift 
towards isolated systolic hypertension commonly occurs in the sixth decade of life (10), 
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is associated with increased cardiovascular risk among the elderly (36, 37) and often 
requires treatment intensification which is often accompanied by tolerability, 
affordability (29), compliance and other associated issues that in turn influence blood 
pressure control.  Among the treated hypertensives with uncontrolled blood pressure in 
this study sample, the majority of subjects in each racial/ethnic group (African American, 
58%; non-Hispanic white, 67%) had isolated systolic hypertension (SBP≥140/DBP<90 
mmHg), reflecting the influence of age on blood pressure, particularly systolic, control.    
National blood pressure control rates among treated elderly individuals have 
steadily improved to approximately 50% over recent years (4), providing further support 
to trials (38-40) that have demonstrated the ability to achieve blood pressure control 
among elderly populations.  Control rates among the elderly GENOA subjects compared 
favorably, possibly reflecting a general recognition of the importance of managing blood 
pressure, particularly SBP, among the elderly in order to reduce overall cardiovascular 
risk, as well as a shift away from clinical inertia among older individuals. Although this 
recent trend is encouraging, treatment efforts that couple drug therapy with lifestyle 
interventions should be increased among the elderly, as treated control rates among 
individuals ≥ 60 years of age remain sub-optimal and lower than younger age groups.  
Particular attention to the African American elderly population is warranted, as 
racial/ethnic disparities in uncontrolled treated hypertension among the elderly still 
remain and data indicates that African American women ≥ 60 years of age have the 
poorest blood pressure control rates among those treated for their condition (4). Although 
sex differences among GENOA subjects within racial/ethnic group did not significantly 
influence blood pressure control, the vast majority of the African American subjects were 
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female and this may well have contributed to lower blood pressure control among 
African Americans compared to non-Hispanic whites, given the difficulty of blood 
pressure control among African American women.  Furthermore, studies have shown 
that, compared to non-Hispanic whites, African Americans (particularly females) have 
steeper age-gradients for hypertension prevalence (41, 42), suggesting that the influences 
of the aging process and life-course exposures may differentially impact blood pressure 
control among the African American population.  
Type 2 diabetes and hypertension are intimately connected and poor blood 
pressure control among diabetic individuals with co-morbid hypertension has been 
consistently noted (4, 43-45).  The coexistence of diabetes and hypertension is associated 
with dramatically increased risk of CHD, stroke, renal disease, and mortality (16).  
Mechanisms contributing to both additive and multiplicative effects of hypertension and 
diabetes on cardiovascular risk have been proposed (46).  Within this GENOA sample, 
the prevalence of diabetes was statistically significantly higher in African Americans 
compared to non-Hispanic whites, in line with trends from national data (47-50).  This 
higher percentage of diabetes may be a contributing factor to the more aggressive drug 
treatment (i.e.- the higher use of combination antihypertensive therapies) observed among 
African Americans, compared to non-Hispanic whites, in this study.   
Recent studies have indicated that African Americans with diabetes may be 3 
times less likely to have controlled blood pressure compared to hypertensive African 
Americans without type 2 diabetes, even after accounting for age and treatment intensity 
differences, and that the use of 3 or more antihypertensive drugs may be required to 
adequately achieve and maintain blood pressure control among diabetics (51), 
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particularly to the more stringent control level of <130/85 mmHg recommended for 
diabetics in JNC-VI (52).  Despite this information, only 24% of the treated African 
American GENOA subjects with co-existent hypertension and diabetes were treated with 
3 or more antihypertensive drugs, while 37% were solely prescribed monotherapy 
antihypertensive regimens.  Although this discrepancy with treatment recommendations 
among diabetic subjects may point to an area for improvement in blood pressure 
management among this subgroup, the types of drugs prescribed were found to be 
relatively consistent with national guidelines (16), with 60% taking a diuretic and 35% 
taking a calcium channel blocker, alone or in combination, and 20 % were taking both in 
combination.    
Low-dose thiazide diuretics and calcium channel blockers are both effective first-
line agents in African Americans (53).  Thiazide-type diuretics are also beneficial in 
hypertensive patients with diabetes, even though these agents pose a small risk for 
worsening hyperglycemia, and calcium channel blockers, particularly in combination, 
may also be effective at lowering blood pressure and reducing diabetic related 
cardiovascular events (16).  Studies have shown the benefits of angiotensin-converting 
enzyme (ACE) inhibitors among diabetic patients (54).  These drugs are common first-
line agents in this group of patients (53), but ACE inhibitors are potentially less effective 
in African Americans due to low-renin and salt sensitive profiles (22, 55).   
Among the treated African American GENOA subjects with diabetes, 48% were 
taking RAAS inhibitors, a general class that includes ACE inhibitors and angiotensin 
receptor blockers, in some form.  This potentially reflects a tendency to treat diabetic 
patients with agents acting on the RAAS system, despite the perceived lack of efficacy of 
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these agents among African Americans compared to non-Hispanic whites.  JNC-VI 
guidelines highlighted the ability to overcome lack of antihypertensive efficacy by RAAS 
blockade in African Americans and low-renin populations by increasing RAAS agent 
dosage and/or adding agents that activate the RAAS system, such as diuretics and 
calcium channel blockers, in combination (18, 56).  Accordingly, 66% of the African 
American GENOA subjects with diabetes that were taking a RAAS inhibitor were also 
taking a diuretic and/or a calcium channel blocker.  While this may be an encouraging 
sign that many clinicians are adhering to treatment guidelines, particularly in high-risk 
hypertensive patients, 22% of the African American GENOA subjects with diabetes that 
were taking a RAAS inhibitor were taking then in monotherapy form.  Paying greater 
attention to treatment guidelines and key factors that contribute to drug effectiveness in 
individuals within specific subgroups of the population may be an important step towards 
achieving blood pressure reduction goals.  However, data from a recent study suggests 
that prescribing patterns are not a major contributor to ethnic differences in blood 
pressure control (57) and other factors are certain to play contributing roles in both the 
lack of blood pressure control in the general population, as well as the disparities in blood 
pressure control that have been consistently noted between African Americans and other 
(particularly non-Hispanic white) racial/ethnic groups.  Nonetheless, the need for 
adequate drug therapy, coupled with lifestyle interventions, including diet modifications 
and increased physical activity, is crucial among all hypertensive subjects generally, and 
among African Americans in particular.  
The inverse relationship between SES, for which education has been a common 
proxy, and cardiovascular disease has been described (58) and many health disparities 
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between racial/ethnic groups appear to be partially explained by SES differences (59).  
Inverse, albeit weak, associations between SES and blood pressure have also generally 
been detected (60).  African Americans in the GENOA study had significantly lower 
levels of education compared to the non-Hispanic whites.  Increasing levels of education 
among the African American subjects were related to increased probabilities of blood 
pressure control, even after controlling for other cardiovascular risk factors.  This effect 
did not appear to be present among the non-Hispanic white subjects, indicating that 
targeting areas of intervention indexed by SES may be effective at improving the 
probability of blood pressure control among African Americans, and reducing disparities 
in blood pressure control and cardiovascular sequelae.  The effects of SES on blood 
pressure are likely mediated via a range of influences including dietary practices, 
physical activity levels, and psychosocial stressors.  Access to quality health care and 
proper drug compliance are also likely influenced by SES differences, and numerous 
studies have related each of these factors to uncontrolled blood pressure (29, 61-63).  
Promoting the adoption of healthy lifestyles (64) and ensuring access to quality 
comprehensive health care are essential for blood pressure management and should 
constitute constructive components of a national initiative to reduce ethnic disparities in 
blood pressure control and cardiovascular risk (65).  
Several limitations and strengths of this study warrant brief discussion.  This 
study utilized cross-sectional data from the first phase of the GENOA study and, as such, 
the ability to make inferences about causality is limited.   The GENOA subjects in this 
study were aware and treated hypertensives and the results may not be generalizable to 
the general hypertensive population, or moreover, the general population.  Further, as the 
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African American and non-Hispanic white cohorts of this study were recruited from 
distinct metropolitan areas (Jackson, MS and Rochester, MN, respectively) the findings 
may not be generalizable to African Americans or non-Hispanic whites from other 
regions in the US.  Still, many of the findings in this study reflect those derived from US 
representative samples (1, 4, 11).  Although it is standard for many studies investigating 
hypertension, cross-sectional blood pressure measurements may have lead to 
misclassification of hypertension and/or blood pressure control status for some subjects.  
The standard blood pressure control definition (<140/90 mmHg) that was used in this 
study may have overestimated the clinical blood pressure control rate, as those with co-
morbid conditions should clinically be identified as having their blood pressure 
controlled under a more stringent definition (<130/85 mmHg) (18).  Results on the odds 
of age and sex adjusted blood pressure control using this more stringent definition where 
applicable did not significantly alter from results using the standard control definition 
(<140/90 mmHg) in either racial/ethnic group.  Given the cross-sectional nature of this 
study, pre-treatment blood pressure values were not available, precluding the prospective 
assessment of treatment effects and efficacy of particular regimens.  The study did, 
however, examine the influence of taking combination therapies, relative to monotherapy 
treatment, on the odds of blood pressure control and found no statistically significant 
associations in either racial/ethnic group.  The definition of ‘treatment’ in this study only 
included pharmacological treatment(s) and did not incorporate other interventions such as 
diet and exercise.  Despite this, this study’s assessment of treatment based on Medi-Span 
coding of pharmacological agents used at baseline is more robust than other studies using 
treatment based on self-reports.   
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This bi-racially diverse study sample uniquely provided information on both 
African American and non-Hispanic racial/ethnic groups and allowed for crude 
comparisons that offered potential insights into the myriad reasons for observed health 
disparities in hypertension and blood pressure outcomes.  It should be noted that the 
racial/ethnic differences in hypertension and blood pressure control outcomes noted from 
the comparisons that were made in this study are only valid for demonstrating variability 
in subgroups of the population and that etiologic inferences based on ‘race’ as a risk 
factor in observational studies are hazardous and inherently flawed (66).  Despite these 
caveats, the results from this study lend additional support to other studies (3, 4, 8, 9, 29, 
67) indicating that, while general improvements have been made, public health efforts 
need to remain focused on reducing the observed racial/ethnic disparities in blood 
pressure control among treated hypertensives. Efforts aiming to achieving goal SBP 
levels should be a general focus in all hypertensive patients, particularly those that are 
older, have co-morbid conditions, and/or are in lower SES groups, regardless of 
race/ethnicity.  Although still disparate compared to non-Hispanic whites, blood pressure 
control rates among the treated African Americans in this study and similar rates recently 
reported for African Americans in the JHS (29) were better than the comparable rates 
reported for African Americans nationally (4).  This suggests that focused interventions 
may have been effective at increasing blood pressure control among African Americans 
in this southern region of the US, and that, as Wyatt et al. (29) conclude, continued 
efforts using ethnic specific approaches could prove equally effective for African 
Americans from other regions and help narrow the current gap in blood pressure control 






Table 2.1.  Characteristics of the hypertensive GENOA study subjects by 
race/ethnicity 
 African American  non-Hispanic white 
 n = 1329  n = 1129 
Age (years) 60.0 (9.4)‡  57.6 (10.0) 
Height (cm) 168.3 (8.7)  168.6 (9.3) 
Weight (kg) 89.7 (18.8)  88.7 (20.0) 
BMI (kg/m2) 31.8 (6.8)*  31.2 (6.5) 
Total cholesterol (mg/dL) 206.2 (47.4)†  211.3 (38.8) 
HDL cholesterol (mg/dL) 55.4 (17.9)‡  51.0 (16.2) 
LDLa cholesterol (mg/dL) 121.8 (42.7)  120.7 (33.9) 
Triglycerides (mg/dL) 150.8 (83.1)‡  202.5 (106.4) 
Age hypertension diagnosis (years) 43.6 (10.2)‡  45.2 (11.5) 
Education (years completed) 11.7 (3.6)‡  13.1 (2.4) 
Jog/walk (miles/month) 2.8 (6.2)‡  6.5 (9.0) 
Female (%) 71‡  55 
Type 2 diabetes (%) 26‡  12 
History of CHD (%) 7*  10 
History of CBVD (%) 5*  4 
Current smoker (%) 18‡  12 
Alcohol consumption (%) 31‡  70 
Married (%) 50‡  80 
SBP (mmHg) 142.5 (22.6)‡  137.9 (16.6) 
DBP (mmHg) 79.8 (12.9)  80.0 (9.7) 
Blood pressure controlledb (%) 44‡  52 
Quantitative variables are presented as mean (SD); categorical variables as percentages.  a LDL values 
calculated by the Friedewald formula.  Friedewald calculation is only valid for subjects with 
triglyceride levels ≤ 400 mg/dL.  30 African American and 53 non-Hispanic white subjects had 
triglyceride values that exceeded this validated cutpoint and, as such, LDL values were calculated for 
1299 African American subjects and 1076 non-Hispanic white subjects.  Blood pressure control 
defined as systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg.  p-values for 
contrasts between racial/ethnic groups: *<0.05; †<0.01; ‡<0.001.  BMI = body mass index; HDL = 
high-density lipoprotein; LDL = low-density lipoprotein; CHD = coronary heart disease; CVBD = 
cerebrovascular disease; SBP = systolic blood pressure; DBP = diastolic blood pressure. 
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Table 2.2.  Hypertension awareness, treatment, and control by baseline characteristics among African Americans 
Category % Sample N Awarenessa, n (%) Treatmentb, n (%) Controlc, n (%) 
Overall  1329 1294 (97.4) 1123 (86.8) 590 (52.5) 
Age, years   ‡  † 
     20 - 39 2 34 32 (94.1) 30 (93.8) 18 (60.0) 
     40 - 59 48 636 605 (95.1) 525 (86.8) 304 (57.9) 
     >=60 50 659 657 (99.7)  568 (86.4) 268 (47.2) 
Sex    ‡  
     Female 71 942 917 (97.3) 816 (89.0) 421 (51.6) 
     Male 29 387 377 (97.4) 307 (81.4) 169 (55.0) 
BMI, kg/m2   † ‡  
     < 25 13 174 163 (93.7) 129 (79.1) 60 (46.5) 
     25 to 29 32 425 416 (97.9) 354 (85.1) 190 (53.7) 
     >= 30 55 730 715 (97.9) 640 (89.5) 340 (53.1) 
High-risk lipid profiled   **   
     No 64 855 826 (96.6) 714 (86.4) 378 (52.9) 
     Yes 36 473 467 (98.7) 408 (87.4) 212 (52.0) 
Type 2 diabetes    ** ‡ 
     Absent 74 983 951 (96.7) 811 (85.3) 454 (56.0) 
     Present 26 346 343 (99.1) 312 (91.0) 136 (43.6) 
History of CHD    †  
     Absent 93 1233 1198 (97.2) 1031 (86.1) 541 (52.5) 
     Present 7 96 96 (100) 92 (95.8) 49 (53.3) 
History of CBVD    †  
     Absent 95 1257 1222 (97.2) 1053 (86.2) 556 (52.8) 
     Present 5 72 72 (100) 70 (97.2) 34 (48.6) 
Current smoker    **  
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     No 82 1086 1061 (97.7) 933 (87.9) 489 (52.4) 
     Yes 18 243 233 (95.9) 190 (81.5) 101 (53.2) 
Alcohol consumption    †  
     No 69 913 888 (97.3) 789 (88.9) 413 (52.3) 
     Yes 31 416 406 (97.6) 334 (82.3) 177 (53.0) 
Education     ** 
     >= 16 years 17 226 220 (97.3) 190 (86.4) 114 (60.0) 
     >= 12 years, <16 years 42 560 538 (96.1) 477 (88.7) 257 (53.9) 
     < 12 years 41 543 536 (98.7) 456 (85.1) 219 (48.0) 
Marital status      
     Married 50 666 648 (97.3) 564 (87.0) 295 (52.3) 
     Single 50 663 646 (97.4) 559 (86.5) 295 (52.8) 
a Awareness of hypertension diagnosis among all subjects identified as hypertensive.  b Hypertension treatment with antihypertensive 
medications among those aware of their hypertension diagnosis. c Control of blood pressure to 140/90 mmHg among those that are both 
aware and treated. d High-risk lipid profile defined as positive for one or more of the following: high-density lipoprotein (HDL) cholesterol 
<35 mg/dL; triglycerides >200 mg/dL; total cholesterol >240 mg/dL; total cholesterol to HDL ratio >6.  p-value contrasts between baseline 
characteristic groups: *<0.10; **<0.05; †<0.01; ‡<0.001.  BMI = body mass index; CHD = coronary heart disease; CVBD = cerebrovascular 




Table 2.3.  Hypertension awareness, treatment, and control by baseline characteristics among non-Hispanic whites  
Category 
% 
Sample N Awarenessa, n (%) Treatmentb, n (%) Controlc, n (%) 
Overall  1129 1025 (90.8) 970 (94.6) 587 (60.5) 
Age, years   †  ‡ 
     20 - 39 4 50 39 (78.0) 35 (89.7) 29 (82.9) 
     40 - 59 54 604 550 (91.1) 520 (94.5) 352 (67.7) 
     >=60 42 475 436 (91.8)  415 (95.2) 206 (49.6) 
Sex   ** **  
     Female 55 622 576 (92.6) 554 (96.2) 346 (62.5) 
     Male 45 507 449 (88.6) 416 (92.7) 241 (57.9) 
BMI, kg/m2    *  
     < 25 15 165 151 (91.5) 148 (98.0) 92 (62.2) 
     25 to 29 34 388 346 (89.2) 329 (95.1) 189 (57.4) 
     >= 30 51 575 527 (91.7) 492 (93.4) 305 (62.0) 
High-risk lipid profiled      
     No 47 531 484 (91.1) 456 (94.2) 282 (61.8) 
     Yes 53 598 541 (90.5) 514 (95.0) 305 (59.3) 
Type 2 diabetes     * 
     Absent 88 990 897 (90.6) 847 (94.4) 522 (61.6) 
     Present 12 139 128 (90.8) 123 (96.1) 65 (52.8) 
History of CHD     † 
     Absent 90 1017 919 (90.4) 868 (94.5) 539 (62.1) 
     Present 10 112 106 (94.6) 102 (96.2) 48 (47.1) 
History of CBVD      
     Absent 96 1088 985 (90.5) 932 (94.6) 564 (60.5) 
     Present 4 41 40 (97.6) 38 (95.0) 23 (60.5) 
Current smoker     * 
     No 88 993 906 (91.2) 856 (94.5) 508 (59.3) 
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     Yes 12 136 119 (87.5) 114 (95.8) 79 (69.3) 
Alcohol consumption      
     No 30 334 306 (91.6) 292 (95.4) 169 (57.9) 
     Yes 70 795 719 (90.4) 678 (94.3) 418 (61.7) 
Education   *  ** 
     >= 16 years 17 191 181 (94.8) 172 (95.0) 116 (67.4) 
     >= 12 years, <16 years 74 840 759 (90.4) 718 (94.6) 432 (60.2) 
     < 12 years 9 98 85 (86.7) 80 (94.1) 39 (48.8) 
Marital status      
     Married 80 899 822 (91.4) 775 (94.3) 470 (60.6) 
     Single 20 230 203 (88.3) 195 (96.1) 117 (60.0) 
a Awareness of hypertension diagnosis among all subjects identified as hypertensive.  b Hypertension treatment with antihypertensive 
medications among those aware of their hypertension diagnosis. c Control of blood pressure to 140/90 mmHg among those that are both 
aware and treated. d High-risk lipid profile defined as positive for one or more of the following: high-density lipoprotein (HDL) cholesterol 
<35 mg/dL; triglycerides >200 mg/dL; total cholesterol >240 mg/dL; total cholesterol to HDL ratio >6.  p-value contrasts between baseline 
*<0.10; **<0.05; †<0.01; ‡<0.001.  BMI = body mass index; CHD = coronary heart disease; CVBD = cerebrovascular  
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Table 2.4.  Use of antihypertensive drug class by race/ethnicity* 
 African American 
n=1123 
 non-Hispanic white 
n=970 
Diuretic 57%‡ (14%)  48% (13%) 
Β-blocker 17% (4%)  40%‡ (16%‡) 
Calcium channel blocker 36%‡ (13%‡)  21% (6%) 
RAAS Inhibitor 35% (9%)  41%‡ (16%‡) 
Other** 23%‡ (7%‡)  6% (2%) 
Mono-therapy 47%  53%* 
2 of the above drugs in combination 39%  38% 
3 or more of the above drugs in combination 14%‡  9% 
*Top portion of table data represent percentages of aware and treated hypertensive subjects taking each respective antihypertensive drug 
class as part of any regimen.  Percentages using each class in mono-therapy form shown in parentheses; **Other antihypertensive class 
includes alpha-blockers, vasodilators, sympatholytics, and study drugs. RAAS = renin angiotensin aldosterone system.  p-value contrasts 
between racial/ethnic groups; p<0.05*; p<0.01†; p<0.001‡. 
 
55 
Table 2.5.  Multivariablea predictors of combination antihypertensive treatment by race/ethnicity 
 
 
Relative Odds of Combination Therapyb in  
Treated Hypertensives, OR (95% CI) 
Category African American (n=1123) non-Hispanic white (n=970) 
Age, years 1.02**(1.01-1.03) 1.04**(1.03-1.05) 
Sex   
     Male+   
     Female 1.12 (0.86-1.46) 1.01 (0.78-1.31) 
BMI, kg/m2 1.06**(1.04-1.08) 1.03**(1.01-1.05) 
High-risk lipid profilec   
     No+   
     Yes 0.95 (0.74-1.21) 1.33**(1.02-1.72) 
Type 2 diabetes   
     Absent+   
     Present 1.71**(1.30-2.23) 2.16**(1.44-3.23) 
History CHD   
     Absent+   
     Present 3.62**(2.15-6.10) 1.58**(1.02-2.45) 
History of CVBD   
     Absent+   
     Present 2.05**(1.21-3.47) 2.37**(1.15-4.90) 
Current smoker   
     No+   
     Yes 0.86 (0.63-1.19) 1.13 (0.76-1.69) 
Alcohol consumption   
     No+   
     Yes 0.85 (0.65-1.11) 0.72**(0.54-0.96) 
Jog/Walk, miles/week. 0.99 (0.97-1.01) 1.01 (1.00-1.03) 
Education, years 1.02 (0.99-1.06) 1.05 (0.99-1.11) 
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Education   
     16+ years+   
     12 - 15 years 0.94 (0.67-1.32) 0.90 (0.64-1.28) 
     <12 years 0.88 (0.62-1.25) 0.82 (0.46-1.45) 
Hypertension duration   
     ≤ 5 years+   
     > 5 years 2.19**(1.52-3.17) 2.31**(1.69-3.15) 
Married   
     No+   
     Yes 1.01 (0.79-1.30) 0.62**(0.45-0.87) 
aAll associations age and sex adjusted.  Age associations adjusted for sex.  Sex associations adjusted for age.  All models account for sibling 
correlations through fitting of generalized linear mixed models.  bRelative odds of taking 2 or more antihypertensive drugs vs. taking an 
antihypertensive drug as a monotherapy.  cHigh-risk lipid profile defined as positive for one or more of the following: high-density 
lipoprotein (HDL) cholesterol <35 mg/dL; triglycerides >200 mg/dL; total cholesterol >240 mg/dL; total cholesterol to HDL ratio >6.  
+Referent; OR = odds ratio; CI = confidence interval; BMI = body mass index; CHD = coronary heart disease; CVBD = cerebrovascular 




Table 2.6.  Multivariablea predictors of blood pressure control by race/ethnicity 
 
 
Relative Odds of Blood Pressure Controlb in  
Treated Hypertensives, OR (95% CI) 
Category African American (n=1123) non-Hispanic white (n=970) 
Age, years 0.97**(0.95-0.98) 0.95**(0.94-0.97) 
Sex   
     Male+   
     Female 0.82(0.63-1.08) 1.23 (0.94-1.61) 
BMI, kg/m2 1.00 (0.98-1.02) 0.99 (0.97-1.02) 
High-risk lipid profilec   
     No+   
     Yes 0.99 (0.77-1.27) 0.90(0.69-1.18) 
Type 2 diabetes   
     Absent+   
     Present 0.62**(0.47-0.82) 0.76 (0.51-1.13) 
History CHD   
     Absent+   
     Present 1.03 (0.66-1.61) 0.71 (0.46-1.11) 
History of CVBD   
     Absent+   
     Present 0.83 (0.50-1.36) 1.26 (0.63-2.51) 
Current smoker   
     No+   
     Yes 0.93 (0.67-1.29) 1.58**(1.03-2.43) 
Alcohol consumption   
     No+   
     Yes 0.90 (0.68-1.18) 1.13 (0.84-1.52) 
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Jog/Walk, miles/week. 1.00 (0.98-1.02) 1.00 (0.98-1.01) 
Education, years 1.04**(1.00-1.08) 1.01 (0.95-1.07) 
Education   
     16+ years+   
     12 - 15 years 0.73*(0.51-1.04) 0.83 (0.57-1.21) 
     <12 years 0.72*(0.49-1.04) 0.77 (0.42-1.40) 
Hypertension duration   
     ≤ 5 years+   
     > 5 years 0.62**(0.42-0.90) 0.70**(0.51-0.97) 
Number of antihypertensive medications   
     Monotherapy+   
     2 medications 0.98 (0.75-1.27) 1.22 (0.92-1.63) 
     3 or more medications 1.03 (0.73-1.46) 0.81 (0.50-1.31) 
Married   
     No+   
     Yes 0.89 (0.69-1.15) 1.08 (0.77-1.52) 
aAll associations age and sex adjusted.  Age associations adjusted for sex.  Sex associations adjusted for age.  All models account for sibling 
correlations through fitting of generalized linear mixed models.  bRelative odds of having blood pressure controlled to <140/90 mmHg.  
cHigh-risk lipid profile defined as positive for one or more of the following: high-density lipoprotein (HDL) cholesterol <35 mg/dL; 
triglycerides >200 mg/dL; total cholesterol >240 mg/dL; total cholesterol to HDL ratio >6.  +Referent; OR= odds ratio; CI = confidence 
interval; BMI = body mass index; CHD = coronary heart disease; CVBD = cerebrovascular disease. p-value **P<0.05; *P<0.10 
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Table 2.7.  Blood pressure controla by race/ethnicity among GENOA subjects with treated hypertension 
(n=2093) 
  Unadjusted Model 1 Model 2 Model 3 
  OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
non-Hispanic white 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
African American 0.69 (0.57-0.84) 0.77 (0.63-0.93) 0.81 (0.66-0.99) 0.84 (0.68-1.03) 
a Blood pressure controlled to <140/90 mmHg.  OR = odds ratio; CI = confidence interval; ref = referent group. 
Model 1 includes age and sex. 
Model 2 includes Model 1 and BMI, type 2 diabetes, history of coronary heart disease, and history of cerebrovascular disease. 
Model 3 includes Model 2 and number of years of education completed. 
All models account for sibling correlations through fitting of generalized linear mixed models.   
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non - Hispanic white African - American 




 *Blood  pressure control among subjects that were aware of their hypertension diagnosis and currently taking antihypertensive medication(s); ** Blood 
pressure control among all hypertensive subjects, regardless of awareness and/or treatment status. 
 
61 
Figure 2.2.  Mean systolic and diastolic blood pressures by age and race/ethnicity for men and women, US population 
18 years of age and older* 
 
 
*From Burt, V. L. et al. Hypertension 1995; 25:305-313.   
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Appendix 2.1 Multivariablea predictors of systolic blood pressure in GENOA study 
African American 
Covariate N Coef. 95% CI p-value Cross-validated R2 
Age (years) 1123 0.510 (0.367, 0.652) 0.0000 0.0446 
Female sex 1123 2.403 (-0.511, 5.317) 0.1066 0.0017 
BMI (kg/m2) 1123 0.074 (-0.12, 0.268) 0.4531 -0.0007 
Total cholesterol (mg/dL) 1122 0.024 (-0.003, 0.052) 0.0821 0.0023 
HDL (mg/dL) 1122 0.064 (-0.011, 0.138) 0.0959 0.0017 
LDL (mg/dL) 1097 0.020 (-0.011, 0.051) 0.2064 0.0010 
Triglycerides (mg/dL) 1122 0.005 (-0.011, 0.020) 0.5629 -0.0004 
LOG triglycerides (mg/dL) 1122 1.982 (-5.009, 8.973) 0.5787 -0.0004 
Type 2 diabetes  1123 5.459 (2.577, 8.342) 0.0002 0.0112 
History of CHD  1123 -1.287 (-6.012, 3.438) 0.5936 -0.0001 
History of CBVD  1123 2.982 (-2.333, 8.297) 0.2720 0.0004 
Current smoker 1123 1.389 (-2.070, 4.849) 0.4315 0.0000 
Alcohol consumption 1123 0.534 (-2.313, 3.381) 0.7132 -0.0005 
Jog/walk (miles/week) 1123 -0.067 (-0.283, 0.149) 0.5431 -0.0008 
Education (years) 1123 -0.522 (-0.895, -0.149) 0.0063 0.0062 
Parental history of hypertension 1123 2.335 (-0.677, 5.347) 0.1292 0.0020 
Married 1123 1.318 (-1.269, 3.904) 0.3185 0.0004 
Hypertension duration ≥ 5 years 1114 3.186 (-0.477-6.849) 0.0888 0.0016 
non-Hispanic white 
Covariate N Coef. 95% CI p-value Cross-validated R2 
Age (years) 970 0.486 (0.379, 0.592) 0.0000 0.0806 
Female sex 970 0.043 (-1.951, 2.036) 0.9667 -0.0008 
BMI (kg/m2) 969 0.187 (0.034, 0.340) 0.0170 0.0052 
Total cholesterol (mg/dL) 970 0.015 (-0.011, 0.041) 0.2565 0.0012 
HDL (mg/dL) 970 -0.008 (-0.069, 0.054) 0.8087 -0.0005 
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LDL (mg/dL) 924 0.007 (-0.024, 0.038) 0.6418 -0.0002 
Triglycerides (mg/dL) 970 0.011 (0.001, 0.021) 0.0274 0.0049 
LOG triglycerides (mg/dL) 970 5.698 (0.524, 10.872) 0.0314 0.0048 
Type 2 diabetes  970 2.793 (-0.173, 5.758) 0.0656 0.0031 
History of CHD  970 2.192 (-1.021, 5.405) 0.1818 0.0007 
History of CBVD  970 -0.650 (-5.733, 4.433) 0.8021 -0.0010 
Current smoker 970 -1.607 (-4.666, 1.452) 0.3038 -0.0006 
Alcohol consumption 970 -1.428 (-3.594, 0.738) 0.1970 0.0013 
Jog/walk (miles/week) 970 0.031 (-0.079, 0.140) 0.5828 -0.0004 
Education (years) 970 -0.057 (-0.487, 0.374) 0.7966 -0.0005 
Parental history of hypertension 904 2.333 (-0.968, 5.635) 0.1668 0.0020 
Married 970 -0.389 (-2.849, 2.071) 0.7568 -0.0005 
Hypertension duration ≥ 5 years 970 2.325 (0.165, 4.485) 0.0354 0.0032 
aAll associations are age and sex adjusted.  Age associations adjusted for sex.  Sex associations adjusted for age.  Boldface indicates p-value 
<0.05 and Cross-validated R2 >0.005 respectively.  BMI = body mass index; HDL = high-density lipoprotein cholesterol; LDL = low-density 




Appendix 2.2 Multivariablea predictors of diastolic blood pressure in GENOA study 
African American 
Covariate N Coef. 95% CI p-value Cross-validated R2 
Age (years) 1123 -0.346 (-0.424, -0.268) 0.0000 0.0688 
Female sex 1123 -2.970 (-4.542, -1.397) 0.0002 0.0119 
BMI (kg/m2) 1123 -0.095 (-0.200, 0.010) 0.0773 0.0034 
Total cholesterol (mg/dL) 1122 0.026 (0.012, 0.041) 0.0005 0.0094 
HDL (mg/dL) 1122 0.028 (-0.012, 0.069) 0.1685 0.0010 
LDL (mg/dL) 1097 0.029 (0.012, 0.046) 0.0008 0.0093 
Triglycerides (mg/dL) 1122 -0.001 (-0.009, 0.008) 0.8577 -0.0003 
LOG triglycerides (mg/dL) 1122 -0.195 (-3.972, 3.581) 0.9193 -0.0006 
Type 2 diabetes  1123 -0.897 (-2.461, 0.668) 0.2618 0.0004 
History of CHD  1123 -2.268 (-4.812, 0.276) 0.0812 0.0031 
History of CBVD  1123 0.186 (-2.672, 3.043) 0.8986 -0.0006 
Current smoker 1123 0.025 (-1.841, 1.891) 0.9790 -0.0005 
Alcohol consumption 1123 1.164 (-0.373, 2.701) 0.1383 0.0012 
Jog/walk (miles/week) 1123 0.050 (-0.066, 0.167) 0.3959 0.0004 
Education (years) 1123 -0.198 (-0.402, 0.006) 0.0576 0.0017 
Parental history of hypertension 1123 1.346 (-0.293, 2.948) 0.1081 0.0021 
Married 1123 0.691 (-0.702, 2.085) 0.3313 0.0010 
Hypertension duration ≥ 5 years 1114 1.770 (-0.203, 3.744) 0.0793 0.0023 
non-Hispanic white 
Covariate N Coef. 95% CI p-value Cross-validated R2 
Age (years) 970 -0.284 (-0.344, -0.224) 0.0000 0.0844 
Female sex 970 -3.831 (-4.942, -2.721) 0.0000 0.0446 
BMI (kg/m2) 969 -0.017 (-0.103, 0.069) 0.6928 -0.0001 
Total cholesterol (mg/dL) 970 0.030 (0.015, 0.044) 0.0001 0.0182 
HDL (mg/dL) 970 -0.002 (-0.037, 0.032) 0.8890 -0.0010 
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LDL (mg/dL) 924 0.033 (0.016, 0.050) 0.0002 0.0150 
Triglycerides (mg/dL) 970 0.005 (0.000, 0.011) 0.0562 0.0034 
LOG triglycerides (mg/dL) 970 3.201 (0.306, 6.095) 0.0307 0.0037 
Type 2 diabetes  970 -1.993 (-3.643, -0.343) 0.0184 0.0058 
History of CHD  970 -1.145 (-2.934, 0.643) 0.2100 0.0010 
History of CBVD  970 -1.950 (-4.778, 0.878) 0.1771 0.0009 
Current smoker 970 -0.561 (-2.265, 1.143) 0.5191 -0.0006 
Alcohol consumption 970 -0.055 (-1.265, 1.155) 0.9288 -0.0009 
Jog/walk (miles/week) 970 0.044 (-0.017, 0.105) 0.1556 0.0006 
Education (years) 970 0.013 (-0.229, 0.255) 0.9171 -0.0006 
Parental history of hypertension 904 1.641 (-0.226, 3.508) 0.0856 0.0019 
Married 970 -0.049 (-1.419, 1.321) 0.9439 -0.0009 
Hypertension duration ≥ 5 years 970 1.169 (-0.037, 2.374) 0.0581 0.0024 
aAll associations are age and sex adjusted.  Age associations adjusted for sex.  Sex associations adjusted for age.  Boldface indicates p-value 
<0.05 and Cross-validated R2 >0.005 respectively.  BMI = body mass index; HDL = high-density lipoprotein cholesterol; LDL = low-density 
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Investigating the Influence of Neighborhood Socioeconomic Status on the Treatment 
and Control of Hypertension in African Americans in the Genetic Epidemiology 
Network of Arteriopathy (GENOA) Study 
 
INTRODUCTION 
 Individual socioeconomic status (SES), commonly quantified by education, income 
and occupation, is a key determinant of health status and has shown consistent, generally 
inverse, relationships with cardiovascular disease (CVD), CVD mortality, and CVD risk 
factors, including hypertension (1).  Consistent with this, findings discussed in Chapter 2 
of this dissertation suggested that increasing individual education was significantly 
associated with decreases in quantitative systolic blood pressure (SBP) levels and 
increases in the relative odds of blood pressure control (<140/90 mmHg) among African 
Americans.  In addition to individual SES, interest in the effects of contextual attributes 
of neighborhoods and other area-based measures, independent of individual-level 
attributes, on health outcomes has grown in recent years (2).   Numerous studies have 
identified significant associations between neighborhood socioeconomic environment 
and coronary heart disease incidence (3-7), stroke risk (8), and blood pressure outcomes 
(9-13).  Many of these and other studies have documented that area characteristics may 
provide additional information about social inequalities in health that are not fully 
captured by individual level data.     
 A majority of the neighborhood effects studies of hypertension outcomes have 
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focused on quantitative blood pressure measures, hypertension prevalence, and/or 
hypertension incidence.  One previous study examined the influence of neighborhood 
socioeconomic environment in Chicago neighborhoods on quantitative blood pressure 
values, hypertension prevalence, as well as awareness, treatment, and control of 
hypertension, and concluded that residential contexts may play a role in accounting for 
racial/ethnic and socioeconomic disparities in hypertension prevalence and awareness, 
but not in the treatment or control of hypertension (12).  The central aim of this chapter 
was to further examine the potential influence of neighborhood socioeconomic 
environment on quantitative blood pressure measures, as well as the treatment and 
control of hypertension.  I hypothesized that, even after adjustment for other individual-
level factors, subjects residing in socioeconomically disadvantaged neighborhoods would 
have higher quantitative blood pressure measures, would be less likely to be treated with 
multiple antihypertensive medications, and would be less likely to have their blood 
pressure controlled to clinical recommendations (<140/90 mmHg) (14), compared to 
subjects residing in more socioeconomically advantaged neighborhoods. 
METHODS 
Study Population 
In 1995, the National Heart, Lung and Blood Institute (NHLBI) established The 
Family Blood Pressure Program (FBPP) to assess the genetic influence on inter-
individual blood pressure variation, hypertension, and hypertensive target organ damage. 
One of the four networks established by the NHLBI to meet this objective is the Genetic 
Epidemiology Network of Arteriopathy (GENOA).  GENOA field centers in Jackson, 
MS, Starr County, TX, and Rochester, MN recruited hypertensive African American, 
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Hispanic, and non-Hispanic white sibships, respectively, for linkage and family-based 
association studies. Subject were diagnosed with hypertension if they had a previous 
clinical diagnosis of hypertension by a physician with current antihypertensive treatment 
or an average SBP >=140 mmHg and/or an average diastolic blood pressure (DBP) >=90 
mmHg.  
In Rochester, MN and Jackson, MS, recruitment was restricted to sibships that 
contained a minimum of two individuals diagnosed with essential hypertension before the 
age of 60.  Once this criterion was met, the entire sibship was invited to participate in the 
study. As the prevalence of diabetes among Mexican-Americans is high, the Starr County 
recruitment was restricted to Mexican-American sibships containing at least two 
individuals diagnosed with type-2 diabetes (15).  Data was collected through personal 
interviews, and physical and laboratory examinations.  The initial phase of the GENOA 
study took place from September 1995 through June 2001 (16).   
The study presented here focuses on the hypertensive subjects from the Jackson, 
MS cohort that were both aware of their hypertension status and taking antihypertensive 
medication(s) to lower blood pressure.  Although a majority of the subjects in this cohort 
were diagnosed as hypertensive, a number of the sibship members invited to participate 
were identified as normotensive during the baseline examination and have been excluded 
from this analysis. Other exclusion criteria included secondary hypertension, alcoholism 
or drug abuse, pregnancy, insulin-dependent diabetes, or active malignancy. Of the 1854 
African American subjects enrolled in the study, 1123 (61%) subjects were identified as 
having essential hypertension and were taking antihypertensive medication(s), 
conditional upon being aware of their hypertension status.  Of these subjects, 1049 (93%) 
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had valid addresses that were successfully geocoded to the census tract level.  An 
additional 101 of these subjects were excluded from the analyses for residing outside of 
the tri-county Jackson, MS area (i.e. - Hinds, Madison, or Rankin counties) (n=37), or 
residing in a census tract within the tri-county Jackson, MS area that was represented by 
fewer than 5 study subjects (n=64).  The final analytic sample for this study contained 
948 aware and treated, hypertensive, African American subjects from 48 census tracts 
within the tri-county Jackson, MS geographic area.  
Covariates 
Trained interviewers asked subjects standard questions on numerous factors, 
including sociodemographic, lifestyle, behavioral, and cardiovascular health history. Age 
in years was assessed on the baseline examination date.  Education was defined as the 
total number of years of education completed.  Height was measured by stadiometer, 
weight by electronic balance, and body mass index (BMI) was calculated as weight in 
kilograms divided by the square of height in meters. Diabetes was defined as having a 
fasting glucose level ≥ 126 mg/dL or currently being treated with insulin or oral agents.  
Blood Pressure Readings 
Blood pressure measurements were made with random zero sphygmomanometers 
and cuffs appropriate for arm size. Three readings were taken in the right arm after the 
subject rested in the sitting position for at least five minutes according to the Seventh 
report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC-7, 2003) guidelines (14).  The SBP and DBP 
values were determined by the first and fifth phase Korotkoff sounds, respectively, and 
the last two blood pressure readings were averaged for the analyses.  The diagnosis of 
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hypertension was established based on blood pressure levels measured at the study visit 
(≥140/90 mmHg), or a prior diagnosis of hypertension and current treatment with 
antihypertensive medications.  
Antihypertensive Medications 
Based on lists of all antihypertensive medications available in the US each 
prescription antihypertensive drug recorded at the study visit was assigned a code number 
corresponding to the first 6 digits of the Medi-Span Generic Product Identifier. This 
number, which identifies pharmacologically equivalent drug products, was used to 
categorize agents with similar mechanisms of antihypertensive action.  
Blood Pressure Awareness, Treatment and Control 
Subjects were considered to be “aware” of their hypertension status if they were 
(a) defined as hypertensive, and (b) answered yes to the question, “Have you ever been 
told by a physician that you have high blood pressure or hypertension?”  Conditional 
upon being hypertensive and aware of their hypertension status, subjects were considered 
to be “treated” if they answered yes to the questions, “Has medication ever been 
prescribed by a physician to lower your blood pressure?” and “During the last month, 
have you used any medication that was prescribed or recommended by a physician?”  
The number of prescribed antihypertensive medications was tallied for each subject.  
Subjects taking only one prescribed antihypertensive medication were defined as being 
treated with a monotherapy regimen, while those taking two or more prescribed 
antihypertensive medications were defined as being treated with a combination therapy 
regimen.  Official guidelines propose that patients with a SBP ≥ 140 mmHg or DBP ≥ 90 
mmHg be considered as hypertensive (14, 17).  Accordingly, in this study controlled 
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blood pressure was defined as SBP < 140 mmHg and DBP < 90 mmHg for a treated 
subject with hypertension. If either one, or both, of the two requirements were not met, a 
hypertensive subject’s blood pressure was defined as uncontrolled.  
Addresses and Geocoding 
  Home addresses were assessed and recorded at baseline examination of the 
GENOA study.  Available, valid addresses were geocoded to the census tract level based 
on US Census 2000 tract definitions, using the Federal Financial Institutions Examination 
Council (FFIEC) Geocoding System (18). 
US Census Data 
 Census tracts are subdivisions of a county.  They generally have between 2,500 
and 8,000 residents, and, when first delineated, are designed to be homogeneous with 
respect to population characteristics, economic status, and living conditions. Summary 
File 3 was used to gather neighborhood socioeconomic indicator variables.  Summary 
File 1 was used to assess total race tallies by tract and subsequently generate a tract-level 
percent African American variable that served as a racial composition proxy. 
Neighborhood Socioeconomic Indicators and Neighborhood Summary Score 
 US census tracts were used as neighborhood proxies and data from the US Census 
2000 was used to obtain measures of the socioeconomic characteristics of each subject’s 
neighborhood (i.e.- census tract) of residence.   Previous factor analyses of census 
derived socioeconomic indicators have highlighted the following six variables that reflect 
dimensions of income/wealth, education, and occupation: annual median household 
income; median value of occupied housing units; percentage of households receiving 
interest, dividends, or net rental income; percentage of adults who completed high school; 
 78 
 
percentage of adults who completed college; and percentage of employed adults in 
executive, managerial, or professional occupations (3).  Based on previous methods (3), 
these six indicator variables were combined to construct neighborhood summary scores 
(NSS).  Briefly, for each census-derived indicator variable, a mean and standard 
deviation (SD) was calculated across the 48 census tracts represented in the study.  Z 
scores for each census tract were estimated for each of the census-derived variables by 
subtracting the overall mean (across all 48 census tracts) from each respective census 
tract and dividing by the SD.  The z scores for each of the six census-derived variables 
were then summed to construct the NSS.  The NSS for the 48 census tracts represented in 
the analytical sample ranged from -8.6 to 14.6 (see Table 3.2), with increasing NSS 
representing increasing neighborhood-level socioeconomic advantage.  Investigation of 
the distribution of these census-derived indicator variables in this study revealed skewed 
distributions for annual median household income and median value of occupied housing 
units.  As such, these variables were log transformed to approximate normal distributions, 
prior to constructing the NSS.  The constructed NSS was used as the primary indicator of 
neighborhood-level socioeconomic status in this study.  Additionally, log transformed 
median annual household income, percentage of poverty, and percentage of African 
American residential composition were also separately investigated to determine the 
potential influence of neighborhood context on quantitative blood pressure levels, blood 
pressure treatment, and blood pressure control.  Percentage of poverty was analyzed 
based on a constructed “poor neighborhood” variable, where a neighborhood was defined 
as poor if the percentage of poverty was greater than 25%, and more socioeconomically 
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advantaged otherwise.  Individual-level education was used as a measure of individual 
socioeconomic position. 
Statistical Analysis 
There is an inherent organizational structure that extends from biological 
components that comprise individuals to higher order groupings of individuals, such as 
families and neighborhoods, to even higher order classifications of such groupings, such 
as counties and states.  Within this natural organizational structure, a multitude of nesting 
structures arises.  In order to retain such data structures, multilevel analysis is a useful 
approach, as all available data is not collapsed to the individual-level or aggregated to the 
group-level.  In addition to retaining the multilevel structure of data, multilevel analysis 
permits simultaneous examination of the effects of individual- and group-level 
characteristics on individual-level outcomes, controls for correlations within groups by 
modeling intercepts (as well as coefficients) as random, and allows for examination of 
both inter-individual (within-group) and inter-group (between-group) variation [46].     
The analytic study sample had a natural hierarchical structure, with 948 subjects 
nested within 48 neighborhoods (defined as US Census 2000 tracts).  Given this data 
structure, multilevel models with a random intercept for each neighborhood were fit to 
examine the associations of neighborhood socioeconomic characteristics with continuous 
blood pressure measures, before and after adjustment for individual-level variables.   A 
series of model types were fit: models with a neighborhood-level variable only (i.e.-
unadjusted for individual-level variables); and models with both individual-level 
variables (including age, gender, BMI, type 2 diabetes, and education) and neighborhood-
level variables.  
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The first (individual) level of the model type including individual and 
neighborhood variables took the following form:  
 
Yij = β0j + β1jageij + β2jgenderij + β3jBMIij + β4jdiabetesij + β5jeducationij + εij,     (1)            
 
where Yij represents the predicted quantitative blood pressure outcome for the ith 
individual in the jth neighborhood; β0j is the intercept specific to the jth neighborhood; β1j, 
β2j, β3j, β4j , and β5j are the individual level, fixed effects of age, gender, BMI, diabetes, 
and education, respectively, that are specific to the jth neighborhood; and εij represents the 
individual level error for the ith individual in the jth neighborhood.  Individual-level errors 
are assumed to be independent and normally distributed (εij ~ N(0,σ2)).    
In the second (neighborhood) level, the coefficients listed in model equation (1) 
were modeled as a function of neighborhoods as follows: 
 
β0j = γ00 + γ01NSSj + Uoj 
            β1j = γ10 
β2j = γ20                                                                                     
β3j = γ30 
β4j = γ40 
β5j = γ50,                                                                                                                (2) 
where γ00 represents the common intercept across neighborhoods; γ01 is the fixed effect of 
the jth neighborhood socioeconomic summary score; γ10, γ20, γ30, γ40, γ50 are the common 
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slopes of age, gender, BMI, diabetes, and education, respectively, across neighborhoods;   
and Uoj is a macro error, assumed to be independent and normally distributed (Uoj ~ 
N(0,τ00)), that measures the unique deviation of each neighborhood intercept from the 
common intercept (γ00).  Applying substitution to combine model equations (1) and (2) 
yields the full multilevel model form: 
 
Yij = γ00 +γ01NSSj +γ10agej +γ20genderij +γ30BMIij + γ40diabetesij + γ50educationij + U0j+εij. 
 
A similar modeling strategy was employed to investigate the dichotomous 
hypertension outcomes (blood pressure combination treatment and blood pressure 
control).  Given the non-normal distribution of errors when considering dichotomous 
outcomes, logistic multilevel models were used to assess the odds of these hypertension 
outcomes.  Models were fitted in R (19) using the “lme” function for quantitative 
outcomes (SBP and DBP) and the “glmm” function for dichotomous outcomes (blood 
pressure combination treatment and blood pressure control). 
RESULTS 
 Select characteristics of the study sample are presented in Table 3.1.  The mean 
age of the subjects was 61 years of age.  Females comprised 73% of the subjects, while 
diabetics comprised 28%.  The subjects were generally obese (mean BMI = 32), and on 
average completed less than 11.5 years of education.   
 The median number of subjects per census tract was 11 (range, 5 – 92).  The 
distributions of the selected, US Census derived, neighborhood socioeconomic indicators, 
as well as the constructed NSS, are presented in Table 3.2.  The range of the NSS across 
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the 48 census tracts included in the present study was -8.6 to 14.6.  Compared to men, 
women had slightly lower mean NSS (p=0.035).  Individual education level demonstrated 
a highly significant, graded positive association with NSS, with subjects who had 
completed 16 or more years of education having NSS that were on average 4.05 points 
higher compared to those who had completed less than 12 years of education.  Compared 
to subjects that were between 20 and 39 years of age, subjects that were between 40 and 
59 had higher NSS, while subjects that were 60 or older had lower NSS, although neither 
of these differences reached statistical significance.  NSS did not differ by obesity or 
diabetes status.  The median percentage of individuals per census tract living in poverty 
was 30% (interquartile range, 21-37).  The median percentage of African American 
residents per census tract was 97% (interquartile range, 92-98), indicating that the racial 
composition across the 48 census tracts investigated was notably homogeneous. 
Neighborhood Socioeconomic Summary Score  
Table 3.3 presents the associations between NSS and SBP, before and after 
adjustment for individual-level variables.  Modeled continuously and unadjusted for 
individual level variables (Model 1), a one unit increase NSS was statistically 
significantly associated with a –0.40 mmHg decrease in SBP (p=0.012).  Upon additional 
adjustment for age, sex, BMI, and diabetes (Model 2), the association between NSS and 
SBP was attenuated and lost statistical significance.  Further adjustment for individual 
education (Model 3) attenuated the association even further and the association remained 
non-significant.  In a separate model, unadjusted for individual variables, that divided the 
NSS into quintiles, a graded increase in SBP was noted from the highest to lowest 
quintile.  Only the difference between the highest and lowest NSS quintiles reached 
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statistical significance, with subjects with NSS in the lowest quintile having SBP values 
6.85 mmHg higher than those with NSS in the highest quintile (p=0.007).  Upon 
additional adjustment for individual age, sex, BMI, and diabetes, the difference in SBP 
values between subjects in the highest and lowest NSS quintiles was attenuated (3.95 
mmHg higher in subjects in the lowest quintile), yet remained marginally significant 
(p=0.10).  This difference was attenuated even further with additional adjustment for 
individual education attainment, and resulted in no significant differences in SBP values 
for any of the NSS quintiles, relative to the highest quintile.  No statistically significant 
associations between NSS and DBP were detected before (Model 1, Table 3.4) or after 
(Models 2 and 3, Table 3.4) adjustment for individual-level variables.   
Table 3.5 presents the association of NSS with taking antihypertensive 
medications in combination therapy form (versus taking an antihypertensive medication 
as part of a monotherapy regimen).  After adjustment for age, sex, BMI, and diabetes 
(Model 2), NSS was statistically significantly associated with increased odds of taking 2 
or more antihypertensive medications that were prescribed to lower blood pressure 
(OR=1.03, p=0.044).  The magnitude and direction of this association remained upon 
additional adjustment for individual education (Model 3), however the association was 
only marginally statistically significant (OR=1.03, p=0.084).  No statistically significant 
associations were detected between NSS and blood pressure control, before (Model 1, 
Table 3.6) or after (Models 2 and 3, Table 3.6) adjustment for individual-level variables. 




Appendices 3.1-3.4 list the associations between (log) median household income 
and SBP, DBP, combination antihypertensive therapy, and blood pressure control, 
respectively.  Of note, increasing (log) median household income at the neighborhood 
level was statistically significantly associated with decreasing SBP, unadjusted (Model 1, 
Appendix 3.1) for individual-level variables (p=0.006).  Additional adjustment for 
individual-level variables (Models 2 and 3, Appendix 3.1) resulted in no statistically 
significant association of census tract level (log) median household income with SBP.  
Log-transformed median household income at the neighborhood level was also 
statistically significantly associated with increased odds of taking 2 or more prescribed 
antihypertensive medications to lower blood pressure, even after adjustment for age, sex, 
BMI, and diabetes (Model 2, Appendix 3.3), and additional adjustment for individual 
education (Model 3, Appendix 3.3).   
62% of the study subjects were residing in a neighborhood that was defined as 
“poor” (i.e.- a neighborhood with greater than 25 % poverty).  Table 3.7 presents the 
distributions of the types of antihypertensive medications prescribed by neighborhood of 
residence poverty status.  Appendices 3.5-3.8 list the associations between poor 
neighborhood of residence and SBP, DBP, combination antihypertensive therapy, and 
blood pressure control, respectively.  Poor neighborhood of residence was statistically 
significantly associated with increased SBP values (4.5 mmHg higher than those residing 
in more socioeconomically advantaged neighborhoods), before adjustment for individual-
level variables (Model 1, Appendix 3.5) (p=0.005).  This association was attenuated, yet 
remained marginally statistically significant (p=0.071) upon adjustment for age, sex, 
BMI, and diabetes (Model 2, Appendix 3.5), and attenuated further and fell out of 
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statistical significance (p=0.113) with the additional adjustment for individual education 
(Model 3, Appendix 3.5).   Although the distributions of the types of antihypertensive 
medications prescribed did not differ significantly by neighborhood poverty (Table 3.7), 
residing in a poor neighborhood was statistically significantly associated with a decreased 
odds of being treated with 2 or more prescribed antihypertensive medications to lower 
blood pressure, after adjustment for age, sex, BMI, and diabetes (Model 2, Appendix 3.7) 
(OR=0.71, p=0.019).  This association remained, even after additional adjustment for 
individual education (Model 3, Appendix 3.7) (OR=0.72, p = 0.03).  No statistically 
significant associations with quantitative DBP values or blood pressure control were 
detected in any models using either (log) median household income (Appendices 3.2 and 
3.4, respectively) or poor neighborhood of residence (Appendices 3.6 and 3.8, 
respectively) as the neighborhood-level independent variable.   
Models, unadjusted and adjusted for individual-level variables, were fit for all 
outcomes (SBP, DBP, combination therapy, and blood pressure control) using % African 
American residents per neighborhood as the neighborhood-level independent variable.  
This racial composition variable was investigated to explore the potential mechanisms, 
for example racial segregation, that may influence hypertension outcomes.  No 
statistically significant associations were detected between % African American residents 
per neighborhood and any of the hypertension outcomes, before or after adjustment for 
individual-level variables (results not shown).  Although racial composition may exert 
important contextual effects on hypertension outcomes through a variety of mechanisms, 
the high degree of racial homogeneity (97% African American) across the neighborhoods 
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investigated in this study limited the ability to thoroughly investigate such potential 
effects.  
DISCUSSION 
 The main aim of this study was to determine the extent to which neighborhood 
socioeconomic environment influenced blood pressure levels, as well as the probabilities 
of more aggressive antihypertensive pharmacological treatment and blood pressure 
control, after controlling for other influential individual-level factors.  Neighborhood 
socioeconomic context did not appear to be an important determinant of quantitative DBP 
levels or blood pressure control, before or after adjustment for potential confounding 
factors at the individual-level.  In analyses unadjusted for individual-level factors, lower 
NSS were associated with higher SBP levels.  However, this association was attenuated 
and lost statistical significance after adjustment for age, sex, co-morbid conditions, and 
education, suggesting that the potential influence of neighborhood socioeconomic context 
(as quantified by NSS) was confounded by individual-level factors.  Residing in 
neighborhoods marked by a high degree of poverty was associated with higher SBP 
levels, even after adjustment for individual age, sex and co-morbid conditions.  However, 
this association was also attenuated and lost statistical significance after adjusting for 
individual education.  While the contextual factors of neighborhood socioeconomic 
environments may indeed influence SBP levels, findings from this study seem to indicate 
that neighborhood compositional factors, including individual-level SES, may play more 




 The key significant finding in this study suggests that residing in a 
socioeconomically disadvantaged neighborhood may reduce the likelihood of being 
treated for hypertension more aggressively with multiple medications.  This finding was 
consistent regardless of the neighborhood-level variable used to capture neighborhood 
socioeconomic environments, and associations detected withstood individual-level 
adjustments, including individual SES.  Although this study did not investigate specific 
mechanisms that may help to explain this finding, several mechanisms (including health 
and social resource quality/availability, and logistics) are plausible and may warrant 
further investigation.   
 Availability of and access to quality health resources is often more limited for 
minority populations and individuals of lower SES (20-24).  Racial/ethnic and 
socioeconomic differences in prescription practices have been noted (25, 26), and 
treatment for hypertension has been shown to be less aggressive among African 
Americans (27).  The presence of quality clinics and pharmacies plays an obvious critical 
role in the delivery of adequate healthcare services and certain clinical services are less 
accessible in socioeconomically disadvantaged areas (28).  The importance of 
pharmacists and pharmacy services in effectively helping patients with essential 
hypertension manage their blood pressure has been recognized for decades (29).  
Socioeconomically disadvantaged areas may be less likely to have quality clinical and 
pharmacy services available, which could directly and negatively impact both the 
treatment and control of hypertension.  The lack of availability for certain medications in 
pharmacies located in poorer areas has been noted (30-32), which may restrict acquiring 
certain medications, even if they were prescribed.  Quality of care may be poorer in 
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socioeconomically disadvantaged, poor-resource areas (33, 34).  Proximity to wealthier 
areas with adequate health resources has been linked with insulin resistance (35), 
providing further evidence that the general lack of adequate health resources in poorer, 
underserved areas is a barrier to the delivery of health services and directly impacts 
health outcomes. 
 Strong social networks and support can positively influence a variety of health 
outcomes.  A recent study has shown that low SES is related to poor social networks and 
support (36), and the quality and quantity of such social resources are likely more limited 
in areas marked by socioeconomic disadvantage.  Numerous studies have shown that 
these social resources are important for hypertension treatment, treatment adherence, and 
control, particularly among African American populations (37-42).  Neighborhood social 
participation has also been linked to adherence with antihypertensive medications (43), 
and use of hormone replacement therapy among women (44).  In addition to many 
positive influences, including the promotion of positive health-related group norms, 
social networking and support provides an excellent platform for education and the 
exchange of information through group interaction.  As a result of missed opportunities to 
access and/or utilize social resources, hypertensive individuals living in 
socioeconomically disadvantaged areas may be less likely to receive the pertinent 
information (e.g. – the fact that multiple antihypertensive medications are often required 
to achieve and maintain target blood pressure), which could influence the likelihood of 
being treated with combination therapy regimens. 
 In addition to a variety of patient, medication, and disease specific factors, basic 
logistic issues have been reported as barriers to antihypertensive treatment (40).  A key 
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reported logistic issue is difficulty in reaching appointments at clinics and/or pharmacies.  
Effective blood pressure management commonly calls for antihypertensive medication 
adjustment and/or intensification, which require repeated provider contact through 
frequent clinical visits.  Low neighborhood SES may be associated with factors (such as 
inadequate public transportation) that restrict access to health (and social) care resources, 
which may negatively impact health outcomes. 
This study had several limitations that warrant discussion.  This study was based 
on cross-sectional data and residential histories of the subjects were unavailable.  As 
such, temporality, and hence causality, is difficult to establish, as a subject’s exposure to 
certain risk factors (e.g. - neighborhood of residence) at the time of enrollment may not 
equal exposure status when the disease process began and cumulative exposures may be 
more relevant.  The study findings pertain to hypertensive African American subjects 
from the tri-county Jackson, MS area and may not be generalizable to other racial/ethnic 
groups or African Americans in other geographic locations.  Baseline address information 
was not available for the non-Hispanic white GENOA subjects from Rochester, MN or 
the Mexican American subjects from Starr County, TX, which precluded the examination 
of neighborhood socioeconomic environment in other racial/ethnic groups from other US 
geographic locations.   
Census tracts were used as proxies for neighborhoods in this study.  Census tracts 
have been commonly employed as an area measure in health research and previous 
studies indicate that differences between census tracts and smaller area measures (block-
groups) are likely small (45).  Still, defining neighborhoods in this way has limitations, as 
the boundaries used to define them may not correspond with what people define/perceive 
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as their neighborhoods, and a proxy used to define the relevant area may, “grossly 
underspecify neighborhood contexts” (46).  Furthermore, census tracts may not be the 
most appropriate spatial scale relevant to hypertension (13).  Neighborhood SES was 
relatively homogeneous across the census tracts investigated, which may have limited the 
ability to detect neighborhood contextual associations. 
Data sparseness within certain census tracts may have biased the estimates of 
neighborhood socioeconomic indicators.  Unbalanced data and/or small group size (<2 
individuals per group) can lead to over-estimation of group-level random effects and 
standard errors of these effects, and this decrease in precision can result in decreased 
power to detect between-group variance.  Monte-Carlo simulation work has suggested 
that 5 observations per group are sufficient for robust estimation of group-level effects 
(47).  Accordingly, this study focused exclusively on subjects residing in neighborhoods 
with 5 or more subjects and a number of subjects were excluded for residing in 
neighborhoods with fewer than 5 subjects.  Subjects residing in neighborhoods outside of 
the tri-county Jackson, MS area were also excluded in order to create an analytic sample 
that was more homogeneous geographically.  If the neighborhood socioeconomic 
indicators related to the excluded subjects systematically differed from those of the 
subjects included in the study, neighborhood socioeconomic estimates may have been 
biased.   
The need to “identify the specific characteristics of residential environments that 
are deleterious to health” (48) has been recognized for decades.  This study used 
individual census-derived socioeconomic indicators, as well as constructed NSS, to 
capture the socioeconomic contexts of the neighborhoods investigated.  While such 
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measures have been used in “area-effects” research (3, 4, 49, 50), they may be poor 
proxies for the specific neighborhood mechanisms that are potentially relevant to health 
outcomes (51).  This study was limited in this regard, due to the absence of data on 
specific neighborhood features (e.g. - healthy food availability, built environment, access 
to quality health care, social cohesion, and stress) that may have more direct influences 
on the hypertension outcomes examined.   
 It should also be noted that the detected associations between the neighborhood 
socioeconomic context and SBP and combination treatment could simply reflect 
unmeasured individual-level socioeconomic characteristics rather than a contextual effect 
of the neighborhood (46, 52).  The potential for this possibility existed in this study, 
particularly since individual education was the only measure of individual-level SES 
investigated, as data on other individual-level measures of SES, such as income and 
health insurance, was not available.  Despite this, education is less prone to reverse 
causation and has commonly been used as an indicator of individual SES.  Given the 
potential for misspecification of models at one or more of the levels in the proposed 
analyses, effect estimates at each level should be interpreted with caution, as 
misspecification at one level can also impact estimates at another level.  The degree of 
familial correlation in the study sample overall, and within given neighborhoods, had the 
potential to influence the associations (or lack thereof) detected in this study.  Despite 
this, it was unlikely that neighborhood contextual effect estimates were seriously 
impacted by familial correlations, as the degree of within-neighborhood relatedness was 
small across the neighborhoods investigated (Appendix 3.9).  Furthermore, the inclusion 
of macro errors in the multilevel regression models theoretically allowed for correlations 
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within neighborhoods.  Still, the individual- and neighborhood-level estimates may have 
been impacted by unspecified familial factors.  Independent of neighborhood context, the 
familial aggregation of quantitative blood pressure levels and blood pressure control is 
examined and discussed further in Chapter 4.  
 The extent to which individuals from different neighborhoods are “exchangeable” 
and the inability to draw correct causal inferences about neighborhood effects in the 
absence of the exchangeability assumption has been discussed (46, 53). It has been noted 
that individuals ‘select’ into certain neighborhoods for a variety of reasons and such 
selection may lead to systematic differences in the compositional factors of individuals 
across neighborhoods.  If all relevant compositional factors are not controlled for, 
obtaining accurate estimates of "independent" neighborhood effects may be difficult (53).  
Furthermore, if there is little overlap between individual-level characteristics across 
neighborhoods, adjustment for these variables may bias the estimate of the neighborhood 
effect, as a result of extrapolation (46).  Without more complete data on individual-level 
SES characteristics, the extent to which this characteristic truly overlaps across 
neighborhoods was difficult to estimate in this study.   
 The degree to which neighborhood-level contexts exert “independent” effects on 
individual-level health outcomes may have important implications for public health 
efforts.  If neighborhood-level characteristics influence hypertension outcomes, apart 
from individual-level characteristics, interventions that are community focused and 
directed towards neighborhoods may prove beneficial in reducing blood pressure levels 
and increasing the levels of hypertension awareness, treatment, and control.   Accounting 
for group-level features may also be important in providing the context that determines 
the distribution of hypertension risk factors.  This study contributed to the “area effects” 
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research and detected the novel finding that neighborhood socioeconomic environment 
may influence hypertension treatment and treatment intensity.  Future research 
investigating specific characteristics of neighborhood socioeconomic environments, such 
as accessibility and proximity to clinics and pharmacies, may highlight areas that need to 
be addressed in order to improve adequate treatment and control among minority and 










Table 3.1.  Selected sample characteristics of the treated hypertensive African 
American GENOA study subjects included in the analyses (n=948) 
 Mean (SD) 
Age (years) 60.7 (9.0) 
  
Height (cm) 168.0 (8.6) 
  
Weight (kg) 89.9 (18.5) 
  
BMI (kg/m2) 31.9 (6.7) 
  
Education (years completed) 11.5 (3.6) 
  
SBP (mmHg) 139.8 (22.9) 
  
DBP (mmHg) 78.0 (12.5) 
  
Female (%) 73 
  
Type 2 diabetes (%) 28 
  
Blood pressure controlleda (%) 53 
  
Taking 2 or more antihypertensive medications (%) 53 
  
Residence within poor neighborhoodb 62 
Quantitative variables are presented as mean (SD); categorical variables as percentages.  aBlood 
pressure control defined as systolic blood pressure <140 mmHg and diastolic blood pressure <90 
mmHg.  bPoor neighborhood based on percentage of census tract poverty, where a neighborhood was 
defined as “poor” if the percentage of poverty was greater than 25%, and “more advantaged” 




Table 3.2. Descriptive statistics of US Census 2000 socioeconomic indicator variables and neighborhood 
socioeconomic summary scores across 48 census tracts within the tri-county Jackson, MS geographic region 
Variable Min Median Max Interquartile range 
Annual household income in 1999 (US dollars) 10510 25480 66350 18960, 30730 
     
Value of occupied housing units (US dollars) 29400 47200 133200 38500, 57300 
     
% of households receiving interest, dividend or net rental 
income 1 11 49 9, 18 
     
% of adults who completed high school 45 67 95 62, 77 
     
% of adults who completed college 5 17 49 11, 19 
     
% of adults in managerial or professional occupations 8 22 63 18, 26 
     
% poverty in 1999** 3 30 54 21, 37 
     
% African American 7 97 99 92, 98 
     
Neighborhood socioeconomic summary score* -8.6 -1.3 14.6 -4.3, 0.7 
* Neighborhood socioeconomic summary score derived from summation of calculated z-scores from the following indicators: Annual 
household income in 1999 (US dollars); Value of occupied housing units (US dollars); % of households receiving interest, dividend or net 
rental income; % of adults who completed high school; % of adults who completed college; % of adults in managerial or professional 






Table 3.3. Association of neighborhood socioeconomic score with systolic blood pressure in the African 
American GENOA subjects included in multilevel linear model analyses (n=948) 
 Model 1 Model 2  Model 3 
 Coef (CI) Coef (CI) Coef (CI) 






Individual-level variables    
     Age (years)  0.46** (0.31, 0.63) 0.42** (0.25, 0.59) 
     Gender    
          Male (ref)    
          Female  1.75 (-1.57, 5.07) 2.21 (-1.14, 5.56) 
     BMI (kg/m2)  -0.03 (-0.26, 0.20) -0.05 (-0.27, 0.18) 
     Type 2 diabetes    
          Absent (ref)    
          Present  5.79** (2.57, 9.03) 5.73** (2.51, 8.96) 
     Education (years completed)   -0.44** (-0.88, -0.01) 
Neighborhood level variable    
     NSSa -0.40** (-0.70, -0.10) -0.23 (-0.52, 0.07) -0.16 (-0.46, 0.15) 
All models fit using hierarchical linear models with random intercept components. 
Model 1 is unadjusted for individual factors. 
Model 2 adjusted for individual age, sex, BMI and diabetes. 
Model 3 adjusted for individual age, sex, BMI, diabetes, and education. 
aNSS = Neighborhood socioeconomic summary score. Neighborhood socioeconomic summary score derived from summation of calculated 
z-scores from the following indicators: Annual household income in 1999 (US dollars); Value of occupied housing units (US dollars); % of 
households receiving interest, dividend or net rental income; % of adults who completed high school; % of adults who completed college; % 




Table 3.4. Association of neighborhood socioeconomic score with diastolic blood pressure in the African 
American GENOA subjects included in multilevel linear model analyses (n=948) 
 Model 1 Model 2  Model 3 
 Coef (CI) Coef (CI) Coef (CI) 






Individual-level variables    
     Age (years)  -0.37** (-0.46, -0.29) -0.40** (-0.49, -0.31) 
     Gender    
          Male (ref)    
          Female  -2.99** (-4.78, -1.21) -2.75** (-4.55, -0.95) 
     BMI (kg/m2)  -0.11* (-0.23, 0.01) -0.12* (-0.24, 0.00) 
     Type 2 diabetes    
          Absent (ref)    
          Present  -1.10 (-2.84, 0.64) -1.13 (-2.87, 0.60) 
     Education (years completed)   -0.23* (-0.47, 0.00) 
Neighborhood level variable    
     NSSa 0.06 (-0.11, 0.23) -0.08 (-0.24, 0.08) -0.04 (-0.20, 0.12) 
All models fit using hierarchical linear models with random intercept components. 
Model 1 is unadjusted for individual factors. 
Model 2 adjusted for individual age, sex, BMI and diabetes. 
Model 3 adjusted for individual age, sex, BMI, diabetes, and education. 
aNSS = Neighborhood socioeconomic summary score. Neighborhood socioeconomic summary score derived from summation of calculated 
z-scores from the following indicators: Annual household income in 1999 (US dollars); Value of occupied housing units (US dollars); % of 
households receiving interest, dividend or net rental income; % of adults who completed high school; % of adults who completed college; % 







Table 3.5. Association of neighborhood socioeconomic score with combination antihypertensive 
pharmacologic treatment in the African American GENOA subjects included in multilevel logistic regression 
model analyses (n=948) 
 Model 1 Model 2  Model 3 
 OR (CI) OR (CI) OR (CI) 
Individual-level variables    
     Age (years)  1.02** (1.01, 1.04) 1.02** (1.01, 1.04) 
     Gender    
          Male (ref)    
          Female  0.81 (0.59, 1.09) 0.79 (0.58, 1.07) 
     BMI (kg/m2)  1.05** (1.03, 1.08) 1.06** (1.03, 1.08) 
     Type 2 diabetes    
          Absent (ref)    
          Present  1.49** (1.10, 2.01) 1.50** (1.11, 2.02) 
     Education (years completed)   1.02 (0.98, 1.07) 
Neighborhood level variable    
     NSSa 1.02 (0.99, 1.05) 1.03** (1.00, 1.06) 1.03* (1.00, 1.06) 
All models fit using hierarchical linear models with random intercept components. 
Model 1 is unadjusted for individual factors. 
Model 2 adjusted for individual age, sex, BMI and diabetes. 
Model 3 adjusted for individual age, sex, BMI, diabetes, and education. 
aNSS = Neighborhood socioeconomic summary score. Neighborhood socioeconomic summary score derived from summation of calculated 
z-scores from the following indicators: Annual household income in 1999 (US dollars); Value of occupied housing units (US dollars); % of 
households receiving interest, dividend or net rental income; % of adults who completed high school; % of adults who completed college; % 







Table 3.6. Association of neighborhood socioeconomic score with blood pressure controla in the African 
American GENOA subjects included in multilevel logistic regression model analyses (n=948) 
 Model 1 Model 2  Model 3 
 OR (CI) OR (CI) OR (CI) 
Individual-level variables    
     Age (years)  0.97** (0.96, 0.99) 0.97** (0.96, 0.99) 
     Gender    
          Male (ref)    
          Female  0.82 (0.61, 1.12) 0.80 (0.59, 1.09) 
     BMI (kg/m2)  1.01 (0.99, 1.03) 1.01 (0.99, 1.03) 
     Type 2 diabetes    
          Absent (ref)    
          Present  0.66** (0.49, 0.89) 0.67** (0.50, 0.90) 
     Education (years completed)   1.03 (0.99, 1.07) 
Neighborhood level variable    
     NSSb 1.02 (0.99, 1.04) 1.00 (0.98, 1.03) 1.00 (0.97, 1.03) 
All models fit using hierarchical linear models with random intercept components. 
Model 1 is unadjusted for individual factors. 
Model 2 adjusted for individual age, sex, BMI and diabetes. 
Model 3 adjusted for individual age, sex, BMI, diabetes, and education. 
aBlood pressure controlled to <140/90 mmHg.   bNSS = Neighborhood socioeconomic summary score. Neighborhood socioeconomic 
summary score derived from summation of calculated z-scores from the following indicators: Annual household income in 1999 (US 
dollars); Value of occupied housing units (US dollars); % of households receiving interest, dividend or net rental income; % of adults who 
completed high school; % of adults who completed college; % of adults in managerial or professional occupations. CI = estimated 95% 






Table 3.7.  Use of antihypertensive drug class by poor neighborhood of residencea 
 Poor neighborhood 
n= 584 
 More advantaged 
neighborhood 
n= 364 
Diuretic 57% (14%)  57% (13%) 
β-blocker 15% (3%)  17% (4%) 
Calcium channel blocker 33% (13%)  39% (13%) 
RAAS inhibitor 34% (10%)  37% (10%) 
Otherb 24% (9%)  21% (5%) 
Mono-therapy 49%  45% 
2 of the above drugs in combination 37%  41% 
3 or more of the above drugs in combination 14%  14% 
Top portion of table data represent percentages of aware and treated hypertensive subjects taking each respective antihypertensive drug class 
as part of any regimen.  Percentages using each class in mono-therapy form shown in parentheses;  aPoor neighborhood based on percentage 
of census tract poverty, where a neighborhood was defined as “poor” if the percentage of poverty was greater than 25%, and “more 
advantaged” otherwise.  bOther antihypertensive class includes alpha-blockers, vasodilators, sympatholytics, and study drugs. RAAS = renin 








Appendix 3.1. Association of log median household income with systolic blood pressure in the African 
American GENOA subjects included in multilevel linear model analyses (n=948) 
 Model 1 Model 2  Model 3 
 Coef (CI) Coef (CI) Coef (CI) 






Individual-level variables    
     Age (years)  0.47** (0.30, 0.63) 0.41** (0.24, 0.59) 
     Gender    
          Male (ref)    
          Female  1.67 (-1.66, 5.00) 2.14 (-1.21, 5.50) 
     BMI (kg/m2)  -0.03 (-0.26, 0.20) -0.05 (-0.28, 0.18) 
     Type 2 diabetes    
          Absent (ref)    
          Present  5.79** (2.56, 9.02) 5.73** (2.50, 8.95) 
     Education (years completed)   -0.44** (-0.87, 0.00) 
Neighborhood level variable    
     Log median household incomea -12.82** (-21.62, -4.01) -7.19 (-16.00, 1.61) -5.23 (-14.23, 3.78) 
All models fit using hierarchical linear models with random intercept components. 
Model 1 is unadjusted for individual factors. 
Model 2 adjusted for individual age, sex, BMI and diabetes. 
Model 3 adjusted for individual age, sex, BMI, diabetes, and education. 
aThe distribution of median household income by census tract in the study sample was right-skewed and was log-transformed to approximate 







Appendix 3.2. Association of log median household income with diastolic blood pressure in the African 
American GENOA subjects included in multilevel linear model analyses (n=948) 
 Model 1 Model 2  Model 3 
 Coef (CI) Coef (CI) Coef (CI) 




Individual-level variables    
     Age (years)  -0.37** (-0.46, -0.29) -0.40** (-0.49, -0.31) 
     Gender    
          Male (ref)    
          Female  -2.99** (-4.79, -1.20) -2.73** (-4.54, -0.93) 
     BMI (kg/m2)  -0.11* (-0.23, 0.01) -0.12* (-0.24, 0.00) 
     Type 2 diabetes    
          Absent (ref)    
          Present  -1.10 (-2.84, 0.64) -1.13 (-2.87, 0.60) 
     Education (years completed)   -0.24** (-0.47, -0.01) 
Neighborhood level variable    
     Log median household incomea 2.99 (-2.04, 8.02) -1.69 (-6.43, 3.05) -0.61 (-5.45, 4.24) 
All models fit using hierarchical linear models with random intercept components. 
Model 1 is unadjusted for individual factors. 
Model 2 adjusted for individual age, sex, BMI and diabetes. 
Model 3 adjusted for individual age, sex, BMI, diabetes, and education. 
aThe distribution of median household income by census tract in the study sample was right-skewed and was log-transformed to approximate 







Appendix 3.3. Association of log median household income with combination antihypertensive pharmacologic 
treatment in the African American GENOA subjects included in multilevel logistic regression model analyses 
(n=948) 
 Model 1 Model 2  Model 3 
 OR (CI) OR (CI) OR (CI) 
Individual-level variables    
     Age (years)  1.02** (1.01, 1.04) 1.02** (1.01, 1.04) 
     Gender    
          Male (ref)    
          Female  0.82 (0.60, 1.11) 0.80 (0.58, 1.09) 
     BMI (kg/m2)  1.06** (1.03, 1.08) 1.06** (1.03, 1.08) 
     Type 2 diabetes    
          Absent (ref)    
          Present  1.49** (1.10, 2.02) 1.50** (1.11, 2.02) 
     Education (years completed)   1.02 (0.98, 1.06) 
Neighborhood level variable    
     Log median household incomea 1.99* (0.91, 4.32) 2.75** (1.21, 6.24) 2.49** (1.08, 5.77) 
All models fit using hierarchical linear models with random intercept components. 
Model 1 is unadjusted for individual factors. 
Model 2 adjusted for individual age, sex, BMI and diabetes. 
Model 3 adjusted for individual age, sex, BMI, diabetes, and education. 
aThe distribution of median household income by census tract in the study sample was right-skewed and was log-transformed to approximate 







Appendix 3.4. Association of log median household income with blood pressure controla in the African 
American GENOA subjects included in multilevel logistic regression model analyses (n=948) 
 Model 1 Model 2  Model 3 
 OR (CI) OR (CI) OR (CI) 
Individual-level variables    
     Age (years)  0.97** (0.96, 0.99) 0.98** (0.96, 0.99) 
     Gender    
          Male (ref)    
          Female  0.83 (0.61, 1.13) 0.81 (0.59, 1.10) 
     BMI (kg/m2)  1.01 (0.99, 1.03) 1.01 (0.99, 1.03) 
     Type 2 diabetes    
          Absent (ref)    
          Present  0.66** (0.50, 0.89) 0.67** (0.50, 0.90) 
     Education (years completed)   1.03 (0.99, 1.07) 
Neighborhood level variable    
 Log median household incomeb 1.86 (0.86, 4.05) 1.32 (0.59, 2.96) 1.17 (0.51, 2.68) 
All models fit using hierarchical linear models with random intercept components. 
Model 1 is unadjusted for individual factors. 
Model 2 adjusted for individual age, sex, BMI and diabetes. 
Model 3 adjusted for individual age, sex, BMI, diabetes, and education. 
a Blood pressure controlled to <140/90 mmHg.   bThe distribution of median household income by census tract in the study sample was right-
skewed and was log-transformed to approximate a normal distribution. CI = estimated 95% confidence interval.  BMI = body mass index.  







Appendix 3.5. Association of poor neighborhood of residence with systolic blood pressure in the African 
American GENOA subjects included in multilevel linear model analyses (n=948) 
 Model 1 Model 2  Model 3 
 Coef (CI) Coef (CI) Coef (CI) 






Individual-level variables    
     Age (years)  0.46** (0.30, 0.62) 0.41** (0.24, 0.58) 
     Gender    
          Male (ref)    
          Female  1.71 (-1.61, 5.03) 2.15 (-1.19, 5.49) 
     BMI (kg/m2)  -0.04 (-0.27, 0.19) -0.06 (-0.28, 0.17) 
     Type 2 diabetes    
          Absent (ref)    
          Present  5.84** (2.61, 9.07) 5.76** (2.54, 8.99) 
     Education (years completed)   -0.45** (-0.88, -0.03) 
Neighborhood level variable    
     Poor neighborhooda 4.51** (1.53, 7.50) 2.81* (-0.17, 5.79) 2.46 (-0.53, 5.45) 
All models fit using hierarchical linear models with random intercept components. 
Model 1 is unadjusted for individual factors. 
Model 2 adjusted for individual age, sex, BMI and diabetes. 
Model 3 adjusted for individual age, sex, BMI, diabetes, and education. 
aPoor neighborhood based on percentage of census tract poverty, where a neighborhood was defined as “poor” if the percentage of poverty 






Appendix 3.6. Association of poor neighborhood of residence with diastolic blood pressure in the African 
American GENOA subjects included in multilevel linear model analyses (n=948) 
 Model 1 Model 2  Model 3 
 Coef (CI) Coef (CI) Coef (CI) 




Individual-level variables    
     Age (years)  -0.37** (-0.46, -0.28) -0.40** (-0.49, -0.31) 
     Gender    
          Male (ref)    
          Female  -2.95** (-4.74, -1.16) -2.70** (-4.50, -0.91) 
     BMI (kg/m2)  -0.11* (-0.23, 0.01) -0.12* (-0.24, 0.00) 
     Type 2 diabetes    
          Absent (ref)    
          Present  -1.09 (-2.83, 0.65) -1.13 (-2.87, 0.61) 
     Education (years completed)   -0.25** (-0.48, -0.02) 
Neighborhood level variable    
     Poor neighborhooda -1.31 (-2.95, 0.32) 0.19 (-1.41, 1.80) 0.00 (-1.61, 1.61) 
All models fit using hierarchical linear models with random intercept components. 
Model 1 is unadjusted for individual factors. 
Model 2 adjusted for individual age, sex, BMI and diabetes. 
Model 3 adjusted for individual age, sex, BMI, diabetes, and education. 
aPoor neighborhood based on percentage of census tract poverty, where a neighborhood was defined as “poor” if the percentage of poverty 






Appendix 3.7. Association of poor neighborhood of residence with combination antihypertensive 
pharmacologic treatment in the African American GENOA subjects included in multilevel logistic regression 
model analyses (n=948) 
 Model 1 Model 2  Model 3 
 OR (CI) OR (CI) OR (CI) 
Individual-level variables    
     Age (years)  1.02** (1.01, 1.04) 1.03** (1.01, 1.04) 
     Gender    
          Male (ref)    
          Female  0.81 (0.59, 1.10) 0.79 (0.58, 1.07) 
     BMI (kg/m2)  1.06** (1.03, 1.08) 1.06** (1.03, 1.08) 
     Type 2 diabetes    
          Absent (ref)    
          Present  1.48** (1.10, 2.00) 1.49** (1.10, 2.01) 
     Education (years completed)   1.03 (0.99, 1.07) 
Neighborhood level variable    
     Poor neighborhooda 0.80 (0.62, 1.04) 0.71** (0.54, 0.94) 0.72** (0.55, 0.96) 
All models fit using hierarchical linear models with random intercept components. 
Model 1 is unadjusted for individual factors. 
Model 2 adjusted for individual age, sex, BMI and diabetes. 
Model 3 adjusted for individual age, sex, BMI, diabetes, and education. 
aPoor neighborhood based on percentage of census tract poverty, where a neighborhood was defined as “poor” if the percentage of poverty 







Appendix 3.8. Association of poor neighborhood of residence with blood pressure controla in the African 
American GENOA subjects included in multilevel logistic regression model analyses (n=948) 
 Model 1 Model 2  Model 3 
 OR (CI) OR (CI) OR (CI) 
Individual-level variables    
     Age (years)  0.97** (0.96, 0.99) 0.98** (0.96, 0.99) 
     Gender    
          Male (ref)    
          Female  0.83 (0.61, 1.12) 0.81 (0.59, 1.10) 
     BMI (kg/m2)  1.01 (0.99, 1.03) 1.01 (0.99, 1.03) 
     Type 2 diabetes    
          Absent (ref)    
          Present  0.66* (0.49, 0.89) 0.67** (0.50, 0.90) 
     Education (years completed)   1.03 (0.99, 1.07) 
Neighborhood level variable    
     Poor neighborhoodb 0.81 (0.62, 1.05) 0.89 (0.68, 1.17) 0.91 (0.69, 1.20) 
All models fit using hierarchical linear models with random intercept components. 
Model 1 is unadjusted for individual factors. 
Model 2 adjusted for individual age, sex, BMI and diabetes. 
Model 3 adjusted for individual age, sex, BMI, diabetes, and education. 
aBlood pressure controlled to <140/90 mmHg.   bPoor neighborhood based on percentage of census tract poverty, where a neighborhood was 







Appendix 3.9.  Distribution of within-tract family relatedness across 48 census tracts in Jackson, MS tri-county 
area 
      
Census Tract 
ID 
# Subjects within 
tract 








28079000300 6 6 no 0 NA 
28049000400 5 5 no 0 NA 
28049000500 92 82 yes 8 13 
28049000600 88 81 yes 7 7 
28049000700 22 20 yes 2 2 
28049000800 55 54 yes 1 1 
28049000900 47 43 yes 4 4 
28049001000 37 36 yes 1 1 
28049001100 32 27 yes 4 6 
28049001200 26 23 yes 3 3 
28049001300 10 9 yes 1 1 
28049001700 7 6 yes 1 1 
28049001900 32 29 yes 3 3 
28049002000 13 13 no 0 NA 
28049002100 27 24 yes 2 4 
28049002200 9 9 no 0 NA 
28049002300 13 10 yes 1 6 
28049002400 42 40 yes 2 2 
28049002500 17 17 no 0 NA 
28049002600 9 9 no 0 NA 
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28049002700 8 8 no 0 NA 
28049003000 11 11 no 0 NA 
28049003100 12 10 yes 1 3 
28049003200 15 13 yes 2 2 
28049003300 9 8 yes 1 1 
28049003400 5 5 no 0 NA 
28049003700 5 4 yes 1 1 
28049010201 13 12 yes 1 1 
28049010202 69 66 yes 3 3 
28049010203 13 13 no 0 NA 
28049010301 44 36 yes 7 9 
28049010400 5 5 no 0 NA 
28049010500 27 18 yes 5 13 
28049010801 11 10 yes 1 1 
28049010802 12 11 yes 1 1 
28049010807 6 3 yes 1 6 
28049010901 10 9 yes 1 1 
28049010902 20 19 yes 1 1 
28049011001 7 7 no 0 NA 
28049011200 11 9 yes 2 2 
28089030101 5 4 yes 1 1 
28089030105 6 4 yes 1 3 
28089030302 5 5 no 0 NA 
28121020102 5 3 yes 2 2 
28120120204 8 8 no 0 NA 
28121020302 6 5 yes 1 1 
28121020600 5 5 no 0 NA 
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Investigating Familial Correlations of Quantitative Blood Pressure Measures and 
the Control of Hypertension  
 
INTRODUCTION 
In addition to a variety of individual-level sociodemographic, anthropometric, and 
lifestyle related factors, a positive family history of hypertension is a known risk for 
developing hypertension.  An estimated 30% of the general population variability in 
blood pressure is due to genetic heritability and 60% -70% of familial aggregation of 
blood pressure is due to common genetic backgrounds (1).  Genetic factors play key roles 
in inter-individual blood pressure variation and it is now widely accepted that essential 
hypertension results from complex interactions between genetic and environmental 
factors.  In addition to sharing similar genetic profiles, individuals within the same family 
share a number of environmental factors throughout the life course, such as physical 
environment, dietary habits, and health beliefs and practices.  These shared genetic and 
environmental factors may condition a common blood pressure level and, if evident, such 
between-family variation in blood pressure levels would suggest that genetic and 
environmental (or interactions between the two) effects could operate in ways that might 
influence individual blood pressure levels and/or the probability of hypertension control.  
Furthermore, evidence for familial clustering of blood pressure levels and hypertension 
outcomes may suggest that strategies directed for preventing hypertension should also be 
focused at the family level rather than on the individual level exclusively.  The goal of 
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this study was to estimate the degree of familial clustering of quantitative blood pressure 
values in hypertensive sibships, and to investigate the influence of blood pressure 
determinants at multiple levels on such clustering. 
METHODS 
Study Population 
 In 1995, the National Heart, Lung and Blood Institute (NHLBI) established The 
Family Blood Pressure Program (FBPP) to assess the genetic influence on inter-
individual blood pressure variation, hypertension, and hypertensive target organ damage. 
One of the four networks established by the NHLBI to meet this objective is the Genetic 
Epidemiology Network of Arteriopathy (GENOA).  GENOA field centers in Jackson, 
MS, Starr County, TX, and Rochester, MN recruited hypertensive African American, 
Hispanic, and non-Hispanic white sibships, respectively, for linkage and family-based 
association studies. Subject were diagnosed with hypertension if they had a previous 
clinical diagnosis of hypertension by a physician with current antihypertensive treatment 
or an average systolic blood pressure (SBP) >=140 mmHg and/or an average diastolic 
blood pressure (DBP) >=90 mmHg.  
In Rochester, MN and Jackson, MS, recruitment was restricted to sibships that 
contained a minimum of two individuals diagnosed with essential hypertension before the 
age of 60.  Once this criterion was met, the entire sibship was invited to participate in the 
study. As the prevalence of diabetes among Mexican-Americans is high, the Starr County 
recruitment was restricted to Mexican-American sibships containing at least two 
individuals diagnosed with type-2 diabetes (2).  Data was collected through personal 
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interviews, and physical and laboratory examinations.  The initial phase of the GENOA 
study took place from September 1995 through June 2001 (3).   
The primary analytic samples for the study presented here contained African 
American subject (n = 1123 from 598 sibships) and non-Hispanic white (n = 970 from 
528 sibships) hypertensive subjects that were both aware of their hypertension status and 
taking antihypertensive medication(s) to lower blood pressure.  Although a majority of 
the subjects in this cohort were diagnosed as hypertensive, a number of the sibship 
members invited to participate were identified as normotensive during the baseline 
examination and have been excluded from this analysis. Other exclusion criteria included 
secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent 
diabetes, or active malignancy.  A second analytic sample (described below) was created 
to investigate the influence of neighborhood poverty concordance among African 
American sibpairs on the sib-sib correlations of quantitative blood pressure values and 
the aggregation of blood pressure control.  Subjects sharing the same mother and father 
(assessed by concordance for both de-identified, parental personal identifier numbers) 
were assigned into respective sibpairs.  
Covariates 
Trained interviewers asked subjects standard questions on numerous factors, 
including sociodemographic, lifestyle and behavior, and cardiovascular health history. 
Age in years was assessed on the baseline examination date.  Education was defined as 
the total number of years of education completed.  Height was measured by stadiometer, 
weight by electronic balance, and body mass index (BMI) was calculated as weight in 
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kilograms divided by the square of height in meters. Diabetes was defined as having a 
fasting glucose level ≥ 126 mg/dL or currently being treated with insulin or oral agents.  
Blood Pressure Readings 
Blood pressure measurements were made with random zero sphygmomanometers 
and cuffs appropriate for arm size. Three readings were taken in the right arm after the 
subject rested in the sitting position for at least five minutes according to the Seventh 
report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC-7, 2003) guidelines (4).  The SBP and DBP 
values were determined by the first and fifth phase Korotkoff sounds, respectively, and 
the last two blood pressure readings were averaged for the analyses.  The diagnosis of 
hypertension was established based on blood pressure levels measured at the study visit 
(≥140/90 mmHg), or a prior diagnosis of hypertension and current treatment with 
antihypertensive medications.  
Blood Pressure Treatment and Antihypertensive Medications 
Based on lists of all antihypertensive medications available in the US each 
prescription antihypertensive drug recorded at the study visit was assigned a code number 
corresponding to the first 6 digits of the Medi-Span Generic Product Identifier. This 
number, which identifies pharmacologically equivalent drug products, was used to 
categorize agents with similar mechanisms of antihypertensive action.  
Conditional upon being hypertensive and aware of their hypertension status, 
subjects were considered to be “treated” if they answered yes to the questions, “Has 
medication ever been prescribed by a physician to lower your blood pressure?” and 
“During the last month, have you used any medication that was prescribed or 
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recommended by a physician?”  The number of prescribed antihypertensive medications 
was tallied for each subject.  Subjects taking only one prescribed antihypertensive 
medication were defined as being treated with a monotherapy regimen, while those 
taking two or more prescribed antihypertensive medications were defined as being treated 
with a combination therapy regimen. 
Blood Pressure Control 
Official guidelines propose that patients with a SBP ≥ 140 mmHg or DBP ≥ 90 
mmHg be considered as hypertensive (4, 5).  Accordingly, in this study controlled blood 
pressure was defined as SBP < 140 mmHg and DBP < 90 mmHg for a treated subject 
with hypertension. If either one, or both, of the two requirements were not met, a 
hypertensive subject’s blood pressure was defined as uncontrolled.  
Statistical Analysis 
Familial Clustering of Blood Pressure and Variance Partitioning 
 In order to account for the potential residual correlation between individual SBP 
and DBP levels that may arise from family factors that influence these quantitative 
measures, a multilevel analysis was conducted.  Given the hierarchical nature of the data, 
with individuals nested within sibships, regression analyses with individuals at the first 
level and sibships at the second level were performed.  Individual-level predictor 
variables included age, gender, body mass index (BMI), type 2 diabetes, and education.  
Age, BMI, and education were assessed as continuous variables.  Gender and diabetes 
status were treated as dichotomous variables, with male sex and non-diabetic set as the 
referent groups respectively.  Maternal and paternal histories of hypertension were 
investigated as family-level variables.  Both variables were dichotomized with negative 
 121 
 
history for hypertension set as the referent group.  To examine the extent to which 
individual SBP and DBP variation could be attributed to a higher contextual level, four 
models were fit, intra-class coefficients (ICC) were calculated, and variance proportional 
changes were estimated. 
 The first model did not include any explanatory variables and aimed to partition 
the total SBP (and separately DBP) variance (Vt) into individual (Vi) and sibship (Vs) 
components.  Doing so allows for the potential detection of a contextual effect that can be 
quantified as clustering of blood pressure values within sibships.  The first level of this 
model took the following form:  Yij = β0j+εij, where Yij represents the predicted blood 
pressure level for the ith individual in the jth sibship, the intercept (β0j) is constant within 
sibship and allowed to vary from one sibship to another, and the individual level errors 
are assumed to be independent and normally distributed (εij ~ N(0,σ2)).   In the second 
level, the intercept defined in the first level (β0j) is modeled as a function of sibships, such 
that β0j = γ00+Uoj, where γ00 represents the common intercept across sibships and Uoj is a 
macro error, assumed to be independent and normally distributed (Uoj ~ N(0,τ00)), that 
measures the unique deviation of each sibship intercept from the common intercept.  
Applying substitution yields the full form of the null model: Yij = γ00+Uoj +εij. 
The second model expanded the null model by including only individual-level 
fixed effects for age, gender, BMI, diabetes, and education.  This model took the 
following full form: Yij = γ00 + γ10Ageij  + γ20Genderij + γ30BMIij + γ40Diabetesij + 
γ50Education + U0j +εij .  The third model expanded the null model by including family-
level fixed effects for maternal and paternal history of hypertension and took the 
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following full form: Yij = γ00 + γ01Maternal history of hypertensionj + γ02Paternal history 
of hypertensionj + U0j +εij.  The fourth model combined the second and third models to 
include fixed effects at both the individual and family levels.  This model took the 
following full form: Yij = γ00 + γ01Maternal history of hypertensionj + γ02Paternal history 
of hypertensionj + γ10Ageij  + γ20Genderij + γ30BMIij + γ40Diabetesij + γ50Education + U0j 
+εij . 
In the null model (i.e. – random intercepts model), the variance partition 
coefficient (VPC) is equivalent to the (ICC):  VPC = (Vs/(Vs+Vi)) * 100 = ICC = (τ00/(σ2 
+ τ00)) *100, where τ00 equals the variance of the macro error Uoj,, and σ2 equals the 
variance of the individual level error εij.  This coefficient measures the percent of the total 
inter-individual variability in blood pressure that is between sibships and is a general 
measure of clustering of individual blood pressure in sibships.  ICCs were calculated for 
the null models to establish a general measure of the extent of familial clustering of blood 
pressure.  ICCs were also calculated for models 2-4 and each estimate was compared to 
those derived from the null models.  Estimates of proportional variance explained were 
calculated and the degree to which the proportions of total variance in individual blood 
pressure levels that were within and between sibships (i.e.- families) changed as variables 
were added at both the individual- and family-levels was assessed.  To assess the 
reduction in within-family variance, the following formula was applied: (σ21- σ22) / σ21, 
with σ21 derived from model 1 and σ22 derived from models 2-4 separately.  Similarly, the 
reduction in between-family variance was assessed using the following formula: (τ00 1- τ00 
2) / τ00 1, with τ00 1 derived from model 1 and τ00 2 derived from models 2-4 separately.  
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Comparing models 1 and 2 yielded estimates of the proportions of both variance 
components explained due to individual-level factors.  Comparing models 1 and 3 
yielded an estimate of the proportion of between-family variance explained due to family 
specific, parental histories of hypertension.  Comparing models 1 and 4 allowed for the 
examination of how both variance components changed due to the addition of individual 
and family-level predictor variables. 
 To assess the odds and the magnitude of variation between families in 
hypertension control, an unconditional logistic multilevel model was fit.  This model took 
the full form: Log odds (blood pressure controlij) = γ00 +U0j.  The estimate for the 
resulting γ00 coefficient was interpreted as the log odds of hypertension control across 
families, while the variance of U0j (τ00), was interpreted as the variance between families 
in family-average log odds of hypertension control.  Exponentiation of the estimate for 
γ00 yielded an estimate of the odds of hypertension control and an estimate for the 
corresponding probability was determined by the following formula: 1 / (1 + e(-logit)).  A 
95% confidence interval around the odds of hypertension control across families was 
determined by the following formula: γ00 ± 1.96*√τ00.  Transforming these upper- and 
lower-bound odds into probabilities yielded a range of hypertension control probabilities 
across families. 
Sib-Sib Blood Pressure Correlations by Neighborhood Poverty 
 To investigate the potential influence of neighborhood socioeconomic 
environment on sib-sib quantitative blood pressure correlations and aggregation of blood 
pressure control, a separate sibpair analysis, stratified by neighborhood poverty, was 
performed.  As highlighted in Chapter 3, baseline address information was only available 
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for the African American GENOA subjects.  As such, the sibpair analyses were restricted 
to African American sibpairs.  The analytic sample consisted of full sibpairs only.  All 
subjects in the analytic sample were hypertensive, aware of their hypertension status, 
currently taking prescribed antihypertensive medication(s) to lower blood pressure, had 
baseline address information that was successfully geo-coded to the census tract level and 
linked to tract level socioeconomic indicator data, and had at least one full sibling that 
met the same criteria.  The final analytic sibpair sample contained 969 subjects from 387 
sibships.  A total of 871 possible sibpairs were analyzed.   As in Chapter 3, 
neighborhoods were defined as poor if the percentage of poverty within a given census 
tract exceeded 25%, and more socioeconomically advantaged otherwise. For all possible 
sibpairs, concordance of neighborhood poverty was determined (i.e. - both residing in 
poor neighborhood(s), one residing in poor neighborhood, neither residing in poor 
neighborhood).  Pearson’s correlation coefficients (unadjusted, and age-sex adjusted) 
were estimated to assess sib-sib correlations of SBP and DBP levels by neighborhood 
concordance.  Odds ratios (OR) (odds that siblings were concordant for blood pressure 
control divided by the odds that they were discordant) were calculated as a measure of 
familial aggregation blood pressure control by neighborhood concordance.  All statistical 
analyses were performed in the R statistical package (6).  An alpha-level of 0.05 was 
used to determine statistical significance. 
RESULTS 
Systolic Blood Pressure 
Variance components and calculated ICCs for models 1 – 4, and the fixed effects 
from the full model (Model 4) for the African American cohort are illustrated in Table 
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4.1.  The ICC from the null model (Table 4.1, Null model) suggests moderate clustering 
of SBP within families, as approximately 13.5% of the inter-individual variability in SBP 
was at the family-level.  The addition of only individual-level variables to the null model 
led to a 3.6% reduction in within-family variability and a 22.3% reduction in the 
between-family variability.  In general, the addition of group-level variables does not 
impact within-group variability, but can have an impact on between-group variability.  
The addition of only family-level variables to the null model did not lead to reductions in 
between-family variability (nor within-family variability as expected).  The reductions in 
both types of variability due to the addition of both individual- and family-level variables 
to the null model were essentially the same as the reductions due to the addition of 
individual-level variables only, although the addition of family-level variables after 
accounting for individual-level variables (model 4) led to a slightly higher overall 
reduction (23.4%) in the between-family variability.  The average SBP across families 
(i.e. - common intercept as assessed from null model) was 139.83 mmHg.  In the 
comprehensive model including individual- and family-level variables (Table 4.1, Model 
4), increasing age, female sex, diabetes, and both parental histories of hypertension were 
all associated with increases in SBP.  Conversely, increasing levels of education was 
associated with decreases in SBP.  Age, diabetes, and education use all reached statistical 
significance.   
Variance components and calculated ICCs for models 1 – 4, and the fixed effects 
from the full model (Model 4) for the non-Hispanic white cohort are illustrated in Table 
4.2.  The ICC from the null model (Table 4.2, Null model) indicates that approximately 
16.8% of the inter-individual variability in SBP was at the family-level.  Although still 
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moderate, this degree of familial clustering was slightly higher compared to the African 
American cohort.  The addition of only individual-level variables to the null model led to 
a 4.8% reduction in within-family variability and a 26.1% reduction in the between-
family variability.  The addition of only family-level variables to the null model led to a 
small 1% reduction in the between-family variability (and no reduction in the within-
family variability as group-level variables will only reduce between-group variability).  
The addition of both individual- and family-level variables to the null model led to a 
5.1% reduction in within-family variability and a 26.8% reduction in the between-family 
variability. The average SBP across families was 135.90 mmHg, slightly lower than that 
of the African American cohort.  In the comprehensive model including individual- and 
family-level variables (Table 4.2, Model 4), increasing age, BMI, diabetes, and maternal 
history of hypertension were all associated with increases in SBP, while female sex and 
paternal history of hypertension were associated with decreases in SBP. Age, BMI, and 
maternal history of hypertension all reached statistical significance.   
Diastolic Blood Pressure 
Variance components and calculated ICCs for models 1 – 4, and the fixed effects 
from the full model (Model 4) for the African American cohort are illustrated in Table 
4.3.  Approximately 20% of the inter-individual variability in DBP was at the family-
level (ICC from null model (Table 4.3, Null model) = 19.7).  The addition of only 
individual-level variables to the null model led to a 3.6% reduction in within-family 
variability and a 27.0% reduction in the between-family variability in individual DBP.  
The addition of only family-level variables to the null model led to a 6.0% reduction in 
between-family variability and the fixed effect for maternal history of hypertension was 
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statistically significant. The addition of both individual- and family-level variables to the 
null model led to a 3.3% reduction in within-family variability and a 27.9% reduction in 
the between-family variability. The average DBP across families was 78.21 mmHg.  In 
the comprehensive model including individual- and family-level variables (Table 4.3 
Model 4), only parental histories of hypertension were associated with increases in DBP.  
Conversely, all individual-level fixed effects (age, female sex, BMI, diabetes, and 
education) were associated with decreases in DBP.  The age, female sex, and education 
associations were statistically significant, and the BMI association was marginally 
significant.  
Variance components and calculated ICCs for models 1 – 4, and the fixed effects 
from the full model (Model 4) for the non-Hispanic white cohort are illustrated in Table 
4.4.  As in the African American cohort, approximately 20% of the inter-individual 
variability in DBP was at the family-level (ICC from null model (Table 4.4, Null model) 
= 20.4).  The addition of only individual-level variables to the null model led to a 9.5% 
reduction in within-family variability and a 22.7% reduction in the between-family 
variability in individual DBP.  The addition of only family-level variables to the null 
model did not lead to reductions in variable components, although the fixed effect for 
maternal history of hypertension was statistically significant. The addition of both 
individual- and family-level variables (Table 4.4, Model 4) to the null model led to a 
10.6% reduction in within-family variability and a 21.3% reduction in the between-
family variability.  The average DBP across families was 79.06 mmHg. Maternal history 
of hypertension was associated increased DBP.  Conversely, increasing age, female sex, 
diabetes, and paternal history of hypertension were all associated with decreases in DBP. 
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The age, female sex, diabetes and maternal history of hypertension associations were 
statistically significant.   
Blood Pressure Control 
 Among African Americans, the log odds of hypertension control across families 
was 0.10, corresponding to an odds of 1.11 and a probability of 0.52 (95% confidence 
interval (CI), 0.24, 0.80).  Among non-Hispanic whites, the log odds of hypertension 
control across families was 0.47, corresponding to an odds of 1.60 and a probability of 
0.62 (95% CI, 0.23, 0.90). 
Blood Pressure Correlations and Aggregation of Blood Pressure Control by 
Neighborhood Poverty 
 Descriptive statistics for the hypertensive African American subjects (n=960) 
included in the sibpair by neighborhood poverty analyses are presented in Table 4.5.  
Table 4.6 presents the sib-sib correlations of SBP and DBP.  Of the total 871 possible 
sibpairs, 313 were concordant for residing in poor neighborhoods, 365 were discordant 
for poor neighborhood of residence, and 193 were concordant for residing in more 
socioeconomically advantaged neighborhoods.  In the pooled sample of all 871 possible 
African American sibpairs, significant sib-sib correlations were detected for both SBP (r 
= 0.12, p < 0.001) and DBP (r = 0.14, p < 0.001).  Examination of the sib-sib correlations 
of quantitative blood pressure values by poor neighborhood of residence concordance 
revealed that SBP values among sibpairs in which both siblings resided in poor 
neighborhoods were statistically significant and more strongly correlated (r = 0.20, p < 
0.001).  Similarly, statistically significant sib-sib correlations of DBP values were 
detected among sibpairs in which one or both siblings resided in poor neighborhoods.  
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Conversely, sib-sib correlations of quantitative blood pressure values were not 
significantly correlated among sibpairs in which both siblings resided in more 
socioeconomically advantaged neighborhoods.  There was statistically significant 
familial aggregation (sib-sib concordance) of blood pressure control among sibpairs in 
which both siblings resided in poor neighborhoods (OR = 1.84; 95% CI: 1.17, 2.90), but 
not among sibpairs in which only one (OR = 1.23; 95% CI: 0.81,1.86) or neither (OR = 
0.99; 95% CI: 0.56, 1.75) sibling resided in poor neighborhoods.  
DISCUSSION 
Family aggregation of blood pressure is well recognized (1) and has been 
documented in numerous populations (2, 7, 8).  Results from this study provided further 
evidence of moderate familial aggregation of quantitative blood pressure levels in both 
African Americans non-Hispanic Whites.  For both racial/ethnic groups, the addition of 
individual-level variables led to significant reductions in within- and between-family 
variability in individual SBP and DBP, and expected relationships were detected for the 
individual-level fixed effects of age, BMI, and diabetes.  There was also evidence of an 
inverse relationship between education and SBP (as reported in Chapter 2) and DBP 
among African Americans, after control for other individual and familial factors.  
Furthermore, individual-level education explained approximately 1% of the between-
family variability in SBP.   Maternal histories of hypertension did explain a moderate 
proportion of the between-family variability in SBP and DBP among non-Hispanic 
whites.  Other studies have demonstrated similar associations between maternal history of 
hypertension and offspring blood pressure levels, and familial aggregation of other 
factors known to influence blood pressure (e.g. – dietary intake and physical activity) 
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may be stronger between mothers and their offspring (7).  Despite this, parental history of 
hypertension does not seem to confer strong contextual effects that condition common 
blood pressure levels in non-Hispanic whites or African American families.  The addition 
of individual- and family-level fixed effects reduced, but did not explain all of, 
quantitative blood pressure clustering among sibships in each racial/ethnic group.  This 
likely reflects residual confounding that stems from the omission of potentially important 
predictor variables at one or multiple levels.  
 Previous research on the overall GENOA hypertensive sibships sample detected 
evidence of familial aggregation of hypertension treatment and control (2).  Consistent 
with these earlier findings, unconditional (null) multilevel models fit in this study 
indicated that hypertension control among treated hypertensives aggregates in non-
Hispanic white and African American families.  While the range of probabilities of 
hypertension control were comparably wide for both ethnic groups, the odds and 
probability of hypertension control were greater in non-Hispanic White families, 
compared to African American families (as expected and previously reported in Chapter 
2).  Daniels et al. suggest that the familial aggregation of hypertension treatment and 
control are likely explained by a combination of shared environmental and genetic 
influences, and further point out that, “numerous environmental factors are indexed by 
socioeconomic status, which aggregates in families and correlates inversely with blood 
pressure levels (2).”  Acknowledging this, the study presented here extended the previous 
research on familial aggregation of blood pressure control in the GENOA cohort by 
examining the degree to which neighborhood socioeconomic environment concordance 
among sibs shaped familial aggregation of blood pressure control.  In general, sib-sib 
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correlations of quantitative blood pressure values and familial aggregation of blood 
pressure control were detected among sibpairs in which both siblings resided in poor 
neighborhoods.  These findings represent a possible cross level interaction in which the 
degree of familial similarities in blood pressure outcomes is dependent (at least in part) 
on shared socioeconomic environmental context.  
The present study had several limitations. First, the cross-sectional nature of the 
study limited the ability to make causal inferences.  Second, selection bias may have been 
present in this study, as only families with at least two sibs with essential hypertension 
diagnosed before age 60 were included.  Third, if the individual-level and/or group-level 
models were misspecified, estimates at both levels may have been biased.  This brief 
examination of familial blood pressure correlations was particularly susceptible to 
misspecification of the family-level models, since parental histories of hypertension were 
the only variables modeled at this level and other unavailable family-level variables may 
have demonstrated contextual familial effects that could potentially condition common 
blood pressure levels among families.  Furthermore, the detected moderate contextual 
effect of maternal history for hypertension among non-Hispanic whites may simply 
reflect unmeasured individual-level characteristics rather than a common familial effect.  
The examination of the influence of neighborhood socioeconomic environment was 
specifically carried out among the African American GENOA study subjects from 48 
neighborhoods in the Jackson, MS tri-county area.  As such, these particular findings may 
not be generalizable to other racial/ethnic groups, or to other individuals (regardless of 




In conclusion, this analysis provided new insights into familial aggregation of 
blood pressure outcomes, by specifically examining the influence of numerous factors 
defined at multiple levels (individual, family, and neighborhood).  Significant findings 
across these levels suggest that combinations of family- and community-based 
interventions may be successful in the prevention and control of hypertension.  
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Table 4.1.  Familial correlation of systolic blood pressure in GENOA African Americans (n=1123) 
Covariance parameter estimates         
Estimate  Null model  Model 2  Model 3  Model 4  
τ00  69.65  54.14  70.31  53.39 
σ2  444.81  429.00  445.03  430.08 
ICC *100%  13.54%  11.21%  13.64%  11.04% 
Fixed effect estimates from Model 4         
Effect    Estimate  SE  p-value 
Intercept    116.68  7.41  <0.0001 
Individual-level         
Age (years)    0.43  0.08  <0.0001 
Gender         
   Male (ref)         
   Female    2.46  1.55  0.1131 
BMI (kg/m2)    -0.01  0.11  0.9320 
Diabetes         
   No (ref)         
   Yes    5.56  1.50  0.0002 
Education (years)    -0.58  0.20  0.0041 
Family-level         
Paternal history of hypertension         
   No (ref)         
   Yes    1.08  1.44  0.4540 
Maternal history of hypertension         
   No (ref)         
   Yes    0.84  1.44  0.5635 
Null model – random intercept only model; Model 2 – includes all individual-level variables only; Model 3 includes all family-level 
variables only; Model 4 includes all individual- and family-level variables. τ00  = macro error variance. σ2 = individual error variance.  ICC = 







Table 4.2.  Familial correlation of systolic blood pressure in GENOA non-Hispanic whites (n=970) 
Covariance parameter estimates         
Estimate  Null model  Model 2  Model 3  Model 4  
τ00  45.19  33.40  44.87  33.07 
σ2  224.26  213.42  223.81  212.91 
ICC *100%  16.77%  13.53%  16.70%  13.44% 
Fixed effect estimates from Model 4         
Effect    Estimate  SE  p-value 
Intercept    99.49  6.16  <0.0001 
Individual-level         
Age (years)    0.51  0.06  <0.0001 
Gender         
   Male (ref)         
   Female    -0.35  1.02  0.7353 
BMI (kg/m2)    0.17  0.08  0.0329 
Diabetes         
   No (ref)         
   Yes    2.04  1.56  0.1898 
Education (years)    0.02  0.23  0.9413 
Family-level         
Paternal history of hypertension         
   No (ref)         
   Yes    -0.13  1.08  0.9061 
Maternal history of hypertension         
   No (ref)         
   Yes    2.55  1.13  0.0243 
Null model – random intercept only model; Model 2 – includes all individual-level variables only; Model 3 includes all family-level 
variables only; Model 4 includes all individual- and family-level variables. τ00  = macro error variance. σ2 = individual error variance.  ICC = 
intraclass correlation coefficient.  BMI = body mass index.  Bold type indicates p<0.05. 
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Table 4.3.  Familial correlation of diastolic blood pressure in GENOA African Americans (n=1123) 
Covariance parameter estimates         
Estimate  Null model  Model 2  Model 3  Model 4  
τ00  30.68  22.41  28.86  22.14 
σ2  125.46  120.97  126.48  121.29 
ICC *100%  19.65%  15.63%  18.58%  15.44% 
Fixed effect estimates from Model 4         
Effect    Estimate  SE  p-value 
Intercept    108.49  4.06  <0.0001 
Individual-level         
Age (years)    -0.38  0.04  <0.0001 
Gender         
   Male (ref)         
   Female    -2.41  0.84  0.0044 
BMI (kg/m2)    -0.11  0.06  0.0624 
Diabetes         
   No (ref)         
   Yes    -0.62  0.82  0.4473 
Education (years)    -0.23  0.11  0.0367 
Family-level         
Paternal history of hypertension         
   No (ref)         
   Yes    0.26  0.79  0.7465 
Maternal history of hypertension         
   No (ref)         
   Yes    0.77  0.79  0.3304 
Null model – random intercept only model; Model 2 – includes all individual-level variables only; Model 3 includes all family-level 
variables only; Model 4 includes all individual- and family-level variables. τ00  = macro error variance. σ2 = individual error variance.  ICC 





Table 4.4.  Familial correlation of diastolic blood pressure in GENOA non-Hispanic whites (n=970) 
Covariance parameter estimates         
Estimate  Null model  Model 2  Model 3  Model 4  
τ00  18.05  13.96  18.20  14.20 
σ2  70.36  63.66  69.89  62.93 
ICC *100%  20.42%  17.99%  20.66%  18.41% 
Fixed effect estimates from Model 4         
Effect    Estimate  SE  p-value 
Intercept    96.13  3.46  <0.0001 
Individual-level         
Age (years)    -0.28  0.03  <0.0001 
Gender         
   Male (ref)         
   Female    -3.96  0.57  <0.0001 
BMI (kg/m2)    0.00  0.05  0.9356 
Diabetes         
   No (ref)         
   Yes    -2.03  0.87  0.0195 
Education (years)    0.02  0.13  0.8512 
Family-level         
Paternal history of hypertension         
   No (ref)         
   Yes    -0.64  0.61  0.2903 
Maternal history of hypertension         
   No (ref)         
   Yes    1.74  0.64  0.0066 
Null model – random intercept only model; Model 2 – includes all individual-level variables only; Model 3 includes all family-level 
variables only; Model 4 includes all individual- and family-level variables. τ00  = macro error variance. σ2 = individual error variance.  ICC = 




Table 4.5.  Selected sample characteristics of the treated hypertensive African 
American GENOA study subjects included in the sibpair by neighborhood 
poverty analyses (n=960 from 871 sibpairs) 
Age (years) 60.3 (9.1) 
  
BMI (kg/m2) 31.4 (6.6) 
  
Education (years completed) 11.5 (3.6) 
  
SBP (mmHg) 141.7 (22.4) 
  
DBP (mmHg) 79.1 (12.8) 
  
Female (%) 71 
  
Type 2 diabetes (%) 26 
  
BP controlleda (%) 46 
  
Residence within poor neighborhoodb 58 
Quantitative variables are presented as mean (SD); categorical variables as percentages.  aBlood 
pressure control defined as systolic blood pressure <140 mmHg and diastolic blood pressure <90 
mmHg.  bPoor neighborhood based on percentage of census tract poverty, where a neighborhood was 
defined as “poor” if the percentage of poverty was greater than 25%, and “more advantaged” 
otherwise. BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; 






Table 4.6. Blood pressure correlations between GENOA African American sibpairs (n=871) by neighborhood 
poverty concordance 
 
Systolic blood pressure Unadjusted Age and sex adjusted 
 # of Sib Pairs (# of Families) r p-value r p-value 
Both Sibs in Poor* Neighborhoods 313 (181) 0.206 0.0002 0.183 0.0012 
One Sib in Poor* Neighborhood 365 (197) 0.045 0.3884 0.022 0.6723 
Neither Sib in Poor* Neighborhood 193 (116) 0.101 0.1621 0.051 0.4757 
Total 871 (387) 0.121 0.0003 0.088 0.0090 
 
Diastolic blood pressure Unadjusted Age and sex adjusted 
 # of Sib Pairs (# of Families) r p-value r p-value 
Both Sibs in Poor* Neighborhoods 313 (181) 0.140 0.0133 0.107 0.0594 
One Sib in Poor* Neighborhood 365 (197) 0.187 0.0003 0.133 0.0112 
Neither Sib in Poor* Neighborhood 193 (116) 0.036 0.6233 -0.028 0.7031 
Total 871 (387) 0.137 0.0001 0.088 0.0094 
*Poor Neighborhoods defined as census tracts with >25% poverty, where percent poverty is defined as the % of individuals living below the 













Appendix 4.1.  Calculations for familial aggregation of blood pressure control by 











Both Sibs Residing in Poor Neighborhoods
BP Controlled BP Not Controlled
Sib2 BP Controlled 70 61
BP Not Controlled 70 112
OR = (70*112)/(61*70) = 1.84
SE (log OR) = sqrt ((1/70)+(1/61)+(1/70)+(1/112)) = 0.2321496
Lower 95 % CI = 1.84 * exp - [1.96*0.2321496] = 1.17
Upper 95% CI = 1.84 * exp[1.96*0.2321496] = 2.90
One Sib Residing in Poor Neighborhood
BP Controlled BP Not Controlled
Sib2 BP Controlled 86 79
BP Not Controlled 94 106
OR = (86*106)/(79*94) = 1.23
SE (log OR) = sqrt ((1/86)+(1/79)+(1/94)+(1/106)) = 0.2106143
Lower 95 % CI = 1.23 * exp - [1.96*0.2106143] = 0.81
Upper 95% CI = 1.23 * exp[1.96*0.2106143] = 1.86
Neither Sib Residing in Poor Neighborhood
BP Controlled BP Not Controlled
Sib2 BP Controlled 40 50
BP Not Controlled 46 57
Sib1
Sib1
OR = (40*57)/(50*46) = 0.99
SE (log OR) = sqrt ((1/40)+(1/50)+(1/46)+(1/57)) = 0.2903153
Lower 95 % CI = 0.99 * exp - [1.96*0.2903153] = 0.56
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Interactions Between Cell Adhesion Molecule Genes and Antihypertensive Drug 
Therapies in Determining Systolic Blood Pressure in Hypertensive Subjects 
 
INTRODUCTION 
Hypertension affects more than 65 million adults in the United States (US) and is 
the most common disease for which adults seek medical attention (1, 2).  Uncontrolled 
hypertension is an established risk factor for cardiovascular, cerebrovascular, and renal 
disease morbidity and mortality.  In addition to lifestyle changes and behavior 
modifications, a variety of antihypertensive medications are commonly used as 
monotherapies or in combination to attempt to control hypertension.  Accordingly, 
antihypertensive medications are among the most frequently used medications in the US.  
Despite this, only slightly more than half of subjects with hypertension in the US are 
treated pharmacologically for their condition and roughly two-thirds of those treated have 
their blood pressure adequately controlled (3). A contributing factor to this lack of blood 
pressure control is that hypertensives respond heterogeneously to antihypertensive 
therapies.  In addition to various environmental influences, genetic variation that alters 
the structure, configuration, or quantity of any of the proteins involved in 
pharmacokinetic or pharmacodynamic mechanisms may contribute to interindividual 
variation in drug response (4).  The goal of identifying genetic variations that influence 
these mechanisms regulating blood pressure response to antihypertensive therapies is to 
use the identified genetic predictors of response as a benchmark for ascertaining a given 
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drug’s efficacy and toxicity prior to administering the drug to patients.  If successful, the 
findings from antihypertensive phamacogenetic (and emerging pharmacogenomic) 
research could be used to tailor specific drug interventions based on an individual’s 
biological profile.  This could have major public health and economic impacts by 
improving the effectiveness of therapy, while concurrently reducing the occurrence of 
adverse events and clinical management periods. 
Genetic and epidemiological research efforts, sponsored by the National Heart 
Lung and Blood Institute (NHLBI), have been established to identify genes influencing 
inter-individual blood pressure variation. Genomic regions that potentially influence 
blood pressure variation have been identified on several chromosomes through a variety 
of linkage analyses. Genome-wide linkage analyses have identified evidence of linkage 
on chromosome 1 with hypertension and blood pressure used as phenotypes (5, 6).  
Chang et al. recently conducted genome-wide linkage and candidate gene studies and 
identified multiple genes located on chromosome 1q that were associated with systolic 
blood pressure (SBP) and one positional candidate gene identified in these analyses was 
the E Selectin (SELE) gene (7).  The vascular cell adhesion molecule-1 (VCAM1) gene is 
also located on chromosome 1 in a different region (1p) and has been linked to 
cardiovascular risk factors including blood pressure (8). 
Although it is not clear whether inflammation may contribute to the development 
of hypertension or if the two are independent phenomena interacting bi-directionally to 
promote vascular alterations, a growing interest in the potential pathophysiologic link 
between inflammation and hypertension has emerged (9-17) Recent epidemiological 
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studies have demonstrated that the presence of a chronic low grade inflammatory status 
can anticipate the future development of hypertension (9, 18-20).    
Cell adhesion molecules play an integral role in the inflammatory process in 
general, and are involved in vascular inflammatory responses stemming from mechanical 
stress on the vascular walls and/or the effects of pro-inflammatory humoral factors (9). 
The SELE gene is a 13 kb gene localized to 1q22-q25 and the VCAM1 gene is a 25 kb 
gene localized to 1p32-p31.  Both genes encode for glycoproteins expressed by activated 
endothelium that mediate the adhesion of leukocytes to the vascular lining during the 
inflammatory process and are thought to play a role in the pathogenesis of atherosclerosis 
(21, 22).  Hypertension is a major risk factor for atherosclerosis and is associated with 
endothelial cell alterations.  Several studies have shown that hypertensive subjects have 
elevated serum levels of soluble e-selectin and vascular adhesion molecule-1 compared to 
normotensive controls (23-25), and positive correlations between elevated levels of 
soluble vascular adhesion molecule-1 and SBP have also been reported (26), suggesting 
that SELE  and VCAM1 could be involved in the pathogenesis of hypertension.  The 
relationships between hypertension and several polymorphisms in the SELE gene have 
been studied.  In particular, studies have demonstrated statistically significant 
associations between the L/F554 polymorphism and both SBP and diastolic blood 
pressure (DBP) levels (27). Associations have also been detected between arterial 
stiffness and polymorphisms in candidate genes, including VCAM1 and other 
inflammatory molecule genes (28).  Age-related arterial stiffening is thought to be a 
major contributor to isolated systolic hypertension (29) and the importance of SBP in the 
clinical management of hypertension has been recognized (30, 31). 
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Genes that potentially influence the risk of developing hypertension are prime 
candidates for influencing an individual’s pharmacodynamic response to treatment. 
Therefore we examined whether single nucleotide polymorphisms (SNPs) in the SELE 
and VCAM1genes influence SBP in hypertensive subjects stratified by antihypertensive 
drug therapy category and tested for gene-by-drug interactions in a population-based 
sample of hypertensive African Americans and non-Hispanic whites from the Genetic 
Epidemiology Network of Arteriopathy (GENOA) study.    
METHODS 
Study Population 
In 1995, the National Heart, Lung and Blood Institute (NHLBI) established The 
Family Blood Pressure Program (FBPP) to assess the genetic influence on inter-
individual blood pressure variation, hypertension, and hypertensive target organ damage.  
One of the four networks established by the NHLBI to meet this objective is the Genetic 
Epidemiology Network of Arteriopathy (GENOA).  GENOA field centers in Jackson, 
MS, Starr County, TX, and Rochester, MN recruited hypertensive African American, 
Hispanic, and non-Hispanic white sibships, respectively, for linkage and family-based 
association studies. Subject were diagnosed with hypertension if they had a previous 
clinical diagnosis of hypertension by a physician with current antihypertensive treatment 
or an average SBP >=140 mmHg and/or an average diastolic blood pressure (DBP) >=90 
mmHg.  
In Rochester, MN and Jackson, MS, recruitment was restricted to sibships that 
contained a minimum of two subjects diagnosed with essential hypertension before the 
age of 60.  Once this criterion was met, the entire sibship was invited to participate in the 
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study. As the prevalence of diabetes among Mexican-Americans is high, the Starr County 
recruitment was restricted to Mexican-American sibships containing at least two subjects 
diagnosed with type-2 diabetes (32).  Data was collected through personal interviews, and 
physical and laboratory examinations.  The initial phase of the GENOA study took place 
from September 1995 through June 2001 (33).  The study presented here focused on all 
of the hypertensive African American (n = 1329) and non-Hispanic white (n = 1129) 
hypertensive subjects. 
Blood Pressure Readings 
Blood pressure measurements were made with random zero sphygmomanometers 
and cuffs appropriate for arm size. Three readings were taken in the right arm after the 
subject rested in the sitting position for at least five minutes according to the Seventh 
report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC-7, 2003) guidelines (34).  The SBP and DBP 
values were determined by the first and fifth phase Korotkoff sounds, respectively, and 
the last two blood pressure readings were averaged for the analyses.  The diagnosis of 
hypertension was established based on blood pressure levels measured at the study visit 
(≥140/90 mmHg), or a prior diagnosis of hypertension and current treatment with 
prescription antihypertensive medications.  
Antihypertensive Medications 
Based on lists of all antihypertensive medications available in the US, each 
prescription antihypertensive drug recorded at the study visit was assigned a code number 
corresponding to the first 6 digits of the Medi-Span Generic Product Identifier.  This 
number, which identifies pharmacologically equivalent drug products, was used to 
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categorize agents with similar mechanisms of antihypertensive action.  In this study, 
subjects on monotherapy were classified as taking a “beta-blocker”, “calcium-channel 
blocker”, “renin-angiotensin-aldosterone system (RAAS) inhibitor”, “diuretic only”, or 
“other antihypertensive” drug (e.g. research drugs).  Subjects on combination therapies 
were classified as taking “beta-blocker + diuretic”, “beta-blocker + other”, “diuretic + 
other”, or “neither beta-blocker nor diuretic”.  Due to both the wide variation in the types 
of drugs falling into the monotherapy class of “other antihypertensive” and the 
combination therapy class “neither beta-blocker nor diuretic”, and the relatively low 
group sizes, subjects in these classes were excluded from the regression analyses. 
Genotyping 
SNP genotyping was conducted at the GENOA central genotyping center at the 
University of Texas-Houston.  SNPs were selected in positional candidate genes in the 
region using the public National Center for Biotechnology Information (NCBI) database 
(35) and the private Celera database (36).  SNP genotyping on a total of 11 loci in the 
SELE gene and 16 loci in the VCAM1 gene (Table 5.3) were obtained using a 
combination of two genotyping platforms: mass spectrometer-based detection system 
implemented on a Sequenom MassARRAY system, and the fluorogenic TaqMan assay 
implemented on an ABI Prism 7900 Sequence Detection System.  
Statistical Analysis 
The primary goal of this analysis was to determine if there was evidence of SNP 
effects and gene-drug interactions on SBP levels in African American and non-Hispanic 
white hypertensives.  Given the correlation structure inherent in sibship data of the 
GENOA study cohort, the distribution of subjects within each of the ten treatment groups 
 147 
 
(no treatment, five monotherapy groups and four combination therapy groups) was 
assessed. Although some degree of relatedness within treatment groups was evident in 
both racial/ethnic groups (African Americans, Table 5.1; non-Hispanic whites Table 5.2), 
there were few related subjects within particular treatment groups.  As such, regression 
analyses did not formally account for familial correlations.  The parameter estimates in 
regression modeling are not affected by correlated data, however the standard errors of 
parameters are often underestimated (37).  Differences in the age, BMI, SBP and DBP 
distributions across treatment groups were examined using an F-test. To determine if two 
SNPs were likely to be representing the same variation in the gene we used 
2
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=  (38) as a measure of linkage disequilibrium (LD).  SNPs with high 2r  
values are likely to have the same genotype-phenotype relationship. 
Age- and sex-adjusted SNP effects on mean levels of SBP within each treatment 
class were estimated using linear regression modeling, where SNP genotypes were 
dummy coded.  The dummy variables for each SNP of interest were modeled against the 
SBP residuals from separate multivariable regression models that included age and sex as 
predictor variables.  Modeling the SNP genotype relationship to the resulting residuals 
yielded age- and sex-adjusted associations between each of the selected SNP genotypes 
and SBP.   The regression models within each treatment class took the following basic 
form: 
 
Yi = β0 + β1SNP12i + β2SNP22i + ε,                  (1)     
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where Yi = the age- and sex-adjusted SBP residual for the ith subject, SNP12i = the 
heterozygous genotype of the SNP of interest for the ith subject, and SNP22i = the second 
alphabetically ordered, homozygous genotype of the SNP of interest for the ith subject. 
Because of the limited sample size of some of the drug categories, a leave-one-out 
cross validation strategy was used to provide more accurate estimates of the percent 
variation in SBP explained by the SNPs and to reduce reporting of false positives.  The 
leave-one-out cross validation procedure leaves one person out of the sample (designated 
as the test case) and estimates the genetic model on the N-1 remaining subjects 
(designated as the training cases).  The estimated model was then applied to the test case, 
a predicted SBP was calculated, and the residual variability between observed and 
predicted values was estimated.  A cross-validated R2 value was then calculated by taking 
the total SBP variability in the sample minus the total residual variability divided by the 
total variability.  The results were averaged across all test cases.  The cross-validated R2 
will have a negative value when the model’s prediction is poor (i.e. the predicted values 
deviate substantially from the observed values).  
In order to formally evaluate whether there was evidence of gene-by-drug 
interactions, the effect of each SNP on SBP was compared between each treatment class.  
Using analysis of covariance methods, overall gene-by-drug interactions were 
systematically tested for using the partial F-test and potential SNP effect differences 
among each treatment class were assessed using pair-wise comparisons.  The regression 
models used to assess each pairwise comparison between each of the treatment classes 
extended equation (1) above by adding SNP-treatment class interaction terms and took 




Yi = β0 + β1SNP12i + β2SNP22i + β3SNP12*Ci + β4SNP12*Ci + ε,   (2) 
 
where Yi = the age- and sex-adjusted SBP residual for the ith subject; SNP12i = the 
heterozygous genotype of the SNP of interest for the ith subject; SNP22i = the second 
alphabetically ordered, homozygous genotype of the SNP of interest for the ith subject; 
and C = a dichotomous treatment class variable that is assigned a value of “0” for the first 
treatment class of each possible treatment class pair, and a value of “1” for the second 
treatment class of each possible treatment class pair. 
The lack of replication of genetic effects or gene-environment interactions on 
complex traits such as blood pressure is a major issue in the field of human genetic 
association studies.  In order to minimize false inferences a leave one out cross validation 
strategy was used to estimate the extent to which gene-drug interactions improved 
prediction of SBP levels beyond the SNP main effects.   
Because the cross-validation method provides an alternative to the adjustment of 
p-values (which is often conservative and can lead to type II errors), p-values were not 
formally adjusted for multiple testing.  This issue is particularly important in 
susceptibility gene research since the small effects of relatively common alleles are likely 
to have the greatest public health impact but are unlikely to achieve p-values that 
withstand conservative adjustments.  At the heart of the multiple testing issue is the 
question of how to separate out false positives from true positives.  Adjusting p-values 
for multiple comparisons does not directly address this question, but rather aims to reduce 
the probability of a false positive.  Cross-validation better addresses this question by 
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testing the predictive capability of the model on independent test cases and provides a 
more direct assessment of whether the result is a false positive.   
All regression analyses conducted to assess (a) SNP main effects within the 
various treatment classes, and (b) gene-drug interactions were adjusted for age and sex.  
An alpha level of 0.05 was used to determine statistical significance and a cross-validated 
R2 x 100>0.50 cut point was used to identify SNPs with potential predictive capabilities 
based on their performance in the test cases.  All analyses were performed in R (39). 
RESULTS 
The average age, BMI, SBP and DBP values for African American subjects in 
each treatment class are presented in Table 5.1.  This table also presents analysis of 
variance results used to determine if the sample mean of these traits differed significantly 
between treatment classes.  Age differed significantly (p=0.008) between the treatment 
classes, with the oldest average age among subjects in the “beta-blocker + other” class 
and the youngest average age among those in the “calcium-channel blocker” class.  
Although the mean BMI values in all treatment classes were at or above the clinical 
cutpoint for clinical obesity, they differed significantly (p<0.001) between the various 
treatment classes, with the highest mean BMI values among subjects in the “diuretic + 
other” class.  Overall, there was evidence of significant variation (p<0.001) of SBP across 
treatment classes, with the highest mean level among subjects in the “beta-blocker + 
other” and the lowest mean level among those in the “RAAS inhibitor” class.  Similar 
distribution information for non-Hispanic white subjects within each treatment class is 
presented in Table 5.2. Age differed significantly (p<0.001) between the treatment 
classes, with the oldest average age among subjects in the “beta-blocker + other” class 
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and the youngest average age among those in the “RAAS inhibitor” class.  Statistically 
significant differences in BMI were not noted between the various treatment classes (p = 
0.146), although the mean BMI values within each class nearly met or exceed the clinical 
cutpoint for obesity.  There was also evidence of significant variation (p<0.001) of SBP 
across treatment classes, with the highest mean level among subjects in the “beta-blocker 
+ other” and the lowest mean level among those in the “beta-blocker” class.   
Table 5.3 presents a brief description of the SELE and VCAM1 SNPs that were 
genotyped in this study.  Among the SELE SNPs, three SNPs are located in the 5’ 
untranslated (UTR) region, one synonymous SNP is located in exon 14, three SNPs are 
located in introns, three non-synonymous SNPs are located in exons 10, 9, and 5, and one 
SNP is located in the 3’ UTR region. Among the VCAM1 SNPs, three SNPs are located 
in the 5’ upstream gene region, nine SNPs are located in intronic regions, two 
synonymous and one non-synonymous SNPs are located in exon 9, and one SNP is 
located in the 3’ downstream region.  Tables 5.4 and 5.5 present the total number of 
subjects that were genotyped for each SELE SNP, as well as the frequency and 
percentage of each of the corresponding three genotypes, in African Americans and non-
Hispanic whites respectively. Among the non-Hispanic white sample, the rs5366 variant 
was monomorphic (with the exception of one subject having the heterozygous genotype 
at this locus) and the rs5357 SNP had a low call rate (n= 511).  Similar results for each of 
the VCAM1 SNPs genotyped are presented in Tables 5.6 and 5.7.  The rs3786315 variant 
was monomorphic in the non-Hispanic white sample. 
The LD pattern among variations in the SELE SNPs in African American and 
non-Hispanic white subjects are displayed in Figure 5.1 and Figure 5.2 respectively.  It is 
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evident that the relative frequency of several of the SNPs are significantly correlated 
within each racial/ethnic group and thus the effects of each SNP alone is likely to 
represent influences from multiple SNPs in this region, either measured or unmeasured in 
this study. Among the African American subjects, there are two groups of SNPs that can 
be identified by the LD estimates (r2>0.80) that are likely to be measuring the same 
functional variation: group 1 (rs5357 and rs5361), and group 2 (rs5368 and rs5356).  
Among the non-Hispanic white subjects, there are also two groups of SNPs that can be 
identified by the LD estimates (r2>0.80) that are likely to be measuring the same 
functional variation: group 1 (rs5356, rs5366, and rs5368), and group 2 (rs3917436, 
rs932307, and rs5353).  Two SNPs in particular (rs5368 and rs5356) are likely measuring 
the same functional variation in the SELE gene in both racial/ethnic groups.   
The LD pattern among variations in the VCAM1 SNPs in African American and 
non-Hispanic white subjects are displayed in Figure 5.3 and Figure 5.4 respectively.  
Among the African American subjects, strong LD (r2>0.80) was not detected among the 
SNPs genotyped.  Among the non-Hispanic white subjects, there are two groups of SNPs 
that can be identified by the LD estimates (r2>0.80) that are likely to be measuring the 
same functional variation: group 1 (rs3176876 and rs3181092), and group 2 (rs3176874 
and rs3917016). 
SNP effects within treatment class and gene-drug interactions 
SELE 
African Americans 
Figure 5.5A presents the results from the analysis of each SELE SNP on SBP 
within treatment class, as well as the results from the leave-one-out cross validation 
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procedure, among the African American subjects.  Evidence of statistically significant 
and cross-validated SNP effects on SBP was demonstrated in two of the eight treatment 
categories.  Among hypertensives taking a beta-blocker only, the rs932307 SNP was 
statistically significantly associated with SBP levels and predicted a substantial amount 
of variation in SBP (cross-validated R2 x 100 = 3.2%).  Among hypertensives taking a 
diuretic only, one SNP (rs3917436) was statistically significantly associated with SBP 
and cross validated, predicting approximately 0.5% of the variation in SBP.   
Evidence of SELE SNP-drug interactions among the African American subjects is 
visualized in Figure 5.5B, which summarizes the results of the tests for interaction for 
each pair of treatment classes examined.  Statistically significant and cross-validated 
SNP-drug interactions that predict SBP variation have been highlighted.  Some of the 
strongest evidence for gene-by-drug interaction comes from the comparison of the SNP 
genotype means among subjects in the “no treatment” vs. “beta-blocker” classes, and 
among subjects in the “beta-blocker” class relative to the respective SNP genotype means 
among subjects in the other monotherapy and combination therapy treatment classes.  
Three separate SNPs (rs5366, rs5361, and rs932307) each demonstrated statistically 
significant, cross-validated differences in mean SBP between the “no treatment” and 
“beta-blocker” classes.  The rs932307 SNP demonstrated statistically significant 
differences in mean SBP between the “beta-blocker” class and all 7 other classes, with 
cross-validated differences detected between 4 other (“calcium-channel blocker”, “RAAS 
inhibitor”, “diuretic only”, and “diuretic + other”) classes.  The rs5366 and rs5361 SNPs 
also demonstrated numerous statistically significant mean SBP differences between the 
“beta-blocker” and the 7 other classes, although most failed to cross-validate.  These 
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results suggest that the genotype-specific effects of particular SELE SNPs on SBP 
variation may depend upon the drug that is administered, and highlight the possibility of 
gene-by-beta-blocker interaction in particular.  Genotype-specific mean SBP values by 
treatment class for the rs932307 SNP are displayed in Figure 5.6.  
Non-Hispanic Whites 
Figure 5.7A presents the results from the analysis of each SELE SNP on SBP 
within treatment class, as well as the results from the leave-one-out cross validation 
procedure, among the non-Hispanic white subjects.  Evidence of statistically significant 
and cross-validated SNP effects on SBP was demonstrated in two of the eight drug 
categories.  Among hypertensives taking a beta-blocker, four of the ten (rs5366 
essentially monomorphic in sample) SNPs were statistically significantly associated with 
SBP levels and three of these SNPs (rs5356, rs5368, and rs1076638) each predicted a 
substantial amount of variation in SBP (cross-validated R2 x 100  = 3.3%, 3.2%, and 
2.8% respectively).  Among hypertensives taking a combination therapy of a diuretic plus 
another antihypertensive drug, one SNP (rs932307) demonstrated a statistically 
significant, cross-validated association with SBP and predicted approximately 0.7% of 
the variation in SBP.  These findings suggest possible gene-by-drug interactions between 
SELE and antihypertensive medications (particularly beta blockers) in determining SBP 
levels in hypertensives.   
Evidence of SELE SNP-drug interactions among the non-Hispanic white subjects 
is visualized in Figure 5.7B, which summarizes the results of the tests for interaction for 
each pair of treatment classes examined.  Statistically significant and cross-validated 
SNP-drug interactions that predict SBP variation have been highlighted.  Similar to 
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results detected in the African American racial/ethnic group, some of the strongest 
evidence for gene-by-drug interaction comes from the comparison of SNP genotype 
means among subjects in the “beta-blocker” class relative to the respective SNP genotype 
means among subjects in the other monotherapy and combination therapy treatment 
classes.  Since the SNPs that demonstrated significant and cross-validated effects among 
hypertensives taking a beta-blocker did not seem to have an influence in the other 
treatment classes, significant SNP-drug interactions in drug comparisons involving beta-
blocker usage were expected.  Accordingly, 20 of the 25 statistically significant, cross-
validated comparisons of SNP effects on SBP between treatment classes involved 
treatment classes with beta-blocker use (in monotherapy and/or combination forms).  
Three separate SNPs (rs5356, rs5368, and rs1076638) each demonstrated cross-validated 
differences in mean SBP between the “beta-blocker” class vs. both the “diuretic only” 
and beta-blocker + diuretic” classes.  Two of these SNPs (rs5368 and rs1076638) also 
demonstrated cross-validated differences in mean SBP between comparisons among the: 
“beta-blocker” vs. “beta-blocker + other” classes; “diuretic only” vs. “beta-blocker + 
other” classes; and “beta-blocker + other” vs. “diuretic + other” classes.  Many of the 
results for the rs5356, rs5368, and rs1076638 SNPs were similar and may stem from LD 
relationships.  In particular, rs5356 and rs5368 are in high LD (r2 = 0.98) and likely 
represent similar functional variation within the SELE gene in this non-Hispanic white 
cohort.  Still, these results suggest that the genotype-specific effect of a particular SNP on 
SBP variation may depend upon the drug that is administered.  Furthermore, as observed 
in the African American cohort, SELE SNP genotype effects on SBP may be highly 
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dependent on beta-blocker use.  Genotype-specific mean SBP values by treatment class 
for the rs5368 SNP are displayed in Figure 5.8. 
VCAM1 
African Americans 
Figure 5.9A presents the results from the analysis of each VCAM1 SNP on SBP 
within treatment class, as well as the results from the leave-one-out cross validation 
procedure, among the African American subjects.  Evidence of statistically significant 
and cross-validated SNP effects on SBP was demonstrated in three of the eight treatment 
categories.  Among hypertensives taking a beta-blocker only, the rs3176862 SNP was 
statistically significantly associated with SBP levels and predicted a substantial amount 
of variation in SBP (cross-validated R2 x 100 = 4.2%).  Among hypertensives taking a 
calcium-channel blocker only, the rs3176878 SNP was statistically significantly 
associated with SBP and cross-validated, predicting approximately 6.0% of the variation 
in SBP. Among hypertensives taking a beta-blocker + other drug, rs3176876 was 
statistically significantly associated with SBP and cross-validated, predicting 
approximately 10.5% of the variation in SBP. 
Evidence of VCAM SNP-drug interactions among the African American subjects 
is visualized in Figure 5.9B, which summarizes the results of the tests for interaction for 
each pair of treatment classes examined.  Statistically significant and cross-validated 
SNP-drug interactions that predict SBP variation have been highlighted.  Statistically 
significant and cross-validated genotype effects on mean SBP differences between 
various treatment classes were observed for many of the SNPs investigated.  Some of the 
strongest evidence for gene-by-drug interaction involved three SNPs in particular 
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(rs3176862, rs3176876, and rs3176878), with genotype effects on mean SBP differing 
between many treatment class comparisons.  The rs317682 SNP genotypes were 
associated with different mean SBP profiles between the “beta-blocker” class relative to 
the “no treatment”, “RAAS inhibitor”, “beta-blocker + diuretic”, and “diuretic + other” 
classes.  The rs3176876 and rs3176878 each demonstrated statistically significant, cross-
validated differences in mean SBP between the “beta-blocker + other” class and the “no 
treatment”, “calcium-channel blocker”, “diuretic only”, and “diuretic + other” classes.  
Additionally, the rs3176876 SNP demonstrated statistically significant, cross-validated 
differences in mean SBP between the “beta-blocker + other” class and the remaining 3 
treatment classes (“beta-blocker”, “RAAS inhibitor”, “diuretic only”, and “beta-blocker + 
diuretic”).  Genotype-specific mean SBP values by treatment class for the rs3176876 
SNP are displayed in Figure 5.10.  
Non-Hispanic Whites 
Figure 5.11A presents the results from the analysis of each VCAM1 SNP on SBP 
within treatment class, as well as the results from the leave-one-out cross validation 
procedure, among the non-Hispanic white subjects.  Evidence of statistically significant 
and cross-validated SNP effects on SBP was demonstrated in two of the eight drug 
categories.  Among hypertensives not taking a prescribed antihypertensive medication, 
six of the fifteen (rs3783615 monomorphic in non-Hispanic white sample) SNPs were 
statistically significantly associated with SBP levels and four of these SNPs (rs3170794, 
rs3176862, rs3176874, and rs3917016) each predicted a substantial amount of variation 
in SBP (cross-validated R2 x 100  = 3.5%, 2.8%, 8.0%, and 2.9% respectively).  
However, the rs3176874 and rs3917016 SNPs were in high LD (r2 = 0.95). Among 
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hypertensives taking a combination therapy of a diuretic + other antihypertensive drug, 
five of the fifteen SNPs were statistically significantly associated with SBP levels and 
three of these SNPs (rs3176860, rs3176862, and rs3176876) each predicted a substantial 
amount of variation in SBP (cross-validated R2 x 100  = 6.1%, 0.9%, and 1.0% 
respectively).  
Evidence of VCAM1 SNP-drug interactions among the non-Hispanic white 
subjects is visualized in Figure 5.11B, which summarizes the results of the tests for 
interaction for each pair of treatment classes examined.  Statistically significant and 
cross-validated SNP-drug interactions that predict SBP variation have been highlighted. 
A majority of the strongest evidence for gene-by-drug interaction comes from the 
comparison of SNP genotype means among subjects in the “no treatment” class relative 
to the respective SNP genotype means among subjects in the 4 monotherapy and 3 
combination therapy treatment classes.  Three separate SNPs (rs3170794, rs3176862, and 
rs3176874) each demonstrated cross-validated differences in mean SBP between the “no 
treatment” and the “beta-blocker” classes.  Two of these SNPs (rs3170794 and 
rs3176862) and the rs1041163 SNP also demonstrated cross-validated differences in 
mean SBP between the “no treatment” and the “calcium-channel blocker” classes. Three 
SNPs (rs3176874, rs3176876, and rs3181092) each demonstrated cross-validated 
differences in mean SBP between the “no treatment” and the “RAAS inhibitor” classes.  
The rs3176876 and rs3181092 SNPs were in relatively high LD (r2 = 0.81). Three SNPs 
(rs1409419, rs3176860, and rs3176874) each demonstrated cross-validated differences in 
mean SBP between the “no treatment” and the “diuretic + other” classes.  10 of the 
remaining 15 cross-validated results were among comparisons involving the “diuretic + 
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other” class.  Notably, 11 of the 15 SNPs examined demonstrated statistically significant 
and cross-validated evidence that SNP genotype effects on mean SBP were different 
between one or more of the treatment classes analyzed.  Genotype-specific mean SBP 
values by treatment class for the rs3176860 SNP are displayed in Figure 5.12.  
The results illustrated in Figures 5.5-5.12 provide evidence that for certain SNPs 
located in the SELE and VCAM1 genes, genotype-SBP phenotype associations may vary 
by treatment class.  These findings indicate that genetic susceptibility loci for 
hypertension may also interact with antihypertensive therapies to influence an 
individual’s blood pressure levels.  As such, a particular genetic subgroup in the 
hypertensive population may benefit more from a particular drug regimen. 
DISCUSSION 
 
 Hypertension is a major risk factor for cardiovascular, cerebrovascular, and renal 
disease morbidity and mortality.   Despite the recognized health and economic burdens of 
hypertension, success in achieving and maintaining target blood pressure levels necessary 
to reduce cardiovascular risk has been limited.  This stems largely from low hypertension 
awareness and treatment, as an estimated 67% of hypertensives in the US are aware of 
their condition and only 54% are being treated.  Furthermore, in the midst of increasing 
prevalence, more than two-thirds of treated hypertensives in the US do not have their 
blood pressure adequately controlled (3). 
One of the challenges in achieving broad blood pressure control is the difficulty in 
predicting how effective a particular antihypertensive regimen will be for a particular 
patient.  Without a priori knowledge of how subjects will respond to a medication, a 
“trial-and-error” approach is typically employed to find the ideal drug for a given patient 
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(40).  Furthermore, it is recognized that hypertension is a multifactorial disease and that 
combinations of antihypertensive agents, acting through different mechanisms at different 
sites, are often prescribed, with most patients requiring two or more drugs to achieve 
target blood pressure (41).  
During the earlier years of phamacogenetic investigations, the focus was directed 
towards variants in genes (e.g.- CVP2D6 and N-acetyltransferase 2 genes) that coded for 
enzymes affecting drug metabolism (42).  However, the variations in these genes, known 
to impact the pharmacokinetics (i.e.- mechanisms affecting drug concentration such as 
absorption, distribution, metabolism, and excretion) of particular antihypertensive agents, 
have decreased in importance as the agents they impacted are no longer widely 
prescribed and newer agents have gained widespread use.  More recently, 
pharmacogenetic research has focused on identifying variants in candidate genes that 
impact the pharmacodynamic (i.e.- mechanisms governing the drug-target cell interaction 
and subsequent regulation of drug activity and efficacy) properties influencing individual 
variation in antihypertensive response (4, 40, 42).  Accordingly, numerous variants in 
biological and positional candidate genes (mainly in the RAAS) have been predictive of 
blood pressure response to a variety of antihypertensive therapies, however studies have 
yielded conflicting results, reflecting the heterogeneous nature of hypertension and 
response to antihypertensive treatment (40, 43). 
In the current study, we hypothesized that polymorphisms in the SELE and 
VCAM1 genes could influence interindividual variation in blood pressure response, on the 
premise that hypertension is associated with endothelial cell alteration/dysfunction and 
that cell adhesion molecules, including SELE and VCAM1, are products of activated 
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endothelium.  Numerous studies have demonstrated statistically significant associations 
between hypertension and elevated plasma levels of e-selectin (23-25, 44) and vascular 
adhesion molecule-1 (25, 26), suggesting that these circulating molecules are either by-
products of the endothelial damage caused by hypertension or that the respective proteins 
encoded by the SELE and VCAM1 genes are somehow involved in the determination of 
blood pressure.  Results from recent research show that e-selectin expression correlates 
with vascular structural alterations, and the authors point out the possibility that e-selectin 
might independently contribute to such vascular changes by fostering leukocyte 
adhesion/accumulation (23).  Previous genetic analyses using the GENOA cohort 
detected statistically significant associations between quantitative blood pressure values 
and the non-synonymous rs5368 SNP in the SELE gene among African American 
subjects (7).  The common Ser128Arg (rs5361) and L/F554 (rs5355) polymorphisms in 
SELE have been investigated for their potential role in cardiovascular diseases.  
Associations have been detected between both variants and atherosclerosis (45), between 
the Ser128Arg (rs5361) variant and coronary artery disease (46-48) and recurrent venous 
thromboembolism (49), and between the L/F554 (rs5355) variant and blood pressure (27, 
50).  Furthermore, reductions in soluble selectin molecules (both e- and p-selectin) 
through the administration of the calcium-channel blocker benidipine (51) and variance 
in the degree of vascular effects derived through different antihypertensive therapies (45) 
have been demonstrated, suggesting that variants in genes influencing vascular tone and 
function may also affect blood pressure response.  Administration of the angiotensin 
converting enzyme (ACE) inhibitor fosinopril has been shown to lower circulating 
vascular cell adhesion molecule-1 levels (52). 
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This study detected and cross-validated sets of SNPs within the SELE and 
VCAM1 genes that may influence interindividual variation in blood pressure and blood 
pressure response in African American and non-Hispanic white hypertensive patients.  
Investigation of SELE SNP effects on blood pressure within treatment classes revealed 
that the effects that were significant and cross-validated in independent samples were 
primarily seen within the “beta-blocker” monotherapy class in each racial/ethnic group.  
Subsequent comparisons across treatment classes to investigate the potential evidence for 
gene-by-drug interaction revealed that most of the significant and cross-validated 
differences were between monotherapy and combination therapy classes relative to the 
beta-blocker usage, and these findings were also common to both racial/ethnic groups.   
A potential explanation for the differences detected may be that certain 
antihypertensive therapies confer vasculoprotective properties, in addition to blood 
pressure lowering properties, which may improve outcomes.  Studies comparing such 
properties between antihypertensive agents have noted improved endothelial structure 
and function with RAAS inhibitors (53, 54) and calcium-channel blockers (45), relative 
to no improvements under beta-blocker usage. Interestingly, this study provided similar 
evidence of gene-by-drug interaction involving the common Ser128Arg (rs5361) variant 
was detected between the “calcium-channel blocker” and “beta-blocker + other” 
treatment classes in non-Hispanic whites, and the genotypes of this SNP were associated 
with statistically significant different SBP profiles in several treatment classes (“calcium-
channel blocker”, “diuretic only”, “beta-blocker + other”, and “diuretic + other”) relative 
to the “beta-blocker” class in African Americans.  Although the rs5361 associations 
failed to cross-validate in either racial/ethnic group, these differences may have clinical 
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relevance as subjects with a particular allele at this locus may respond better to calcium-
channel blocker administration, and simultaneously benefit from both blood pressure 
lowering and inhibition of e-selectin molecule expression which could reduce the rate of 
atherosclerotic progression (51). 
  The etiology of hypertension is believed to be multifactorial and polygenic, with 
numerous environmental and genetic factors influencing interindividual blood pressure 
variation.  Studies investigating the role of SELE and VCAM1 polymorphisms have 
detected that SNP effects on blood pressure may depend on environmental factors such as 
age and BMI (26, 27, 50).  While statistically significant age differences were noted 
between subjects within different treatment classes in our study, the actual mean ages 
across classes were within a relatively tight range.  While BMI differed significantly by 
treatment class among the African American subjects, no statistically significant BMI 
differences between treatment classes were observed among the non-Hispanic white 
subjects.  Overall, mean BMI values in both racial/ethnic groups were near or above the 
clinical cutpoint for obesity, regardless of treatment class.  This may indicate that our 
findings are only generalizable to over-weight and obese populations, and may reinforce 
the previously identified (50) BMI-specific effect of polymorphisms in inflammatory 
genes on blood pressure and blood pressure response.   
This study had several limitations that warrant discussion.  Without prospective 
data, genetic influence on blood pressure response to various treatment regimens could 
not be accurately assessed.  Despite this, as illustrated in a identical analysis conducted in 
the GENOA non-Hispanic white cohort that investigated interactions between the 
adducin2 (ADD2) gene and antihypertensive drug therapies on SBP, the various gene 
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effects observed within treatment classes were taken as a reflection of how the certain 
SNP genotypes responded to different antihypertensive drug environments (55).  
Although the within-treatment class samples were somewhat balanced and moderately 
sized in both racial/ethnic groups, results may have been biased by relatively small 
sample sizes within some classes.  In particular, the “beta-blocker” monotherapy and the 
“beta-blocker + other” class sizes were quite small among African American subjects, 
and findings involving these classes (in the form of SNP main effects within these classes 
or SNP-drug interactions) should be interpreted with caution. 
The genetic analyses carried out in these analyses were limited to a select number 
of SNPs within two genes in the inflammatory/endothelial dysfunction pathway(s).  
Genetic variants in other physiologic systems and pathways, including the RAAS, the 
sodium system, signal transduction pathways, the noradrenergic system, and endothelin 
system, influence blood pressure regulation and may be related to relationships between 
various antihypertensive treatments and blood pressure lowering effects.  Given that 
hypertension is believed to be multifactorial and polygenic, further investigation of SNP 
main effects in other genes, as well as appropriately defined gene-environment and gene-
gene interactions may provide additional insights into genetic influences on treatment 
response.  Many ongoing genome-wide association studies have great potential to 
identify variants that could serve as benchmarks for individual treatment response and 
influence the design of novel therapies (56). Numerous statistical genetic tests were 
carried out in the analyses of this study, increasing the chance of false-positive findings.  
As used in previous research investigating the influence of ADD2-drug interactions on 
SBP (55), the cross-validation techniques used in this study reduced the number of 
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statistically significant findings by likely ruling out false-positive associations.  Direct 
comparison of the various SNP effects between the African American and non-Hispanic 
white subject is limited due to genetic heterogeneity (i.e.- population differences in allelic 
distributions), although results specific to racially/ethnically homogeneous cohorts were 
presented.  Despite these limitations, this study contributed to the developing 
pharmacogenetic knowledge base by demonstrating that blood pressure response to 
antihypertensive therapy may be modified by variations in the SELE and VCAM1 genes, 
and presented another avenue of investigation into the potential link between 








Table 5.1.  Distribution of antihypertensive therapies among hypertensive African Americans in GENOA 
Antihypertensive class N 
(1329) 














No Treatment 205  173  58.20 (9.47)  29.80 (6.27)  157.20 (15.20)  88.24 (11.99) 
Mono Therapies            
    Beta-Blocker 42  39  59.16 (10.39)  29.98 (6.96)  143.98 (22.05)  81.57 (11.51) 
    CA-Blocker 148  131  58.24 (9.55)  30.13 (5.13)  142.67 (20.94)  81.26 (12.98) 
    Diuretic 156  144  59.87 (9.05)  32.91 (6.48)  133.59 (20.10)  74.49 (10.67) 
    RAAS Inhibitors  107  101  59.70 (10.10)  30.17 (6.19)  140.50 (20.97)  80.05 (11.06) 
    Other Antihypertensive  75  70  61.53 (8.48)  30.48 (5.89)  143.40 (25.09)  79.89 (10.50) 
Combination Therapies            
    Beta-Blocker + Diuretic 107  97  58.98 (9.81)  32.74 (6.54)  134.40 (21.15)  77.68 (13.12) 
    Beta-Blocker + Other 32  30  62.21 (9.14)  30.93 (5.50)  137.59 (24.89)  76.78 (12.69) 
    Diuretic + Other 351  273  61.63 (9.18)  33.62 (7.51)  139.63 (22.28)  77.06 (13.03) 
    Neither Beta-Blocker Nor Diuretic 106  98  61.01 (8.83)  32.40 (7.00)  146.93 (27.34)  80.72 (12.86) 
   P-value test among treatment classes*    0.008  <0.001  <0.001  <0.001 
* ANOVA did not include the "No Treatment" class. BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; CA = Calcium 
channel; RAAS = renin angiotensin aldosterone system. 
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Table 5.2.  Distribution of antihypertensive therapies among hypertensive non-Hispanic whites in GENOA 
Antihypertensive class N 
(1129) 














No Treatment 148  133  54.99 (11.2)  30.9 (5.6)  149.24 (13.2)  86.53 (9.4) 
Mono Therapies            
    Beta-Blocker 162  147  55.79 (10.4)  30.69 (6.7)  134.43 (16.1)  79.09 (8.1) 
    CA-Blocker 62  59  57.06 (9.3)  29.49 (5.3)  142.37 (15.6)  82.56 (9.0) 
    Diuretic 127  121  58.04 (9.6)  32.01 (6.6)  134.98 (12.5)  79.17 (9.7) 
    RAAS Inhibitors  151  136  54.87 (9.5)  31.11 (7.3)  133.73 (15.9)  80.52 (8.8) 
    Other Antihypertensive  18  17  59.97 (10.7)  29.38 (4.8)  141.67 (22.6)  78.56 (8.1) 
Combination Therapies            
    Beta-Blocker + Diuretic 167  141  59.66 (9.4)  32.01 (6.8)  136.23 (16.0)  77.34 (9.4) 
    Beta-Blocker + Other 72  67  62.57 (8.7)  30.66 (5.9)  143.63 (20.8)  78.36 (9.5) 
    Diuretic + Other 178  159  59.13 (9.4)  31.55 (6.3)  134.64 (15.6)  77.83 (10.2) 
    Neither Beta-Blocker Nor Diuretic 44  42  58.21 (9.3)  30.89 (6.1)  138.64 (19.1)  80.50 (10.5) 
   P-value test among treatment classes*    <0.001  0.146  <0.001  0.004 
* ANOVA did not include the "No Treatment" class. BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; CA = Calcium 
channel; RAAS = renin angiotensin aldosterone system. 
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Table 5.3.  Description of Cell Adhesion Molecule Candidate Genes   
Gene Name                                        Gene              GENOA SNP ID       SNP rs#          SNP Type       Chromosomal Band 
selectin E    SELE   SELE_012037   rs5357   UTR    1q22-q25 
(endothelial adhesion molecule 1)    SELE_010130  rs3917436  UTR    1q22-q25 
   SELE_010054   rs3917434 UTR    1q22-q25 
   SELE_009831   rs5356   synonymous   1q22-q25 
   SELE_007803   rs5368   nonsynonymous  1q22-q25 
   SELE_007532   rs5366   nonsynonymous  1q22-q25 
   SELE_007158   rs1076638  intron    1q22-q25 
   SELE_005924   rs1534904  intron    1q22-q25 
   SELE_003689   rs5361             nonsynonymous  1q22-q25 
   SELE_002043   rs932307  intron    1q22-q25 
   SELE_001774   rs5353   UTR    1q22-q25 
 
vascular cell adhesion molecule 1  VCAM1  VCAM1_000376  rs1409419     1p32-p31 
  VCAM1_000805  rs1041163     1p32-p31 
   VCAM1_001564  rs3170794     1p32-p31 
   VCAM1_004199  rs3176860  intron    1p32-p31 
   VCAM1_004301 rs3176861 intron    1p32-p31 
   VCAM1_004952  rs3176862 intron    1p32-p31 
   VCAM1_011199  rs3176867  intron    1p32-p31 
   VCAM1_013438  rs3176869  intron    1p32-p31 
   VCAM1_015713  rs3181088  intron    1p32-p31 
   VCAM1_016891  rs3176874  intron    1p32-p31 
   VCAM1_017613  rs3176876  intron    1p32-p31 
   VCAM1_018152  rs3917016  intron    1p32-p31 
   VCAM1_020703  rs3176878  synonymous   1p32-p31 
   VCAM1_020770  rs3783615  nonsynonymous  1p32-p31 
   VCAM1_020832  rs3176879  synonymous   1p32-p31 




Table 5.4. SELE SNP sample size information and genotype distribution among 
hypertensive African Americans in GENOA 
 
SNP Ntotal N11 P11 N12 P12 N22 P22 
rs5357 616 572 (0.93) 41 (0.06) 3 (0.01) 
rs3917436 1197 321 (0.27) 630 (0.53) 246 (0.20) 
rs3917434 1211 979 (0.81) 220 (0.18) 12 (0.01) 
rs5356 1229 1082 (0.88) 144 (0.11) 3 (0.01) 
rs5368 1214 1059 (0.87) 151 (0.12) 4 (0.01) 
rs5366 1211 1118 (0.92) 85 (0.07) 8 (0.01) 
rs1076638 1204 564 (0.47) 535 (0.44) 105 (0.09) 
rs1534904 1212 1088 (0.90) 111 (0.09) 13 (0.01) 
rs5361 1239 1132 (0.91) 104 (0.09) 3 (0.01) 
rs932307 1211 504 (0.42) 562 (0.46) 145 (0.12) 
rs5353 1198 345 (0.29) 617 (0.51) 236 (0.20) 
N: number of subjects; P: genotype frequency; 11: homozygous major allele genotype; 12: heterozygous 
genotype; 22: homozygous minor allele genotype.  SNP = single nucleotide polymorphism.
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Table 5.5. SELE SNP sample size information and genotype distribution among 
hypertensive non-Hispanic whites in GENOA 
 
SNP Ntotal N11 P11 N12 P12 N22 P22 
rs5357 511 4 (0.01) 91 (0.18) 416 (0.81) 
rs3917436 965 52 (0.05) 383 (0.40) 530 (0.55) 
rs3917434 994 425 (0.43) 472 (0.47) 97 (0.10) 
rs5356 998 10 (0.01) 159 (0.16) 829 (0.83) 
rs5368 986 814 (0.83) 160 (0.16) 12 (0.01) 
rs5366 996 995 (0.99) 1 (0.00) 0 (0.00) 
rs1076638 979 748 (0.76) 213 (0.22) 18 (0.02) 
rs1534904 983 93 (0.09) 466 (0.47) 424 (0.43) 
rs5361 994 787 (0.79) 196 (0.20) 11 (0.01) 
rs932307 992 572 (0.58) 372 (0.38) 48 (0.05) 
rs5353 962 526 (0.55) 384 (0.40) 52 (0.05) 
N: number of subjects; P: genotype frequency; 11: homozygous major allele genotype; 12: heterozygous 
genotype; 22: homozygous minor allele genotype.  SNP = single nucleotide polymorphism.
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Table 5.6. VCAM1 SNP sample size information and genotype distribution among 
hypertensive African Americans in GENOA 
 
SNP Ntotal N11 P11 N12 P12 N22 P22 
rs1409419 1218 471 (0.39) 568 (0.46) 179 (0.15) 
rs1041163 1188 811 (0.68) 330 (0.28) 47 (0.04) 
rs3170794 1221 876 (0.72) 310 (0.25) 35 (0.03) 
rs316860 1208 333 (0.28) 618 (0.51) 257 (0.21) 
rs3176861 1240 1126 (0.91) 110 (0.08) 4 (0.01) 
rs3176862 1229 771 (0.63) 409 (0.33) 49 (0.04) 
rs3176867 1233 1103 (0.89) 123 (0.10) 7 (0.01) 
rs3176869 1169 1103 (0.94) 66 (0.06) 0 (0.00) 
rs3181088 1227 1156 (0.94) 68 (0.05) 3 (0.01) 
rs3176874 1202 1029 (0.85) 168 (0.14) 5 (0.01) 
rs3176876 1218 338 (0.28) 589 (0.48) 291 (0.24) 
rs3917016 1205 1060 (0.88) 136 (0.11) 9 (0.01) 
rs3176878 1222 902 (0.74) 302 (0.25) 18 (0.01) 
rs3783615 1217 1080 (0.89) 128 (0.10) 9 (0.01) 
rs3176879 1230 591 (0.48) 529 (0.43) 110 (0.09) 
rs3181092 1228 647 (0.53) 494 (0.40) 87 (0.07) 
N: number of subjects; P: genotype frequency; 11: homozygous major allele genotype; 12: heterozygous 
genotype; 22: homozygous minor allele genotype.  SNP = single nucleotide polymorphism.
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Table 5.7. VCAM1 SNP sample size information and genotype distribution among 
hypertensive non-Hispanic whites in GENOA 
 
SNP Ntotal N11 P11 N12 P12 N22 P22 
rs1409419 980 256 (0.26) 485 (0.50) 239 (0.24) 
rs1041163 990 706 (0.71) 268 (0.27) 16 (0.02) 
rs3170794 978 947 (0.97) 31 (0.03) 0 (0.00) 
rs316860 995 362 (0.36) 486 (0.49) 147 (0.15) 
rs3176861 986 597 (0.61) 336 (0.34) 53 (0.05) 
rs3176862 993 962 (0.97) 31 (0.03) 0 (0.00) 
rs3176867 997 562 (0.56) 393 (0.40) 42 (0.04) 
rs3176869 952 682 (0.72) 247 (0.26) 23 (0.02) 
rs3181088 992 637 (0.64) 321 (0.32) 34 (0.04) 
rs3176874 991 768 (0.78) 212 (0.21) 11 (0.01) 
rs3176876 985 458 (0.47) 435 (0.44) 92 (0.09) 
rs3917016 960 754 (0.79) 194 (0.20) 12 (0.01) 
rs3176878 975 696 (0.71) 253 (0.26) 26 (0.03) 
rs3783615 974 974 (100.0) 0 (0.00) 0 (0.00) 
rs3176879 999 933 (0.93) 65 (0.67) 1 (0.00) 
rs3181092 996 432 (0.43) 460 (0.46) 104 (0.11) 
N: number of subjects; P: genotype frequency; 11: homozygous major allele genotype; 12: heterozygous 
genotype; 22: homozygous minor allele genotype.  SNP = single nucleotide polymorphism.
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SNP rs #’s listed from left to right according to relative positions on SELE gene in the 5’ to 3’ direction.  
SNP = single nucleotide polymorphism; CA = Calcium channel; RAAS = renin angiotensin aldosterone 
system.   
Statistically significant p<0.05 and CV R2 * 100 >0.50




Figure 5.6.  SELE rs932307 genotype specific mean systolic blood pressure by 
treatment class in GENOA African American hypertensive subjects  
 
 
*Other antihypertensive class includes alpha-blockers, vasodilators, sympatholytics, and study drugs. SBP 




SNP rs #’s listed from left to right according to relative positions on SELE gene in the 5’ to 3’ direction.  
SNP = single nucleotide polymorphism; CA = Calcium channel; RAAS = renin angiotensin aldosterone 
system.  
Statistically significant p<0.05 and CV R2 * 100 >0.50




Figure 5.8.  SELE rs5368 genotype specific mean systolic blood pressure by 
treatment class in GENOA non-Hispanic white hypertensive subjects  
 
 
*Other antihypertensive class includes alpha-blockers, vasodilators, sympatholytics, and study drugs. SBP 




SNP rs #’s listed from left to right according to relative positions on SELE gene in the 5’ to 3’ direction.  
SNP = single nucleotide polymorphism; CA = Calcium channel; RAAS = renin angiotensin aldosterone 
system.  
Statistically significant p<0.05 and CV R2 * 100 >0.50




Figure 5.10.  VCAM1 rs3176876 genotype specific mean systolic blood pressure by 
treatment class in GENOA African American hypertensive subjects  
 
 
*Other antihypertensive class includes alpha-blockers, vasodilators, sympatholytics, and study drugs. SBP 

















SNP rs #’s listed from left to right according to relative positions on SELE gene in the 5’ to 3’ direction.  
SNP = single nucleotide polymorphism; CA = Calcium channel; RAAS = renin angiotensin aldosterone 
system.   
 
Statistically significant p<0.05 and CV R2 * 100 >0.50




Figure 5.12.  VCAM1 rs3176860 genotype specific mean systolic blood pressure by 
treatment class in GENOA non-Hispanic white hypertensive subjects  
 
 
*Other antihypertensive class includes alpha-blockers, vasodilators, sympatholytics, and study drugs. SBP 
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SUMMARY OF FINDINGS 
The need for a shift in epidemiology to a paradigm that considers many levels of 
organization (molecular, individual, and societal) in the design, analysis, and 
interpretation of epidemiological studies has been described (1).  The purpose of this 
dissertation was to investigate factors across multiple levels that likely shape the 
distribution of quantitative blood pressure (BP) measures and the relative odds of BP 
treatment and control in a bi-ethnic sample of hypertensive subjects from the Genetic 
Epidemiology Network of Arteriopathy (GENOA) study. 
  Findings from Chapter 2 indicated that BP control rates were suboptimal, even 
among treated hypertensives, and BP control rates were lower among African American 
(particularly female) subjects, compared to non-Hispanic white subjects.  These findings 
were in accordance with national data on BP control (2-4).  The distributions of the types 
of antihypertensive drug therapies utilized within each racial/ethnic group suggested that 
prescribing patterns may generally comply with recommended treatment guidelines (5).  
As expected, age was the strongest predictor of both continuous BP measures and the 
probability of BP control in both racial/ethnic groups.  The presence of co-morbidities 
was strongly associated with the relative odds of receiving more aggressive BP treatment 
in both racial/ethnic groups, as expected.  Positive histories of coronary heart disease 
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(CHD) and/or cerebrovascular disease (CBVD) were relatively low and comparable in 
each racial/ethnic group.  In non-Hispanic whites, a positive history of CHD was 
associated with a decreased odds of BP control (unadjusted OR: 0.55, 95% CI: 0.36, 
0.84).  The African American sample had a significantly higher percentage of diabetic 
individuals compared to their non-Hispanic white counter parts (28% vs. 13%).  The 
presence of diabetes was a strong univariate predictor of BP control among African 
Americans (OR: 0.59, 95% CI: 0.45, 0.77) and this effect remained upon adjustment for 
age and sex (OR: 0.61, 95% CI: 0.46, 0.81).  Low levels of education were significantly 
associated with decreased odds of BP control in both racial/ethnic groups in unadjusted 
analyses.  Upon controlling for potential confounders, the education effect was attenuated 
towards non-significance in non-Hispanic whites.  In contrast, the education effect 
remained statistically significant in African Americans, even after adjustment for age, 
sex, BMI, and diabetes (OR: 1.04, 95% confidence interval (CI): 1.00-1.08), providing 
additional supporting evidence that factors indexed by SES may influence BP control and 
contribute to observed disparities in BP control rates between racial/ethnic groups. 
The main finding in Chapter 3 suggested that residing in a socioeconomically 
disadvantaged neighborhood might reduce the likelihood of being treated for 
hypertension more aggressively with multiple medications among treated African 
Americans.  This finding was consistent regardless of the neighborhood-level variable 
used to capture neighborhood socioeconomic environments (neighborhood 
socioeconomic summary score (increasing score represented greater affluence), OR: 1.03, 
95% CI: 1.00, 1.06; poor neighborhood of residence (defined as a neighborhood with 
>25% poverty), OR: 0.72, 95% CI: 0.55, 0.96) and the associations detected withstood 
 192 
 
adjustment for individual age, sex, BMI, diabetes, and education.  Neighborhood 
socioeconomic environment, as measured using census-derived proxy variables, was not 
associated with BP control, and this finding corroborates findings from similar previous 
investigations in other studies (6). 
   Findings from Chapter 4 provided further evidence of moderate familial 
aggregation of quantitative BP levels in both African Americans non-Hispanic Whites.  
Adjustment for individual level variables led to significant reductions in both the within- 
and between-family variance in BP levels in both racial/ethnic groups.  Parental histories 
of hypertension were the only family-level variables available and, in general, did not 
seem to confer strong contextual effects on individual BP levels.  Among African 
subjects, sib-sib correlations of quantitative BP values and familial aggregation of BP 
control were detected among sibpairs in which both siblings resided in poor 
neighborhoods.  These findings suggest that sibs living in similar types of 
neighborhoods may be more likely to demonstrate similar BP outcomes, as opposed to 
sibs living in dissimilar types of neighborhoods.   
The main finding from Chapter 5 was that SELE and VCAM1 single nucleotide 
polymorphism (SNP) main effects, as well as gene-drug interaction effects, were 
associated with SBP in both African Americans and non-Hispanic whites.  These 
findings suggest that SBP response to antihypertensive drug therapies may be partially 
dependent on the effects of SNPs within genes, namely SELE and VCAM1, in the 
inflammation/endothelial dysfunction pathway.  These findings add to the growing body 
of pharmacogenetic knowledge and the promise of developing “personalized medicine” 




The high percentages of hypertension awareness and treatment in the GENOA 
subjects may pose a couple of issues.  First, greater awareness and more frequent 
treatment in our sample may reflect selection bias since hypertension (in at least two 
sibs), with or without prior use of antihypertensive medication, was a criterion for study 
participation.  Second, as a result of such high percentages there was not much variation 
in these hypertension outcomes, which limited the ability to assess/detect significant 
predictors.  Given that the GENOA study was based on hypertensive sibships, data 
correlations may have potentially affected the standard errors of effect estimates in this 
dissertation work.  Multi-level modeling strategies were used to account for familial (and 
neighborhood) correlation in this dissertation.  As the GENOA subjects were generally 
older hypertensives, inferences may not be generalizable to individuals who are younger, 
normotensive. 
All analyses in this dissertation were based on cross-sectional data.  Establishing 
causality from such data can be difficult, since exposure(s) and disease are measured at 
the same time.  This may not be an issue for some exposures (e.g. - individual genotypes) 
that are relatively constant within individuals.  However, it is important to note that an 
individual’s exposure to certain risk factors (e.g. - neighborhood of residence) at the time 
of enrollment in a cross-sectional study may not equal exposure status when the disease 
process began.  This latter point was a particular limitation in the proposed study, as 
residential histories of the GENOA participants are unavailable.  The influence of genetic 
variation (and other factors) on BP response was limited in the absence of longitudinal 
data on BP measures, treatment adherence, and treatment dosage. 
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The quantitative BP measure and BP control outcomes of this study were all 
based on BP measurements taken during one short time period.  As BP continually 
fluctuates in individuals, the measurements taken at the time of examination may have 
been artificially higher (white coat hypertension phenomenon) or lower than a normal 
average for a given individual.  As a result, cross-sectional classifications of BP control, 
for example, may not reflect a given individual’s typical BP control status.  Furthermore, 
although efforts were made to obtain accurate office BP measurements, calibration errors, 
inappropriately sized arm cuffs, or operator digit preference may have led to 
measurement errors.  Despite this, it is likely that such errors are distributed evenly across 
the study samples and may not have biased findings.  There is also the potential for 
similar measurement errors of the various exposures that were based on physical 
examinations at one time point.  In addition, some exposure variables are based on 
information ascertained from questionnaires and are prone to response bias.   
 Census tracts were used as proxies for neighborhoods in this research.  Census 
tracts have been commonly employed as an area measure in health research and previous 
studies indicate that differences between census tracts and smaller area measures (block-
groups) are likely small (7).  Still, defining neighborhoods in this way had limitations, as 
the boundaries used to define them may not have corresponded with what people 
define/perceive as their neighborhoods.  The census-derived socioeconomic proxies used 
may not have accurately represented the neighborhood construct(s) most relevant to the 
BP outcomes tested, and failed to investigate specific mechanisms/characteristics that 
may be causally related to BP levels, treatment, and/or control.  Socioeconomic 
environments (based on the various indicator variables used) were relatively 
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homogeneous across the census tracts investigated in this research, which may have 
limited the ability to parse out important neighborhood socioeconomic contextual effects. 
Several of the analyses conducted in this dissertation (chiefly those in Chapter 5) 
involved many association tests and the results were vulnerable to false positive findings.  
Acknowledging this, cross-validation methods were employed to reduce the possibility of 
Type I errors, increase the internal validity of findings within samples, and assess the 
predictive ability of factors considered.   
The genetic analytic approach used in Chapter 5 was based on the premise that 
susceptibility alleles for common diseases, such as cardiovascular disease (and related 
subclinical disease measures such as BP), are not under strong negative selection, and 
common variants contribute to common disease traits (i.e., the ‘common disease/common 
variant’ hypothesis) (8).  However, the allelic spectrum for complex quantitative traits 
such as BP is not fully delineated, and it is possible that multiple rare variants (not 
assessed) influence BP.  While many genome-wide association studies (GWAS) on BP 
are ongoing (9-12) and have the great potential to identify genomic regions that influence 
BP (and BP response to therapeutic interventions), genome-wide data was not available 
on the GENOA subjects at the time analyses in Chapter 5 were conducted.  Particular 
investigation of SNPs in the SELE and VCAM1 candidate genes was based on previously 
detected associations between SNPs in these genes and cardiovascular outcomes 
(including hypertension), and the hypothesis that inflammation may independently 
promote the development of hypertension.  Although this possible pathogenic direction 
has sparked recent interest, reverse causation (i.e. - inflammation is a response to 
hypertension induced endothelial dysfunction) is equally likely.  Insufficient sample sizes 
in each treatment class or random measurement error may have limited the power to 




SIGNIFICANCE AND FUTURE DIRECTIONS 
Strengthening our understanding of common chronic diseases is a difficult 
challenge given their complex and multi-factorial nature.  It is well accepted that many 
genes influence the risk of developing chronic disease through their additive and 
interactive effects, and that such risk also depends on lifetime environmental exposures, 
as well as interactions between genetic and environmental influences.  Although many 
studies have made (and continue to make) valuable contributions towards the 
identification of important health determinants of chronic diseases, they remain largely 
rooted within scientific disciplines and a need for transdisciplinary approaches exists.   
The work presented in this dissertation was part of a key project with the Center 
for Integrative Approaches to Health Disparities (a collaboration between the University 
of Michigan and the Jackson Heart Study through its partners the University of 
Mississippi Medical Center and Jackson State University) (13).  The future development 
and continuation of such transdisciplinary research is perfectly aligned with the 
aforementioned call for a paradigm shift in epidemiological research (1).  A 
transdisciplinary focus on the determinants of chronic diseases holds the promise of 
yielding new etiological insights, identifying reasons for observed health disparities in 
chronic disease outcomes that persist along racial/ethnic and socioeconomic lines, and 
would help to identify key intervention points to reduce the overall health and economic 
burdens stemming from common chronic diseases.   
A natural future direction of such integrative research will be to thoroughly 
investigate the ways in which health determinants at different levels interact to influence 
the risk of chronic disease development.  In 2006, the Institute of Medicine (IOM) drafted 
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a consensus report containing recommendations that were “designed to explicate and 
facilitate research on the impact on health of interactions among social, behavioral, and 
genetic factors (14).”   The primary recommendations the IOM set forth in this report 
include: the promotion and development of transdisciplinary and collaborative research 
and research training; the development of rich databases containing life course social, 
behavioral, and genetic information in diverse populations; the development and 
implementation of new and innovative modeling strategies (including pattern recognition 
models, multivariate statistics, and pathway analysis) that will yield more comprehensive 
predictions of disease; the investigation of biological signatures as a means of 
discovering biological systems that interact with social and behavioral factors; testing 
gene-environment interactions and pathways of human diseases using controllable animal 
models; and attending to the ethical, legal, and social implications of conducting 
transdisciplinary research (14).   
The IOM report reminds that, “health outcomes are multidetermined and result 
from complex interactions of many factors over time (14).”  It is intuitive then that 
approaches aimed to further our etiological understanding of disease should be integrated 
and reasonably consider the multitude of factors acting in concert to give rise to the 
development of common chronic disease.  This dissertation research took important novel 
first steps in constructing interconnections between factors across a broad framework of 
health determinants that jointly influence BP outcomes.  Significant findings from this 
research highlight the importance of mutually considering factors defined at multiple 
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